<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150276</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2046-6390</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biology open</Title>
                <ISOAbbreviation>Biol Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Conditional inactivation of PDCD2 induces p53 activation and cell cycle arrest.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">BIO20148326</ELocationID>
            <ELocationID EIdType="doi">10.1242/bio.20148326</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">PDCD2 (programmed cell death domain 2) is a highly conserved, zinc finger MYND domain-containing protein essential for normal development in the fly, zebrafish and mouse. The molecular functions and cellular activities of PDCD2 remain unclear. In order to better understand the functions of PDCD2 in mammalian development, we have examined PDCD2 activity in mouse blastocyst embryos, as well as in mouse embryonic stem cells (ESCs) and embryonic fibroblasts (MEFs). We have studied mice bearing a targeted PDCD2 locus functioning as a null allele through a splicing gene trap, or as a conditional knockout, by deletion of exon2 containing the MYND domain. Tamoxifen-induced knockout of PDCD2 in MEFs, as well as in ESCs, leads to defects in progression from the G1 to the S phase of cell cycle, associated with increased levels of p53 protein and p53 target genes. G1 prolongation in ESCs was not associated with induction of differentiation. Loss of entry into S phase of the cell cycle and marked induction of nuclear p53 were also observed in PDCD2 knockout blastocysts. These results demonstrate a unique role for PDCD2 in regulating the cell cycle and p53 activation during early embryonic development of the mouse.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Granier</LastName>
                    <ForeName>Celine J</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>Child Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA rabsonab@rwjms.rutgers.edu graniecj@rwjms.rutgers.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Sequencing and Microarray Core Facility, Lewis-Sigler Institute for Integrative Genetics, Princeton University, Princeton, NJ 08854, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tsang</LastName>
                    <ForeName>Tiffany</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Child Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Steward</LastName>
                    <ForeName>Ruth</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Waksman Institute and Department of Molecular Biology, Rutgers University, Piscataway, NJ 08854, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sabaawy</LastName>
                    <ForeName>Hatem E</ForeName>
                    <Initials>HE</Initials>
                    <Affiliation>Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08903, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhaumik</LastName>
                    <ForeName>Mantu</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Child Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08903, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rabson</LastName>
                    <ForeName>Arnold B</ForeName>
                    <Initials>AB</Initials>
                    <Affiliation>Child Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08903, USA rabsonab@rwjms.rutgers.edu graniecj@rwjms.rutgers.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biol Open</MedlineTA>
            <NlmUniqueID>101578018</NlmUniqueID>
            <ISSNLinking>2046-6390</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cell cycle</Keyword>
            <Keyword MajorTopicYN="N">ESCs</Keyword>
            <Keyword MajorTopicYN="N">Mouse embryo</Keyword>
            <Keyword MajorTopicYN="N">PDCD2</Keyword>
            <Keyword MajorTopicYN="N">Proliferation</Keyword>
            <Keyword MajorTopicYN="N">p53</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">bio.20148326</ArticleId>
            <ArticleId IdType="doi">10.1242/bio.20148326</ArticleId>
            <ArticleId IdType="pubmed">25150276</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150255</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1592-8721</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Haematologica</Title>
                <ISOAbbreviation>Haematologica</ISOAbbreviation>
            </Journal>
            <ArticleTitle>GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">haematol.2014.105692</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The bone marrow microenvironment comprises multiple cell niches derived from bone marrow mesenchymal stem cells. However, the molecular mechanism of bone marrow mesenchymal stem cell differentiation is poorly understood. The transcription factor GATA2 is indispensable for hematopoietic stem cells function as well as other hematopoietic lineages, suggesting that it may maintain bone marrow mesenchymal stem cells in immature state and also contribute to their differentiation. To explore this possibility, we established bone marrow mesenchymal stem cells from GATA2 conditional knockout mice. Differentiation of GATA2-deficient bone marrow mesenchymal stem cells into adipocytes induced accelerated oil-drop formation. Further, GATA2 loss- and gain-of-function analyses based on human bone marrow mesenchymal stem cells confirmed that decreased and increased GATA2 expression accelerated and suppressed bone marrow mesenchymal stem cells differentiation to adipocytes, respectively. Microarray analysis of GATA2 knockdowned human bone marrow mesenchymal stem cells revealed that 90 and 189 genes were upregulated or downregulated by a factor of 2, respectively. Moreover, gene ontology analysis revealed significant enrichment of genes involved in cell cycle regulation, and the number of G1/G0 cells increased after GATA2 knockdown. Concomitantly, cell proliferation was decreased by GATA2 knockdown. When GATA2 knockdowned bone marrow mesenchymal stem cells as well as adipocytes were cocultured with CD34-positive cells, hematopoietic stem cell frequency and colony formation decreased. We confirm the existence of pathological signals that decrease and increase hematopoietic cell and adipocyte numbers, respectively, characteristic of aplastic anemia, suppress GATA2 expression in hematopoietic stem cells and bone marrow mesenchymal stem cells.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, Ferrata Storti Foundation.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kamata</LastName>
                    <ForeName>Mayumi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Okitsu</LastName>
                    <ForeName>Yoko</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fujiwara</LastName>
                    <ForeName>Tohru</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kanehira</LastName>
                    <ForeName>Masahiko</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nakajima</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Takahashi</LastName>
                    <ForeName>Taro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Inoue</LastName>
                    <ForeName>Ai</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fukuhara</LastName>
                    <ForeName>Noriko</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Onishi</LastName>
                    <ForeName>Yasushi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ishizawa</LastName>
                    <ForeName>Kenichi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shimizu</LastName>
                    <ForeName>Ritsuko</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yamamoto</LastName>
                    <ForeName>Masayuki</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Harigae</LastName>
                    <ForeName>Hideo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Tohoku University Graduate School of Medicine, Japan harigae@med.tohoku.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Haematologica</MedlineTA>
            <NlmUniqueID>0417435</NlmUniqueID>
            <ISSNLinking>0390-6078</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adipocyte differentiation</Keyword>
            <Keyword MajorTopicYN="N">Aplastic anemia</Keyword>
            <Keyword MajorTopicYN="N">GATA2</Keyword>
            <Keyword MajorTopicYN="N">Mesenchymal Stem Cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">haematol.2014.105692</ArticleId>
            <ArticleId IdType="doi">10.3324/haematol.2014.105692</ArticleId>
            <ArticleId IdType="pubmed">25150255</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150253</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1592-8721</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Haematologica</Title>
                <ISOAbbreviation>Haematologica</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Kr??ppel-like transcription factors KLF1 and KLF2 have unique and coordinate roles in regulating embryonic erythroid precursor maturation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">haematol.2014.104943</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The Kr??ppel-like transcription factors KLF1 and KLF2 are essential for embryonic erythropoiesis. They can partially compensate for each other during mouse development, and coordinately regulate numerous erythroid genes, including the ??-like globins. Simultaneous ablation of KLF1 and KLF2 results in earlier embryonic lethality and severe anemia. In this study, we determine that this anemia is caused by a paucity of blood cells, and exacerbated by diminished ??-like globin gene expression. The anemia phenotype is dose-dependent, and interestingly, can be ameliorated by a single copy of the KLF2, but not the KLF1 gene. The roles of KLF1 and KLF2 in maintaining normal peripheral blood cell numbers and globin mRNA amounts are erythroid cell-specific. Mechanistic studies led to the discovery that KLF2 has an essential function in erythroid precursor maintenance. KLF1 can partially compensate for KLF2 in this role, but is uniquely crucial for erythroid precursor proliferation, through its regulation of G1- to S-phase cell cycle transition. A more drastic impairment of primitive erythroid colony formation from embryonic progenitor cells occurs with simultaneous loss of KLF1 and KLF2, than with loss of a single factor. KLF1 and KLF2 coordinately regulate several proliferation-associated genes, including Foxm1. Differential expression of FoxM1, in particular, correlates with the observed KLF1 and KLF2 gene dosage effects on anemia. Furthermore, KLF1 binds to the FoxM1 gene promoter in blood cells. Thus KLF1 and KLF2 coordinately regulate embryonic erythroid precursor maturation through the regulation of multiple homeostasis-associated genes, and KLF2 has a novel and essential role in this process.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, Ferrata Storti Foundation.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Vinjamur</LastName>
                    <ForeName>Divya S</ForeName>
                    <Initials>DS</Initials>
                    <Affiliation>Virginia Commonwealth University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wade</LastName>
                    <ForeName>Kristen J</ForeName>
                    <Initials>KJ</Initials>
                    <Affiliation>Virginia Commonwealth University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mohamad</LastName>
                    <ForeName>Safa F</ForeName>
                    <Initials>SF</Initials>
                    <Affiliation>Virginia Commonwealth University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Haar</LastName>
                    <ForeName>Jack L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Virginia Commonwealth University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sawyer</LastName>
                    <ForeName>Stephen T</ForeName>
                    <Initials>ST</Initials>
                    <Affiliation>Virginia Commonwealth University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lloyd</LastName>
                    <ForeName>Joyce A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Virginia Commonwealth University jlloyd@vcu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Haematologica</MedlineTA>
            <NlmUniqueID>0417435</NlmUniqueID>
            <ISSNLinking>0390-6078</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EKLF/KLF1</Keyword>
            <Keyword MajorTopicYN="N">Erythroid precursor maturation</Keyword>
            <Keyword MajorTopicYN="N">Globin gene regulation</Keyword>
            <Keyword MajorTopicYN="N">KLF2</Keyword>
            <Keyword MajorTopicYN="N">Red Cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">haematol.2014.104943</ArticleId>
            <ArticleId IdType="doi">10.3324/haematol.2014.104943</ArticleId>
            <ArticleId IdType="pubmed">25150253</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150251</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2049-3614</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrine connections</Title>
                <ISOAbbreviation>Endocr Connect</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Estriol strongly inhibits DNCB-induced contact dermatitis: role of antigen-specific antibodies in pathogenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">EC-14-0080</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The endogenous estrogens are important modulators of the immune system and its functions. However, their effects are rather complex and many aspects have not been studied. In the present study, we used the 1-chloro-2,4-dinitrobenzene (DNCB)-induced contact dermatitis as a disease model and investigated the effect of estriol, along with two other estrogens, 17??-estradiol and estrone, on the pathogenesis of contact hypersensitivity. A series of parameters, such as ear swelling, skin inflammation, antigen-specific immunoglobulins, and lymphocyte compositions in peripheral lymphoid organs, were evaluated in mice following their development of contact dermatitis. We found while administration of all three estrogens elicited strong inhibition of DNCB-induced dermatitis, estriol exerted the strongest suppressive effect. Administration of estriol alleviated dermatitis, and this effect was accompanied by decreases in serum DNCB-specific immunoglobulins, such as IgA, IgG1, IgG2a and IgG2b. Besides, treatment of estriol reduced B cell population, especially IgG-producing cells in peripheral lymphoid organs following the induction of dermatitis. These observations consistently suggest that the antibody-mediated humoral immune reactions play a critical role in the pathogenesis of DNCB-induced contact dermatitis. The results from this study demonstrate, for the first time, that estrogen administration has a strong suppressive effect on the pathogenesis of contact dermatitis. These findings offer important insights concerning the pathogenic role of antigen-specific antibodies in contact dermatitis and the treatment of chemical-induced, antibody-mediated skin hypersensitivity reactions in humans.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Elizabeth Yan</ForeName>
                    <Initials>EY</Initials>
                    <Affiliation>E Zhang, Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>B T</ForeName>
                    <Initials>BT</Initials>
                    <Affiliation>B Zhu, Pharmacology, Toxicology, Therapeutics, University of Kansas Medical Center, Kansas City, 66160, United States btzhu@kumc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Endocr Connect</MedlineTA>
            <NlmUniqueID>101598413</NlmUniqueID>
            <ISSNLinking>2049-3614</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">EC-14-0080</ArticleId>
            <ArticleId IdType="doi">10.1530/EC-14-0080</ArticleId>
            <ArticleId IdType="pubmed">25150251</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150213</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2968</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical pharmacology</Title>
                <ISOAbbreviation>Biochem. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Brain-derived neurotrophic factor increases vascular endothelial growth factor expression and enhances angiogenesis in human chondrosarcoma cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-2952(14)00463-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bcp.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Chondrosarcomas are a type of primary malignant bone cancer, with a potent capacity for local invasion and distant metastasis. Brain-derived neurotrophic factor (BDNF) is commonly upregulated during neurogenesis. The aim of the present study was to examine the mechanism involved in BDNF-mediated vascular endothelial growth factor (VEGF) expression and angiogenesis in human chondrosarcoma cells. Here, we knocked down BDNF expression in chondrosarcoma cells and assessed their capacity to control VEGF expression and angiogenesis in vitro and in vivo. We found knockdown of BDNF decreased VEGF expression and abolished chondrosarcoma conditional medium-mediated angiogenesis in vitro as well as angiogenesis effects in vivo in the chick chorioallantoic membrane and Matrigel plug nude mouse models. In addition, in the xenograft tumor angiogenesis model, the knockdown of BDNF significantly reduced tumor growth and tumor-associated angiogenesis. BDNF increased VEGF expression and angiogenesis through the TrkB receptor, PLC??, PKC??, and the HIF-1?? signaling pathway. Finally, we analyzed samples from chondrosarcoma patients by immunohistochemical staining. The expression of BDNF and VEGF protein in 56 chondrosarcoma patients was significantly higher than in normal cartilage. In addition, the high level of BDNF expression correlated strongly with VEGF expression and tumor stage. Taken together, our results indicate that BDNF increases VEGF expression and enhances angiogenesis through a signal transduction pathway that involves the TrkB receptor, PLC??, PKC??, and the HIF-1??. Therefore, BDNF may represent a novel target for anti-angiogenic therapy for human chondrosarcoma.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Chih-Yang</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hung</LastName>
                    <ForeName>Shih-Ya</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Epigenome Research Center, China Medical University Hospital, Taichung Taiwan; Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan; Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Hsien-Te</ForeName>
                    <Initials>HT</Initials>
                    <Affiliation>School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan; Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan; Department of Materials Science and Engineering, Feng Chia University,Taichung, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tsou</LastName>
                    <ForeName>Hsi-Kai</ForeName>
                    <Initials>HK</Initials>
                    <Affiliation>Department of Materials Science and Engineering, Feng Chia University,Taichung, Taiwan; Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Early Childhood Care and Education, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli County, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fong</LastName>
                    <ForeName>Yi-Chin</ForeName>
                    <Initials>YC</Initials>
                    <Affiliation>School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan; Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Shih-Wei</ForeName>
                    <Initials>SW</Initials>
                    <Affiliation>Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Chih-Hsin</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan; Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan; Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan. Electronic address: chtang@mail.cmu.edu.tw.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Pharmacol</MedlineTA>
            <NlmUniqueID>0101032</NlmUniqueID>
            <ISSNLinking>0006-2952</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">BDNF</Keyword>
            <Keyword MajorTopicYN="N">Chondrosarcoma</Keyword>
            <Keyword MajorTopicYN="N">TrkB</Keyword>
            <Keyword MajorTopicYN="N">VEGF</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-2952(14)00463-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bcp.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25150213</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150200</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3150</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicon : official journal of the International Society on Toxinology</Title>
                <ISOAbbreviation>Toxicon</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Acute toxicity of karlotoxins to mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0041-0101(14)00232-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.toxicon.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Karlotoxins, polyketide derivatives produced by the dinoflagellate Karlodinium vene???cum, are associated with ???sh kills in temperate estuaries world-wide. In this study, the acute effects of 3 pure karlotoxin analogs (KmTx 1, KmTx 3 and KmTx 2) have been examined in mice. Transient lethargy and increased respiratory rates were observed soon after dosing with the karlotoxins by intraperitoneal injection, but no deaths were recorded in animals dosed with KmTx 2 at up to 500 ??g/kg or with KmTx 1 or KmTx 3 at up to 4,000 ??g/kg. Animals dosed intraperitoneally with KmTx 1 and KmTx 3 at 4,000 ??g/kg showed a pronounced decrease in food and water intake, lasting 3-4 days after dosing, accompanied by a significant decrease in body weight. After this time, the lost body weight was regained and the behavior and appearance of the mice remained normal throughout the following 10-day observation period. No effects were seen in mice dosed orally with KmTx 1 or KmTx 3 at a dose of 4,000 ??g/kg. It is concluded that contamination of seafood if it were to occur with these karlotoxins is unlikely to pose a major risk of acute intoxication in consumers.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Place</LastName>
                    <ForeName>Allen R</ForeName>
                    <Initials>AR</Initials>
                    <Affiliation>Institute of Marine and Environmental Technology, University of Maryland Center for Environmental Sciences, 701 East Pratt Street, Baltimore, MD 21202. Electronic address: place@umces.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Munday</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>AgResearch, Ruakura Research Centre, Private Bag 3123, Hamilton, New Zealand.</Affiliation>
                </Author>
                <Author>
                    <LastName>Munday</LastName>
                    <ForeName>J S</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Private Bag 11222, Palmerston North, New Zealand.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Toxicon</MedlineTA>
            <NlmUniqueID>1307333</NlmUniqueID>
            <ISSNLinking>0041-0101</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Acute toxicity</Keyword>
            <Keyword MajorTopicYN="N">karlotoxins</Keyword>
            <Keyword MajorTopicYN="N">mice</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-0101(14)00232-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.toxicon.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25150200</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150199</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Free radical biology &amp; medicine</Title>
                <ISOAbbreviation>Free Radic. Biol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Valproic acid increases NO production via SH-PTP1-CDK5-eNOS-Ser(116) signaling cascade in endothelial cells and mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0891-5849(14)00374-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.freeradbiomed.2014.07.043</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Valproic acid (VPA) with inhibitory activity of histone deacetylase has been used in the treatment of epilepsy and bipolar disorder that are associated with cerebrovascular dysfunction. Because nitric oxide (NO) produced by endothelial NO synthase (eNOS) plays a role in maintenance of vascular function, NO is likely to mediate VPA's drug effect, but its effect on NO production remains controversial. We investigated whether and how VPA regulates NO production in bovine aortic endothelial cells (BAEC) and mice. VPA increased NO production in BAEC, which was accompanied by decrease in phosphorylations of eNOS at serine 116 (eNOS-Ser(116)) and cyclin-dependent kinase 5 at tyrosine 15 (CDK5-Tyr(15)). Ectopic expression of p25, a CDK5 activator, restored the VPA-inhibited eNOS-Ser(116) phosphorylation. In silico analysis revealed that the CDK5-Tyr(15) residue might be a substrate for SH2 domain-containing protein tyrosine phosphatase 1 (SH-PTP1), and CDK5 actually interacted with SH-PTP1. VPA increased SH-PTP1 expression and its activity. Stibogluconate, a specific SH-PTP1 inhibitor, reversed the VPA-inhibited phosphorylations of CDK5-Tyr(15) and eNOS-Ser(116). Knockdown of SH-PTP1 using small interfering RNA also reversed all the observed VPA's effects. Finally, both serum NO level and acetylcholine-induced aortic relaxation increased in the VPA-medicated male mice. These increases were accompanied by increased SH-PTP1 expression and decreased phosphorylations of CDK5-Tyr(15) and eNOS-Ser(116) in mouse aortas. In conclusion, VPA increases NO production by inhibiting CDK5-Tyr(15)-eNOS-Ser(116) phosphorylation axis; this process is mediated by SH-PTP1. VPA may be useful in the treatment of NO-related cerebrocardiovascular diseases.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Du-Hyong</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>Department of Neurology, Konkuk University Medical Center and Department of Pharmacology, Center for Geriatric Neuroscience Research, SMART Institute of Advanced Biomedical Science, School of Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Korea; Department of Pharmacology, School of Medicine, Eulji University, 77, Gyeryong-ro, 771 Beon-gil, Jung-gu, Daejeon 301-746, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Jung-Hyun</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Department of Molecular Medicine, Ewha Womans University Medical School, 911-1, Mok-6-dong, Yangcheon-gu, Seoul 158-710, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Joo Lee</LastName>
                    <ForeName>Eun</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Neurology, Konkuk University Medical Center and Department of Pharmacology, Center for Geriatric Neuroscience Research, SMART Institute of Advanced Biomedical Science, School of Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jong Won</LastName>
                    <ForeName>Kyung</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Medical Science, Institute of Functional Genomics, Konkuk University School of Medicine, 322 Danwol-dong, Chungju 380-701, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Sang-Hee</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Department of Microbiology, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Yang-Hoon</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Department of Microbiology, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hwang</LastName>
                    <ForeName>Soojin</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Medicine, Ewha Womans University Medical School, 911-1, Mok-6-dong, Yangcheon-gu, Seoul 158-710, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ja Kwon</LastName>
                    <ForeName>Kyoung</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Neurology, Konkuk University Medical Center and Department of Pharmacology, Center for Geriatric Neuroscience Research, SMART Institute of Advanced Biomedical Science, School of Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Young Shin</LastName>
                    <ForeName>Chan</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Neurology, Konkuk University Medical Center and Department of Pharmacology, Center for Geriatric Neuroscience Research, SMART Institute of Advanced Biomedical Science, School of Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Kee-Ho</ForeName>
                    <Initials>KH</Initials>
                    <Affiliation>Department of Internal Medicine, Konkuk University School of Medicine, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-729, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jo</LastName>
                    <ForeName>Inho</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Molecular Medicine, Ewha Womans University Medical School, 911-1, Mok-6-dong, Yangcheon-gu, Seoul 158-710, Korea. Electronic address: inhojo@ewha.ac.kr.</Affiliation>
                </Author>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Seol-Heui</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Department of Neurology, Konkuk University Medical Center and Department of Pharmacology, Center for Geriatric Neuroscience Research, SMART Institute of Advanced Biomedical Science, School of Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Korea. Electronic address: alzdoc@kuh.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Free Radic Biol Med</MedlineTA>
            <NlmUniqueID>8709159</NlmUniqueID>
            <ISSNLinking>0891-5849</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cyclin-dependent kinase 5</Keyword>
            <Keyword MajorTopicYN="N">Endothelial nitric oxide synthase</Keyword>
            <Keyword MajorTopicYN="N">Histone deacetylase</Keyword>
            <Keyword MajorTopicYN="N">Nitric oxide</Keyword>
            <Keyword MajorTopicYN="N">SH2 domain-containing protein tyrosine phosphatase 1</Keyword>
            <Keyword MajorTopicYN="N">Valproic acid</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0891-5849(14)00374-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.07.043</ArticleId>
            <ArticleId IdType="pubmed">25150199</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150175</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-1705</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International immunopharmacology</Title>
                <ISOAbbreviation>Int. Immunopharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immummunomodulatory effect of diethylcarbamazine in mice infected with Nocardia brasiliensis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1567-5769(14)00318-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.intimp.2014.08.004</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">We tested whether diethylcarbamazine (DEC) or ivermectin (IVM), both antiparasitic drugs with reported immunomodulatory properties, were able to affect the immune system to potentiate host defense mechanisms and protect against actinomycetoma in a mouse model. Male BALB/c mice of 10-12weeks of age were injected with either Nocardia brasiliensis or saline solution. Recorded were the effects of a treatment by DEC (6mg/kg per os daily for one week) or IVM (200??g/kg subcutaneously on days 1 and 3) on (i) the development of mycetoma lesion, (ii) the expression of reactive oxygen intermediates (ROI) by phagocytes, (iii) the proliferation index of lymphocytes and (iv) antibody production of IgG and IgM. After an initial lesion in all mice, DEC inhibited a full development and progression of actinomycetoma resulting in a reduced lesion size (p&lt;0.001). IVM had no inhibitory effect on the development of mycetoma. Furthermore, DEC treatment was associated with a significant enhancement of ROI expression (p&lt;0.05) by polymorphonuclear neutrophils at day 3 after infection. Lymphocyte proliferation in response to N. brasiliensis antigens and concanavalin A in DEC-treated group was higher than in non-treated group at day 21 and 28 postinfection (p&lt;0.01). Significant changes in antibody response were not observed. By all parameters tested, DEC was superior to IVM regarding immunostimulatory potency. In conclusion, DEC expressed an in vivo influence on the immune status during the infection by N. brasiliensis leading to retrogression of the mycetoma and increasing cellular immune responses. Our findings may indicate a potential use of DEC as a putative adjuvant in infectious disease or vaccination.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Garc??a-Hern??ndez</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Immunology Department, School of Medicine, Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico; Centro de Investigaci??n y Desarrollo en Ciencias de la Salud (CIDICS), Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico.</Affiliation>
                </Author>
                <Author>
                    <LastName>Castro-Corona</LastName>
                    <ForeName>M A</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Immunology Department, School of Medicine, Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico; Centro de Investigaci??n y Desarrollo en Ciencias de la Salud (CIDICS), Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico.</Affiliation>
                </Author>
                <Author>
                    <LastName>Segoviano-Ram??rez</LastName>
                    <ForeName>J C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Histology Department, School of Medicine, Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico; Centro de Investigaci??n y Desarrollo en Ciencias de la Salud (CIDICS), Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico.</Affiliation>
                </Author>
                <Author>
                    <LastName>Brattig</LastName>
                    <ForeName>N W</ForeName>
                    <Initials>NW</Initials>
                    <Affiliation>Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Medina-De la Garza</LastName>
                    <ForeName>C E</ForeName>
                    <Initials>CE</Initials>
                    <Affiliation>Immunology Department, School of Medicine, Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico; Centro de Investigaci??n y Desarrollo en Ciencias de la Salud (CIDICS), Universidad Auton??ma de Nuevo Le??n (UANL), Monterrey, Mexico. Electronic address: carlos.medina@uanl.mx.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int Immunopharmacol</MedlineTA>
            <NlmUniqueID>100965259</NlmUniqueID>
            <ISSNLinking>1567-5769</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Actinomycetoma</Keyword>
            <Keyword MajorTopicYN="N">Diethylcarbamazine</Keyword>
            <Keyword MajorTopicYN="N">Immunomodulation</Keyword>
            <Keyword MajorTopicYN="N">Ivermectin</Keyword>
            <Keyword MajorTopicYN="N">Nocardia</Keyword>
            <Keyword MajorTopicYN="N">Respiratory burst</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1567-5769(14)00318-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.intimp.2014.08.004</ArticleId>
            <ArticleId IdType="pubmed">25150175</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150149</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-9564</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurobiology of learning and memory</Title>
                <ISOAbbreviation>Neurobiol Learn Mem</ISOAbbreviation>
            </Journal>
            <ArticleTitle>RGS9-2 modulates sensory and mood related symptoms of neuropathic pain.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1074-7427(14)00144-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.nlm.2014.08.005</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The signal transduction modulator Rgs9-2 (Regulator of G protein signaling 9-2) plays a key role in dopaminergic and opioidergic transmission in the striatum. Rgs9-2 is a potent modulator of opiate reward and analgesia, but its role in chronic pain remains unknown. Here, we use the spared nerve injury model (SNI), to evaluate the influence of Rgs9-2 in sensory symptoms, as well as in anxiety and depression-like behaviors observed under neuropathic pain conditions. Our data demonstrate that knockout of the Rgs9 gene reduces the intensity of thermal hyperalgesia and mechanical allodynia the first few days after nerve injury. This small, but significant effect is only observed at early time points after nerve injury, whereas after the first week of SNI, Rgs9 knockout (Rgs9KO) and Rgs9 wildtype (Rgs9WT) mice show similar levels of mechanical allodynia and thermal hyperalgesia. Furthermore, Rgs9-2 deletion exacerbates anxiety and depression like behaviors several weeks after the emergence of the neuropathic pain symptoms. Our findings also reveal a temporal and regional regulation of Rgs9-2 protein expression by neuropathic pain, as Rgs9-2 levels are reduced in the spinal cord a few days after nerve injury, whereas decreased Rgs9-2 levels in the Nucleus Accumbens (NAc) are only observed several weeks after nerve injury. Thus, adaptations in Rgs9-2 activity in the spinal cord and in the NAc may contribute to sensory and affective components of neuropathic pain.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Terzi</LastName>
                    <ForeName>Dimitra</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>University of Crete Faculty of Medicine, Department of Basic Sciences, Heraklion, Crete, Greece, 71003.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gaspari</LastName>
                    <ForeName>Sevasti</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>University of Crete Faculty of Medicine, Department of Basic Sciences, Heraklion, Crete, Greece, 71003.</Affiliation>
                </Author>
                <Author>
                    <LastName>Manouras</LastName>
                    <ForeName>Lefteris</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>University of Crete Faculty of Medicine, Department of Basic Sciences, Heraklion, Crete, Greece, 71003.</Affiliation>
                </Author>
                <Author>
                    <LastName>Descalzi</LastName>
                    <ForeName>Giannina</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Icahn School of Medicine at Mount Sinai, Fishberg Department of Neuroscience and Friedman Brain Institute, Department of Pharmacology and Systems Therapeutics.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mitsi</LastName>
                    <ForeName>Vassiliki</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>University of Crete Faculty of Medicine, Department of Basic Sciences, Heraklion, Crete, Greece, 71003.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zachariou</LastName>
                    <ForeName>Venetia</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>University of Crete Faculty of Medicine, Department of Basic Sciences, Heraklion, Crete, Greece, 71003; Icahn School of Medicine at Mount Sinai, Fishberg Department of Neuroscience and Friedman Brain Institute, Department of Pharmacology and Systems Therapeutics. Electronic address: venetia.zachariou@mssm.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurobiol Learn Mem</MedlineTA>
            <NlmUniqueID>9508166</NlmUniqueID>
            <ISSNLinking>1074-7427</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Chronic pain</Keyword>
            <Keyword MajorTopicYN="N">Forced swim</Keyword>
            <Keyword MajorTopicYN="N">Mechanical allodynia</Keyword>
            <Keyword MajorTopicYN="N">Nociception</Keyword>
            <Keyword MajorTopicYN="N">Signal transduction</Keyword>
            <Keyword MajorTopicYN="N">Spared nerve injury</Keyword>
            <Keyword MajorTopicYN="N">Thermal hyperalgesia</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1074-7427(14)00144-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.nlm.2014.08.005</ArticleId>
            <ArticleId IdType="pubmed">25150149</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150137</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-1708</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Reproductive toxicology (Elmsford, N.Y.)</Title>
                <ISOAbbreviation>Reprod. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preventive effect of non-mitogenic acidic fibroblast growth factor on diabetes-induced testicular cell death.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0890-6238(14)00231-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.reprotox.2014.08.002</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Fibroblast growth factor (FGF)-1 was found to protect the heart from oxidative damage, but clinically its long-term use was restricted for its undesirable proliferating activity on cells. Thus a cluster of amino acids responsible for the proliferation were deleted in the native FGF-1 to create a non-mitogenic FGF-1 (nmFGF-1). Whether the nmFGF-1 protects male germ cells from diabetes-induced apoptotic death was examined in diabetic mice induced with multiple low-doses of streptozotocin, followed by nmFGF-1 treatment for 6 months. Diabetic mice showed a decrease in testicular weight and an increase in apoptotic cell death. Treatment with nmFGF-1 alleviated the diabetic effects on testicular weight and apoptotic cell death. Mechanistically, nmFGF-1 may alleviate diabetes-induced germ cell death by decreasing the BAX/Bcl-2 ratio and endoplasmic reticulum stress as well as associated cell death, which is associated with Nrf-2 activation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Skibba</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology, The University of Louisville, Louisville 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Chi</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>The Chinese-American Research Institute for Diabetic Complications, School of Pharmaceutical Sciences &amp; Key Laboratory of Biotechnology Pharmaceutical Engineering, Wenzhou Medical University, Wenzhou, 325035, China; The Chinese-American Research Institute for Diabetic Complications, the RuiAn Center of Wenzhou Medical University, Wenzhou 325035, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Radiation Oncology of the First Hospital of Jilin University, Changchun 130021, China; KCHRI at the Department of Pediatrics, The University of Louisville, Louisville 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xin</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>KCHRI at the Department of Pediatrics, The University of Louisville, Louisville 40202, USA; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cai</LastName>
                    <ForeName>Lu</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology, The University of Louisville, Louisville 40202, USA; The Chinese-American Research Institute for Diabetic Complications, School of Pharmaceutical Sciences &amp; Key Laboratory of Biotechnology Pharmaceutical Engineering, Wenzhou Medical University, Wenzhou, 325035, China; KCHRI at the Department of Pediatrics, The University of Louisville, Louisville 40202, USA. Electronic address: l0cai001@louisville.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Reprod Toxicol</MedlineTA>
            <NlmUniqueID>8803591</NlmUniqueID>
            <ISSNLinking>0890-6238</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Diabetic infertility</Keyword>
            <Keyword MajorTopicYN="N">FGF-1</Keyword>
            <Keyword MajorTopicYN="N">Germ cell apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Testicular effect</Keyword>
            <Keyword MajorTopicYN="N">Type 1 diabetes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0890-6238(14)00231-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.reprotox.2014.08.002</ArticleId>
            <ArticleId IdType="pubmed">25150137</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150121</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0739</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nutrition research (New York, N.Y.)</Title>
                <ISOAbbreviation>Nutr Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Single-dose oral quercetin improves redox status but does not affect heat shock response in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>623-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nutres.2014.06.005</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0271-5317(14)00090-6</ELocationID>
            <Abstract>
                <AbstractText>Inflammation and oxidative stress are considered as likely contributors to heat injury. However, their roles in regulating the heat shock response in vivo remain unclear. We tested the hypothesis that acute quercetin treatment would improve redox status and reduce heat shock responses in mice. Mice underwent two heat tests before and after single oral administration of either quercetin (15 mg/kg) or vehicle. We measured physiologic and biochemical responses in mice during and 18 to 22 hours after heat tests, respectively. There were no significant differences in core temperature, heart rate, or blood pressure between quercetin and vehicle groups during heat exposure. Mice with relatively severe hyperthermia during the pretreatment heat test showed a significant trend toward a lower peak core temperature during the heat test after quercetin treatment. Compared with mice not exposed to heat, quercetin-treated mice had significantly lower interleukin 6 (P &lt; .01) and higher superoxide dismutase levels (P &lt; .01), whereas vehicle-treated mice had significantly lower total glutathione and higher 8-isoprostane levels in the circulation after heat exposure. Heat exposure significantly elevated heat shock proteins (HSPs) 72 and 90 and heat shock factor 1 levels in mouse liver, heart, and skeletal muscles, but no significant differences in tissue HSPs and heat shock factor 1 were found between quercetin- and vehicle-treated mice. These results suggest that a single moderate dose of quercetin is sufficient to alter redox status but not heat stress response in mice. Acute adaptations of peripheral tissues to heat stress may not be mediated by systemic inflammatory and redox state in vivo.</AbstractText>
                <CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Yifan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. Electronic address: yifan.chen@usuhs.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Islam</LastName>
                    <ForeName>Aminul</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abraham</LastName>
                    <ForeName>Preetha</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deuster</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nutr Res</MedlineTA>
            <NlmUniqueID>8303331</NlmUniqueID>
            <ISSNLinking>0271-5317</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cytokine</Keyword>
            <Keyword MajorTopicYN="N">Flavonoid</Keyword>
            <Keyword MajorTopicYN="N">Hyperthermia</Keyword>
            <Keyword MajorTopicYN="N">Mice</Keyword>
            <Keyword MajorTopicYN="N">SOD</Keyword>
            <Keyword MajorTopicYN="N">Skeletal muscle</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0271-5317(14)00090-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.nutres.2014.06.005</ArticleId>
            <ArticleId IdType="pubmed">25150121</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150120</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0739</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nutrition research (New York, N.Y.)</Title>
                <ISOAbbreviation>Nutr Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A single daily meal at the beginning of the active or inactive period inhibits food deprivation-induced fatty liver in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>613-22</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nutres.2014.06.004</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0271-5317(14)00089-X</ELocationID>
            <Abstract>
                <AbstractText>Food deprivation (FD) induces hepatic steatosis in both rodents and humans. Although body composition, age, and sex influence hepatic triglyceride (TG) levels after FD, whether feeding patterns affect FD-induced liver TG increases is unknown. We hypothesized that restricted feeding (RF) of 1 meal per day during the active or inactive period (especially the inactive period) augments FD-induced elevation of liver TGs because RF in the inactive period impairs the circadian rhythm. Triglyceride levels and the expression of genes related to TG metabolism in the liver were examined by a bioassay and real-time reverse transcription-polymerase chain reaction, respectively. In the first experiment, when compared to nonfasted mice, mice that fasted for 24 hours showed a 1.5-fold (FD starting during the inactive period) to 3-fold (FD started during the active period) increase in liver TG levels. This experiment showed that TG levels depend upon the starting time of FD. In the second experiment, mice were given free access to food for 3 hours at the beginning of either the inactive (&quot;supper-only&quot;) or the active (&quot;breakfast-only&quot;) period for 2 weeks. Restricted feeding inhibited the FD-induced increases in liver and serum TG levels, serum free fatty acids, and the expression of genes related to fatty acid uptake in the liver, including fatty acid transport protein 1 (Fatp1) and 4 (Fatp4). Unexpectedly, compared to free feeding, RF during the active or inactive period resulted in resistance to FD-induced fatty liver. This is the first study to demonstrate that feeding patterns affect FD-induced TG accumulation in the mouse liver.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aoki</LastName>
                    <ForeName>Natsumi</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Laboratory of Physiology and Pharmacology, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshida</LastName>
                    <ForeName>Daisuke</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Laboratory of Physiology and Pharmacology, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ishikawa</LastName>
                    <ForeName>Ryosuke</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Laboratory of Physiology and Pharmacology, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ando</LastName>
                    <ForeName>Midori</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratory of Physiology and Pharmacology, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakamura</LastName>
                    <ForeName>Kaai</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratory of Physiology and Pharmacology, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tahara</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Laboratory of Physiology and Pharmacology, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibata</LastName>
                    <ForeName>Shigenobu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratory of Physiology and Pharmacology, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan. Electronic address: shibatas@waseda.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nutr Res</MedlineTA>
            <NlmUniqueID>8303331</NlmUniqueID>
            <ISSNLinking>0271-5317</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Circadian rhythm</Keyword>
            <Keyword MajorTopicYN="N">Fatty liver</Keyword>
            <Keyword MajorTopicYN="N">Food deprivation</Keyword>
            <Keyword MajorTopicYN="N">Meal timing</Keyword>
            <Keyword MajorTopicYN="N">Metabolic syndrome</Keyword>
            <Keyword MajorTopicYN="N">Mice</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0271-5317(14)00089-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.nutres.2014.06.004</ArticleId>
            <ArticleId IdType="pubmed">25150120</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150118</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0739</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nutrition research (New York, N.Y.)</Title>
                <ISOAbbreviation>Nutr Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Oligonol improves memory and cognition under an amyloid ??25-35-induced Alzheimer's mouse model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>595-603</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nutres.2014.06.008</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0271-5317(14)00093-1</ELocationID>
            <Abstract>
                <AbstractText>Alzheimer's disease is an age-dependent progressive neurodegenerative disorder that results in impairments of memory and cognitive function. It is hypothesized that oligonol has ameliorative effects on memory impairment and reduced cognitive functions in mice with Alzheimer's disease induced by amyloid ??25-35 (A??25-35) injection. The protective effect of an oligonol against A??25-35-induced memory impairment was investigated in an in vivo Alzheimer's mouse model. The aggregation of A??25-35 was induced by incubation at 37??C for 3 days before injection into mice brains (5 nmol/mouse), and then oligonol was orally administered at 100 and 200 mg/kg of body weight for 2 weeks. Memory and cognition were observed in T-maze, object recognition, and Morris water maze tests. The group injected with A??25-35 showed impairments in both recognition and memory. However, novel object recognition and new route awareness abilities were dose dependently improved by the oral administration of oligonol. In addition, the results of the Morris water maze test indicated that oligonol exerted protective activity against cognitive impairment induced by A??25-35. Furthermore, nitric oxide formation and lipid peroxidation were significantly elevated by A??25-35, whereas oligonol treatment significantly decreased nitric oxide formation and lipid peroxidation in the brain, liver, and kidneys. The present results suggest that oligonol improves A??25-35-induced memory deficit and cognition impairment.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Yoon Young</ForeName>
                    <Initials>YY</Initials>
                    <Affiliation>Department of Food Science Nutrition, Pusan National University, Busan 609-735, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maeda</LastName>
                    <ForeName>Takahiro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Amino Up Chemical, Co, Ltd, Sapporo 004-0839, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujii</LastName>
                    <ForeName>Hajime</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Amino Up Chemical, Co, Ltd, Sapporo 004-0839, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yokozawa</LastName>
                    <ForeName>Takako</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Hyun Young</ForeName>
                    <Initials>HY</Initials>
                    <Affiliation>Department of Food Science, Gyeongnam National University of Science and Technology, Jinju 660-758, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Eun Ju</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Department of Food Science Nutrition, Pusan National University, Busan 609-735, Republic of Korea. Electronic address: ejcho@pusan.ac.kr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibamoto</LastName>
                    <ForeName>Takayuki</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Environmental Toxicology, University of California, Davis, CA 95616, USA. Electronic address: tshibamoto@ucdavis.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nutr Res</MedlineTA>
            <NlmUniqueID>8303331</NlmUniqueID>
            <ISSNLinking>0271-5317</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
            <Keyword MajorTopicYN="N">Amyloid beta</Keyword>
            <Keyword MajorTopicYN="N">Memory</Keyword>
            <Keyword MajorTopicYN="N">Mouse</Keyword>
            <Keyword MajorTopicYN="N">Oligonol</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0271-5317(14)00093-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.nutres.2014.06.008</ArticleId>
            <ArticleId IdType="pubmed">25150118</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150117</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0739</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nutrition research (New York, N.Y.)</Title>
                <ISOAbbreviation>Nutr Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>585-94</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nutres.2014.06.010</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0271-5317(14)00095-5</ELocationID>
            <Abstract>
                <AbstractText>Natural products, such as fermented soybeans, have been used to treat various physical conditions, including cancer. MB-6 is a botanical preparation composed of fermented soybean extract, green tea extract, Antrodia camphorata mycelia, spirulina, grape seed extract, and curcumin extract. Based on this, we hypothesized that MB-6 would increase the effectiveness of chemotherapy in patients with colon cancer. In a rodent study, MB-6, in combination with leucovorin/5-fluorouracil chemotherapy, increased the survival rate and life span of colon cancer tumor-bearing BALB/c mice as compared with treatment with chemotherapy alone. In a proof-of-concept clinical study, 72 patients with metastatic colorectal cancer were randomized to receive leucovorin, 5-fluorouracil, and oxaliplatin in combination with either MB-6 or placebo for 16 weeks. The primary outcome was the best overall response, and secondary outcomes included progression-free survival, overall survival, and adverse effects. Up to 77 weeks after treatment, there was follow-up with the patients. No significant difference in the best overall response rate and overall survival was observed between the 2 groups. Patients in the MB-6 group had a significantly lower disease progression rate than patients in the placebo group, during the study period (0.0% vs 15.8%, P = .026). The placebo group had a significantly higher incidence of adverse events at least grade 4 compared with the MB-6 group (28.9% vs 2.9%, respectively, P = .004) and a significantly higher occurrence of increased serum creatinine compared with the MB-6 group (29% vs 5.9%, P = .014). MB-6 is a promising botanical supplement that may increase the effectiveness of chemotherapy in patients with metastatic colorectal cancer.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>William Tzu-Liang</ForeName>
                    <Initials>WT</Initials>
                    <Affiliation>Division of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, Taiwan. Electronic address: wtchen@mail.cmuh.org.tw.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Tsia-Sheng</ForeName>
                    <Initials>TS</Initials>
                    <Affiliation>Division of Medical Oncology in the Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan and Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Hung-Chang</ForeName>
                    <Initials>HC</Initials>
                    <Affiliation>Division of Colorectal Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Hong-Hwa</ForeName>
                    <Initials>HH</Initials>
                    <Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiang</LastName>
                    <ForeName>Hua-Che</ForeName>
                    <Initials>HC</Initials>
                    <Affiliation>Division of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Tsang-Chi</ForeName>
                    <Initials>TC</Initials>
                    <Affiliation>Division of Colorectal Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yeh</LastName>
                    <ForeName>Chung-Hung</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Division of Colon and Rectal Surgery, Jia-Yi St Martin de Porres Hospital, Chiayi, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ke</LastName>
                    <ForeName>Tao-Wei</ForeName>
                    <Initials>TW</Initials>
                    <Affiliation>Division of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jen-Shi</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Division of Medical Oncology in the Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan and Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsiao</LastName>
                    <ForeName>Koung-Hung</ForeName>
                    <Initials>KH</Initials>
                    <Affiliation>Department of Colorectal Surgery, Taipei Buddhist Tzu Chi General Hospital, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuo</LastName>
                    <ForeName>Min-Liang</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>Institute of Biochemical Sciences, National Taiwan University College of Life Science and Institute of Toxicology of Medicine National Taiwan University, Taipei, Taiwan; Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nutr Res</MedlineTA>
            <NlmUniqueID>8303331</NlmUniqueID>
            <ISSNLinking>0271-5317</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BALB/c mice</Keyword>
            <Keyword MajorTopicYN="N">Herbal medicine</Keyword>
            <Keyword MajorTopicYN="N">MB-6</Keyword>
            <Keyword MajorTopicYN="N">Metastatic colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">Overall survival</Keyword>
            <Keyword MajorTopicYN="N">Progression-free survival</Keyword>
            <Keyword MajorTopicYN="N">Tolerability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0271-5317(14)00095-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.nutres.2014.06.010</ArticleId>
            <ArticleId IdType="pubmed">25150117</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150087</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0007</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental eye research</Title>
                <ISOAbbreviation>Exp. Eye Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of neonatal corticosterone and environmental enrichment on retinal ERK1/2 and CREB phosphorylation in adult mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4835(14)00228-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.exer.2014.08.007</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Exposure to Stimulating Environments (SE) during development may improve neuroplasticity in central nervous system, protect against neurotoxic damage, and promote neuronal recovery in adult life. While biochemical mechanisms of SE-promoted neuronal plasticity are well known in the brain, much less is known on the signaling cascade governing plasticity and neuroprotection in the retina. In order to investigate if in the retina signaling molecules involved in neuronal plasticity are affected by SE, neonatal CD-1 mice were exposed to moderate corticosterone levels (NC), supplemented through maternal milk during the first postnatal week, or to environmental enrichment (EE) conditions (physical and social stimuli) from early adolescence. Our results showed that both NC and EE increased the phosphorylation level of Extracellularly Regulated Kinase 1/2 (ERK1/2) and cAMP response element-binding protein (CREB) in the adult retinal tissue. Furthermore, we observed that activated ERK1/2 was restricted to M??ller cells, while pCREB was mostly present in the nuclei of retinal neurons. Neither NC, nor EE modified the expression of GFAP, a marker of M??ller cells activation. In conclusion our results indicate that both NC and EE activate ERK1/2 and CREB in the retina and provide a biochemical background for the neuroprotective activity exerted by SE against retinal damage. Furthermore, they support the role of M??ller glia as a key cell determinant of retinal neuroplasticity.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Matteucci</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Section of Molecular Neurobiology, Dep. Cell Biology &amp; Neuroscience, Istituto Superiore di Sanit??, Rome, Italy. Electronic address: andrea.matteucci@iss.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ceci</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Section of Behavioral Neuroscience, Dep. Cell Biology &amp; Neuroscience, Istituto Superiore di Sanit??, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mallozzi</LastName>
                    <ForeName>Cinzia</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Section of Molecular Neurobiology, Dep. Cell Biology &amp; Neuroscience, Istituto Superiore di Sanit??, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Macr??</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Section of Behavioral Neuroscience, Dep. Cell Biology &amp; Neuroscience, Istituto Superiore di Sanit??, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Malchiodi-Albedi</LastName>
                    <ForeName>Fiorella</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Section of Molecular Neurobiology, Dep. Cell Biology &amp; Neuroscience, Istituto Superiore di Sanit??, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Laviola</LastName>
                    <ForeName>Giovanni</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Section of Behavioral Neuroscience, Dep. Cell Biology &amp; Neuroscience, Istituto Superiore di Sanit??, Rome, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Eye Res</MedlineTA>
            <NlmUniqueID>0370707</NlmUniqueID>
            <ISSNLinking>0014-4835</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">M??ller cells</Keyword>
            <Keyword MajorTopicYN="N">cAMP response element-binding protein</Keyword>
            <Keyword MajorTopicYN="N">environmental enrichment</Keyword>
            <Keyword MajorTopicYN="N">extracellularly regulated kinase 1/2</Keyword>
            <Keyword MajorTopicYN="N">neonatal corticosterone</Keyword>
            <Keyword MajorTopicYN="N">neuronal plasticity</Keyword>
            <Keyword MajorTopicYN="N">retina</Keyword>
            <Keyword MajorTopicYN="N">stimulating environments</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25150087</ArticleId>
            <ArticleId IdType="pii">S0014-4835(14)00228-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.exer.2014.08.007</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150073</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1735-1502</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Iranian journal of allergy, asthma, and immunology</Title>
                <ISOAbbreviation>Iran J Allergy Asthma Immunol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of Dexamethasone and Nigella sativa on Inducible Nitric Oxide Synthase in the Lungs of a Murine Model of Allergic Asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>324-34</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The aim of this study was to investigate the effects of Nigella sativa (NS) fixed oil in comparison to dexamethasone (Dex) on inducible nitric oxide synthase (iNOS), peripheral blood eosinophils (PBE), allergen specific serum IgG1 and interleukins and airway inflammation in a murine model of allergic asthma. Thirty-one mice were divided into four groups. Group I (n = 6) served as the control group. Group II (n = 10) mice were sensitized intraperitoneally and challenged intratracheally with cone albumin with no treatment. Group III(n = 6) mice were sensitized, challenged, and treated with Dex for 17 days starting at 24 hours after the first challenge. Group IV (n = 9) mice were sensitized, challenged, and treated with NS fixed oil for 17 days as well. For all groups, the following procedures were carried out: immunohistochemical study of iNOS in lung tissues, detection of PBE percentage, and histopathological examination of lung tissues for inflammatory cells. Lung tissue iNOS expression increased in sensitized, non-treated mice compared with controls, but this increase was not significant. NS fixed oil treatment significantly reduced PBE and lung inflammation but did not significantly reduce lung tissue iNOS expression compared with the control group. These effects were comparable to the effects of Dex. These results suggest that Nigella sativa exhibits immunomodulatory and anti-inflammatory effect which may be useful for treatment of allergic asthma.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Abdel-Aziz</LastName>
                    <ForeName>Mohamed</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Biotechnology Research Unit, Gastro-enterology Center, Mansoura University, Mansoura, Egypt.. azizhkh@yahoo.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abass</LastName>
                    <ForeName>Ayman</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Biotechnology Research Unit, Gastro-enterology Center, Mansoura University, Mansoura, Egypt andKing Fahd Medical Research Center, King Abdulaziz University, P.O. Box, 80216 Jeddah 21589 ,Kingdom of Saudi Arabia. aymntalat2001@yahoo.co.uk.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zalata</LastName>
                    <ForeName>Khaled</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Pathology Departments ,Faculty of Medicine, Mansoura University, Mansoura, Egypt.. Zalata@yahoo.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abd Al-Galel</LastName>
                    <ForeName>Tarek</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Pediatric Allergy and Immunology Departments ,Faculty of Medicine, Mansoura University, Mansoura, Egypt. desoky@yahoo.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allam</LastName>
                    <ForeName>Umamma</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>King Fahd Medical Research Center, King Abdulaziz University, P.O. Box, 80216 Jeddah 21589 ,Kingdom of Saudi Arabia. umamaabdelalsalam@gmail.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karrouf</LastName>
                    <ForeName>Gamal</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>King Fahd Medical Research Center, King Abdulaziz University, P.O. Box, 80216 Jeddah 21589 ,Kingdom of Saudi Arabia and Department of Surgery, Anesthesiology &amp; Radiology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, 35516 Dakahlia, Egypt. gkarrouf@kau.edu.sa.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Iran J Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>101146178</NlmUniqueID>
            <ISSNLinking>1735-1502</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25150073</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150072</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1735-1502</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Iranian journal of allergy, asthma, and immunology</Title>
                <ISOAbbreviation>Iran J Allergy Asthma Immunol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of inhaled L-arginine administration in a murine model of acute asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>317-23</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Increased arginase activity in the airways decreases L-arginine and causes deficiency of bronchodilating and anti-inflammatory nitric oxide (NO) in asthma. As, it is suggested that L-arginine may have therapeutic potential in asthma treatment, we aimed to investigate the effects of inhaled L-arginine on oxygen saturation (SaO2) and airway histology in a murine model of acute asthma. Twenty eight BALB/c mice were divided into four groups; I, II, III and IV (control). All groups except the control were sensitized and challenged with ovalbumin. After establishement of acute asthma attack by metacholine administration, the mice were treated with inhaled L-arginine (Group I), saline (Group II) and budesonide (Group III), respectively. SaO2 was measured by pulse oximeter just before and 5 min after methacholine. A third measurement of SaO2 was also obtained 15 min after drug administration in these study groups. Inflammation in the lung tissues of the sacrificed animals were scored to determine the effects of the study drugs. The number of eosinophils in bronchoalveolar lavage (BAL) was determined. The results indicated that inflammatory scores significantly improved in groups receiving study drugs when compared with placebo and L-arginine was similar in decreasing scores when compared with budesonide. SaO2 had a tendency to increase after L-arginine administration after acute asthma attack and this increase was statistically significant (p=0.043). Eosinophilia in BAL significantly reduced in group receiving L-arginine when compared with placebo (p&lt;0.05). Thus in this study we demonstrated that L-arginine improved SaO2 and inflammatory scores in an acute model of asthma.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Arikan-Ayyildiz</LastName>
                    <ForeName>Zeynep</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Pediatric Allergy and Immunology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. zeynep.ayyildiz@deu.edu.tr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karaman</LastName>
                    <ForeName>Meral</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Experimental Animal Laboratory, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. meral.karaman@deu.edu.tr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Firinci</LastName>
                    <ForeName>Fatih</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Pediatric Allergy and Immunology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. fatih.firinci@deu.edu.tr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kiray</LastName>
                    <ForeName>Muge</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. muge.kiray@deu.edu.tr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bagriyanik</LastName>
                    <ForeName>Alper</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Histology and Embryology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. alper.bagriyanik@deu.edu.tr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yilmaz</LastName>
                    <ForeName>Osman</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Experimental Animal Laboratory, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. osman.yilmaz@deu.edu.tr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uzuner</LastName>
                    <ForeName>Nevin</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Pediatric Allergy and Immunology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. nuzuner@deu.edu.tr.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karaman</LastName>
                    <ForeName>Ozkan</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Pediatric Allergy and Immunology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. ozkan.karaman@deu.edu.tr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Iran J Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>101146178</NlmUniqueID>
            <ISSNLinking>1735-1502</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25150072</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150071</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1735-1502</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Iranian journal of allergy, asthma, and immunology</Title>
                <ISOAbbreviation>Iran J Allergy Asthma Immunol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation of the adjuvant activity of propranolol, a Beta-adrenergic receptor antagonist, on efficacy of a malaria vaccine model in BALB/c mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>307-16</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We have previously shown the adjuvant activity of propranolol (PRP) (a beta-adrenergic receptor antagonist) using a vaccine model for Salmonella typhimurium. In this study PRP was used as an adjuvant in combination with Plasmodium berghei (P. berghei) whole blood stage (PWBS) antigens. BALB/c mice were immunized three times with a 2-week interval, either PWBS vaccine alone or in combination with the adjuvant alum or propranolol. The control group received phosphate buffered saline. Evaluation of the cellular and humoral immunity was performed by measurement of interferon (IFN)-??, tumor necrosis factor (TNF)-??, lymphocyte proliferation, total IgG and IgG2a in the control and immunized groups. Furthermore, Clinical evaluations were carried out by analyze survival rate and parasitemia of the mice. Our results showed that the mice immunized with propranolol induced higher levels of antibody, IFN-?? and TNF-?? as well as stronger lymphocyte proliferative responses compared with other groups. This resulted in improved protective immunity against Plasmodium berghei. Administration of the PRP as an adjuvant in combination with the PWBS Antigen vaccine can shift the immune responses to a T helper1 pattern and enhance the protective immunity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shahabi</LastName>
                    <ForeName>Shahram</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Cellular and Molecular Research Center; Urmia University of Medical Sciences, Urmia, Iran and Department of Microbiology, Immunology and Genetics, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. shahabirabori@yahoo.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohammadzadeh Hajipirloo</LastName>
                    <ForeName>Habib</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Medical Parasitology and Mycology; Faculty of Medicine;Urmia University of Medical Sciences; Urmia; Iran. habibmhaji@yahoo.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keramati</LastName>
                    <ForeName>Ahmad</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medical Parasitology and Mycology; Faculty of Medicine;Urmia University of Medical Sciences; Urmia; Iran. sa.karamati@yahoo.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hazrati Tappeh</LastName>
                    <ForeName>Khosrow</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Cellular and Molecular Research Center; Urmia University of Medical Sciences, Urmia, Iran and Department of Medical Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. hazrati_tappeh@yahoo.co.nz.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bozorgomid</LastName>
                    <ForeName>Arezoo</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. arezoobozorgomid@yahoo.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Iran J Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>101146178</NlmUniqueID>
            <ISSNLinking>1735-1502</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25150071</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150065</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1504</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Lung cellular and molecular physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Lung Cell Mol. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The role of MMP2 and MMP9 in TRPV4-induced lung injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajplung.00113.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Ca(2+) entry through TRPV4 (transient receptor potential vanilloid 4) results in swelling, blebbing and detachment of the epithelium and capillary endothelium in the intact lung. Subsequently, increased permeability of the septal barrier and alveolar flooding ensue. In this study, we tested the hypothesis that TRPV4 activation provides a Ca(2+) source necessary for proteolytic disruption of cell-cell or cell-matrix adhesion by matrix metalloproteinases (MMPs) MMP2 and MMP9, thus increasing septal barrier permeability. In our study, C57BL/6 or TRPV4(-/-) mouse lungs were perfused with varying doses of the TRPV4 agonist GSK1016790A (Sigma) and then prepared for Western Blot. Lung injury, assessed by increases in lung wet-to-dry weight ratios and total protein levels in the bronchoalveolar lavage fluid, was increased in a dose-dependent fashion in TRPV4(+/+) but not TRPV4(-/-) lungs. In concert with lung injury, we detected increased active MMP2 and MMP9 isoforms, suggesting that TRPV4 can provide the Ca(2+) source necessary for increased MMP2/9 activation. Further, tissue inhibitor of metalloproteinases (TIMP) 2 levels in the TRPV4-injured lungs were decreased, suggesting that TRPV4 activation increases the availability of these active MMPs. We then determined whether MMP2 and MMP9 mediate TRPV4-induced lung injury. Pharmacological blockade (SB-3CT, 1??M, Sigma) of MMP2 and MMP9 resulted in protection against TRPV4-induced lung injury. We conclude that TRPV4 activation and the subsequent Ca(2+) transient initiates a rapid cascade of events leading to release and activation of the gelatinase MMPs, which then contribute to lung injury.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Lung Cellular and Molecular Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Villalta</LastName>
                    <ForeName>Patricia Caridad</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>University of South Alabama.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rocic</LastName>
                    <ForeName>Petra</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>New York Medical College.</Affiliation>
                </Author>
                <Author>
                    <LastName>Townsley</LastName>
                    <ForeName>Mary I</ForeName>
                    <Initials>MI</Initials>
                    <Affiliation>University of South Alabama mtownsley@southalabama.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Lung Cell Mol Physiol</MedlineTA>
            <NlmUniqueID>100901229</NlmUniqueID>
            <ISSNLinking>1040-0605</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MMP2</Keyword>
            <Keyword MajorTopicYN="N">MMP9</Keyword>
            <Keyword MajorTopicYN="N">TRPV4</Keyword>
            <Keyword MajorTopicYN="N">acute lung injury</Keyword>
            <Keyword MajorTopicYN="N">lung permeability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajplung.00113.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajplung.00113.2014</ArticleId>
            <ArticleId IdType="pubmed">25150065</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150064</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1504</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Lung cellular and molecular physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Lung Cell Mol. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Basal levels of glutathione peroxidase correlate with onset of radiation induced lung disease in inbred mouse strains.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajplung.00088.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Biomarkers predicting for the radiation-induced lung responses of pneumonitis or fibrosis are largely unknown. Herein we investigated whether markers of oxidative stress and intracellular antioxidants, measured within days of radiation exposure, are correlated with the lung tissue injury response occurring weeks later. Mice of the eight inbred strains differing in their susceptibility to radiation induced pulmonary fibrosis, and in the duration of asymptomatic survival, received 18 Gy whole thorax irradiation and were euthanized 6h, 24h or 7d later. Control mice were not irradiated. Lung levels of antioxidants superoxide dismutase, catalase, glutathione peroxidase (GPx) and glutathione, and of oxidative damage (reactive oxygen species (ROS) and 8-hydroxydeoxyguanosine (8-OHdG)), were biochemically determined. Glutathione peroxidase was additionally measured through gene expression and immunohistochemical assessment of lung tissue; and activity in serum. ROS and 8-OHdG were increased post irradiation and exhibited significant strain and time dependent variability, but were not strongly predictive of radiation-induced lung diseases. Antioxidant measures were not dramatically changed post irradiation and varied significantly among the strains. Basal GPx activity (r = 0.73, p=0.04) in the lung and the pulmonary expression of GPx2 (r = 0.94, p = 0.0003) correlated with post irradiation asymptomatic survival, while serum GPx activity was inversely correlated (r = -0.80, p=0.01) with fibrosis development, In conclusion pulmonary oxidative stress and antioxidant markers were more affected by inbred strain than radiation over 7 days post treatment. Lung GPx activity, and GPx2 expression, predicted for survival from lethal pneumonitis, and serum GPx for fibrosis, in this panel of mice.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Lung Cellular and Molecular Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kunwar</LastName>
                    <ForeName>Amit</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>McGill University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Haston</LastName>
                    <ForeName>Christina K</ForeName>
                    <Initials>CK</Initials>
                    <Affiliation>McGill University christina.haston@mcgill.ca.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Lung Cell Mol Physiol</MedlineTA>
            <NlmUniqueID>100901229</NlmUniqueID>
            <ISSNLinking>1040-0605</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">glutathione peroxidase</Keyword>
            <Keyword MajorTopicYN="N">mouse strains</Keyword>
            <Keyword MajorTopicYN="N">pneumonitis</Keyword>
            <Keyword MajorTopicYN="N">radiotherapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajplung.00088.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajplung.00088.2014</ArticleId>
            <ArticleId IdType="pubmed">25150064</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150063</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1504</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Lung cellular and molecular physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Lung Cell Mol. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Regulation of fibroblast lipid-storage and myofibroblast phenotypes during alveolar septation in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajplung.00144.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Signaling through platelet-derived growth factor receptor-alpha (PDGFR??) is required for alveolar septation and participates in alveolar regeneration after pneumonectomy. In both adipose tissue and skeletal muscle, bi-potent pdgfr??-expressing progenitors expressing delta-like ligand-1 (Dlk1) or Sex-determining region Y box 9 (Sox9), may differentiate into either lipid-storage cells or myofibroblasts. We analyzed markers of mesenchymal progenitors and differentiation in lung fibroblasts (LF) with different levels (absent, low or high) of pdgfr??-gene expression. A larger proportion of pdgfr??-expressing than non-expressing LF contained Sox9. Neutral lipids, CD166, and Tcf21 were more abundant in LF with a lower compared to a higher level of pdgfr??-gene expression. PDGF-A increased Sox9 in primary LF cultures, suggesting that active signaling through PDGFR?? is required to maintain Sox9. As alveolar septation progresses from postnatal day-8 (P8) to P12, fewer pdgfr??-expressing LF contain Sox9, whereas more of these LF contain myocardin-like transcription factor-A, showing that Sox9 diminishes as LF become myofibroblasts. At P8, neutral lipid droplets predominate in LF with the lower level of pdgfr??-gene expression, whereas transgelin (tagln) was predominantly expressed in LF with higher pdgfr?? gene-expression. Targeted deletion of pdgfr?? in LF which expressed tagln, reduced Sox9 in alpha-actin (??SMA, ACTA2) containing LF, whereas it increased the abundance of cell-surface Dlk1 as well as peroxisome proliferator activated receptor-gamm (ppar?? and tcf21 mRNA in LF which also expressed stem cell antigen-1 (Sca1). Thus pdgfr??-deletion differentially alters Dlk1 and Sox9, suggesting that targeting different downstream pathways in PDGF-A responsive LF could identify strategies which promote lung regeneration without initiating fibrosis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Lung Cellular and Molecular Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>McGowan</LastName>
                    <ForeName>Stephen E</ForeName>
                    <Initials>SE</Initials>
                    <Affiliation>University of Iowa College of Medicine stephen-mcgowan@uiowa.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>McCoy</LastName>
                    <ForeName>Diann M</ForeName>
                    <Initials>DM</Initials>
                    <Affiliation>University of Iowa Carver College of Medicine.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Lung Cell Mol Physiol</MedlineTA>
            <NlmUniqueID>100901229</NlmUniqueID>
            <ISSNLinking>1040-0605</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Sex-determining region Y box 9</Keyword>
            <Keyword MajorTopicYN="N">adipocyte</Keyword>
            <Keyword MajorTopicYN="N">fibroblast</Keyword>
            <Keyword MajorTopicYN="N">lung alveolarization</Keyword>
            <Keyword MajorTopicYN="N">stem cell</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajplung.00144.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajplung.00144.2014</ArticleId>
            <ArticleId IdType="pubmed">25150063</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150062</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1504</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Lung cellular and molecular physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Lung Cell Mol. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>cAMP-dependent protein kinase activation decreases cytokine release in bronchial epithelial cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajplung.00373.2013</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Lung injury caused by inhalation of dust from swine concentrated animal feeding operations (CAFO) involves the release of inflammatory cytokine interleukin 8 (IL-8), which is mediated by protein kinase C epsilon (PKC??) in airway epithelial cells. Once activated by CAFO dust, PKC?? is responsible for slowing cilia beating and reducing cell migration for wound repair. Conversely, the cAMP-dependent protein kinase (PKA) stimulates contrasting effects, such as increased cilia beating and an acceleration of cell migration for wound repair. We hypothesized that a bidirectional mechanism involving PKA and PKC regulates epithelial airway inflammatory responses. To test this hypothesis, primary human bronchial epithelial cells and BEAS-2B cells were treated with hog dust extract (HDE) in the presence or absence of cAMP. PKC?? activity was significantly reduced in cells that were pre-treated for one hour with 8-Br-cAMP before exposure to HDE (p&lt;0.05). HDE-induced IL-6 and IL-8 release was significantly lower in cells that were pre-treated with 8-Br-cAMP (p&lt;0.05). To exclude exchange protein activated by cAMP (EPAC) involvement, cells were pre-treated with either 8-Br-cAMP or 8CPT-2Me-cAMP (EPAC agonist). 8CPT-2Me-cAMP did not activate PKA and did not reduce HDE-stimulated IL-6 release. In contrast, 8-Br-cAMP decreased HDE-stimulated TNF?? converting enzyme (TACE; ADAM-17) activity and subsequent TNF?? release (p &lt;0.001). 8-Br-cAMP also blocked HDE-stimulated IL-6 and keratinocyte-derived chemokine (KC) release in precision-cut mouse lung slices (p&lt;0.05). These data show bidirectional regulation of PKC?? via a PKA-mediated inhibition of TACE activity resulting in reduced PKC??-mediated release of IL-6 and IL-8.</AbstractText>
                <CopyrightInformation>Copyright ?? 2013, American Journal of Physiology - Lung Cellular and Molecular Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wyatt</LastName>
                    <ForeName>Todd A</ForeName>
                    <Initials>TA</Initials>
                    <Affiliation>University of Nebraska Medical Center twyatt@unmc.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Poole</LastName>
                    <ForeName>Jill A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>University of Nebraska Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nordgren</LastName>
                    <ForeName>Tara M</ForeName>
                    <Initials>TM</Initials>
                    <Affiliation>University of Nebraska Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>DeVasure</LastName>
                    <ForeName>Jane M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>1University of Nebraska Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Heires</LastName>
                    <ForeName>Art J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>University of Nebraska Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bailey</LastName>
                    <ForeName>Kristina L</ForeName>
                    <Initials>KL</Initials>
                    <Affiliation>University of Nebraska Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Romberger</LastName>
                    <ForeName>Debra J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>University of Nebraska Medical Center.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Lung Cell Mol Physiol</MedlineTA>
            <NlmUniqueID>100901229</NlmUniqueID>
            <ISSNLinking>1040-0605</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">PKA</Keyword>
            <Keyword MajorTopicYN="N">PKC epsilon</Keyword>
            <Keyword MajorTopicYN="N">cytokine</Keyword>
            <Keyword MajorTopicYN="N">lung</Keyword>
            <Keyword MajorTopicYN="N">organic dust</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajplung.00373.2013</ArticleId>
            <ArticleId IdType="doi">10.1152/ajplung.00373.2013</ArticleId>
            <ArticleId IdType="pubmed">25150062</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150061</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1504</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Lung cellular and molecular physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Lung Cell Mol. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Genome-wide Transcriptional Response to Neonatal Hyperoxia Identifies Ahr as a Key Regulator.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajplung.00200.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Premature infants requiring supplemental oxygen are at increased risk for developing Bronchopulmonary Dysplasia (BPD). Rodent models involving neonatal exposure to excessive oxygen concentrations (hyperoxia) have helped to identify mechanisms of BPD-associated pathology. Genome-wide assessments of the effects of hyperoxia in neonatal mouse lungs could identify novel BPD related genes and pathways. Newborn C57BL/6 mice were exposed to 100% oxygen for 10 days, and whole lung tissue RNA was used for high-throughput, sequencing-based transcriptomic analysis (RNA-Seq). Significance Analysis of Microarrays and Ingenuity Pathway Analysis were used to identify genes and pathways affected. Expression patterns for selected genes were validated by qPCR. Mechanistic relationships between genes were further tested in cultured mouse lung epithelial cells. We identified 300 genes significantly and substantially affected following acute neonatal hyperoxia. Canonical pathways dysregulated in hyperoxia lungs included Nrf2-mediated oxidative stress signaling, p53 signaling, eNOS signaling and aryl hydrocarbon receptor pathways. Cluster analysis identified Ccnd1, Cdkn1a and Ahr as critical regulatory nodes in the response to hyperoxia, with Ahr serving as the major effector node. A mechanistic role for Ahr was assessed in lung epithelial cells, and we confirmed its ability to regulate the expression of multiple hyperoxia markers including Cdkn1a, Pdgfrb and A2m. We conclude that a global assessment of gene regulation in the acute neonatal hyperoxia model of BPD-like pathology has identified Ahr as one driver of gene dysregulation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Lung Cellular and Molecular Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Bhattacharya</LastName>
                    <ForeName>Soumyaroop</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Zhongyang</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yee</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Rochester.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chu</LastName>
                    <ForeName>Chin-Yi</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lopez</LastName>
                    <ForeName>Ashley M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lunger</LastName>
                    <ForeName>Valerie A</ForeName>
                    <Initials>VA</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Solleti</LastName>
                    <ForeName>Siva K</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Resseguie</LastName>
                    <ForeName>Emily</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>University of Rochester Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Buczynski</LastName>
                    <ForeName>Bradley W</ForeName>
                    <Initials>BW</Initials>
                    <Affiliation>The University of Rochester.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mariani</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>Univ Rochester Tom_Mariani@URMC.Rochester.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>O'Reilly</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>The University of Rochester.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Lung Cell Mol Physiol</MedlineTA>
            <NlmUniqueID>100901229</NlmUniqueID>
            <ISSNLinking>1040-0605</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AHR</Keyword>
            <Keyword MajorTopicYN="N">BPD</Keyword>
            <Keyword MajorTopicYN="N">RNA-Seq</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajplung.00200.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajplung.00200.2014</ArticleId>
            <ArticleId IdType="pubmed">25150061</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150043</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1741-7899</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Reproduction (Cambridge, England)</Title>
                <ISOAbbreviation>Reproduction</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Testis tissue xenografting: twelve years of an in vivo spermatogenesis system.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">REP-14-0249</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Spermatogenesis is a dynamic and complex process that involves endocrine and testicular factors. During xenotransplantation of testicular tissue fragments into immunodecifient mouse mice a functional communication between host brain and donor testis is established. This interaction allows for the progression of a normal spermatogenesis and recovery of fertilization-competent spermatozoa from a broad range of mammalian species. In the last years, significant progression have has been achieved in testis tissue xenografting that improves our knowledge about factors determining the success of grafting. The goal of this review is to provide up to date information about the role of factors such as donor age, donor species, testis tissue preservation or type of recipient mouse on the efficiency of this technique. Applications will be are described and compared with other techniques with similar purposes. Recent works demonstrates that testicular tissue xenografting is being used as a model to study gonadotoxicity of drugs and to obtain sperm from valuable young males.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Arregui</LastName>
                    <ForeName>Lucia</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>L Arregui, Department of Biology, Universidad Autonoma de Madrid, Madrid, Spain lucia.arregui@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dobrinski</LastName>
                    <ForeName>Ina</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>I Dobrinski, Department of Comparative Biology &amp; Experimental Medicine, University of Calgary, Calgary, Canada.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Reproduction</MedlineTA>
            <NlmUniqueID>100966036</NlmUniqueID>
            <ISSNLinking>1470-1626</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">REP-14-0249</ArticleId>
            <ArticleId IdType="doi">10.1530/REP-14-0249</ArticleId>
            <ArticleId IdType="pubmed">25150043</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150042</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7549</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioural brain research</Title>
                <ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>6-HYDROXYDOPAMINE LESIONS OF THE ANTEROMEDIAL VENTRAL STRIATUM IMPAIR OPPOSITE-SEX URINARY ODOR PREFERENCE IN FEMALE MICE.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0166-4328(14)00536-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbr.2014.08.024</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Rodents rely upon their olfactory system to perceive opposite-sex pheromonal odors needed to motivate courtship behaviors. Volatile and nonvolatile components of pheromonal odors are processed by the main (MOS) and accessory olfactory system (AOS), respectively, with inputs converging in the medial amygdala (Me). The Me in turn targets the mesolimbic dopamine system, including the nucleus accumbens core (AcbC) and shell (AcbSh), the ventral pallidum (VP), medial olfactory tubercle (mOT) and ventral tegmental area (VTA). We hypothesized that pheromone-induced dopamine (DA) release in the ventral striatum (particularly in the mAcb and mOT) may mediate the normal preference of female mice to investigate male pheromones. We made bilateral 6-OHDA lesions of DA fibers innervating either the mAcb alone or the mAcb+mOT in female mice and tested estrous females' preference for opposite-sex urinary odors. We found that 6-OHDA lesions of either the mAcb alone or the mAcb+mOT significantly reduced the preference of sexually na??ve female mice to investigate breeding male urinary odors (volatiles as well as volatiles+nonvolatiles) vs. estrous female urinary odors. These same neurotoxic lesions had no effect on subjects' ability to discriminate between these two urinary odors, on their locomotor activity, or on their preference for consuming sucrose. The integrity of the dopaminergic innervation of the mAcb and mOT is required for female mice to prefer investigating male pheromones.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>DiBenedictis</LastName>
                    <ForeName>Brett T</ForeName>
                    <Initials>BT</Initials>
                    <Affiliation>Department of Biology, Boston University, Boston, MA 02215, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Olugbemi</LastName>
                    <ForeName>Adaeze O</ForeName>
                    <Initials>AO</Initials>
                    <Affiliation>Department of Biology, Boston University, Boston, MA 02215, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Baum</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Department of Biology, Boston University, Boston, MA 02215, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cherry</LastName>
                    <ForeName>James A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Department of Psychological and Brain Sciences, Boston University, Boston, MA 02215, United States. Electronic address: jcherry@bu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Behav Brain Res</MedlineTA>
            <NlmUniqueID>8004872</NlmUniqueID>
            <ISSNLinking>0166-4328</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Dopamine</Keyword>
            <Keyword MajorTopicYN="N">nucleus accumbens</Keyword>
            <Keyword MajorTopicYN="N">olfactory</Keyword>
            <Keyword MajorTopicYN="N">olfactory tubercle</Keyword>
            <Keyword MajorTopicYN="N">sociosexual behavior</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0166-4328(14)00536-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbr.2014.08.024</ArticleId>
            <ArticleId IdType="pubmed">25150042</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150000</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1734-1140</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological reports : PR</Title>
                <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacokinetics of phosphocreatine and its active metabolite creatine in the mouse plasma and myocardium.</ArticleTitle>
            <Pagination>
                <MedlinePgn>908-14</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharep.2014.05.013</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1734-1140(14)00209-6</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The pharmacokinetic (PK) studies of phosphocreatine (PCr) and its active metabolite creatine (Cr) are considerably lacking. This study is to comparatively investigate the PK profiles of PCr and Cr in mice plasma and myocardium as well as the ATP level.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">After iv administration of equimolar PCr and preformed Cr to healthy and Pit-induced myocardial ischemic mice, plasma and myocardium samples were analyzed for exogenous PCr, Cr and related ATP concentrations using a specific ion-pair reversed-phase HPLC-UV assay.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The plasma C-T data of iv PCr and Cr were well fitted to two-compartment model. Following iv PCr, Cr appeared in plasma as early as 1.0min postdose with a longer t1/2 than PCr and had a fm of 72%. The mice dosed iv PCr preceded 5min by ip Pit 30U/kg showed longer t1/2?? PCr and t1/2 Cr in plasma and elevated Cmax, Cr and Cmax, ATP in myocardium compared with mice dosed iv PCr alone, and it was estimated that about 40% ATP produced by iv PCr was from Cr.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The PCr in plasma is converted to Cr rapidly and mostly, and shows an elimination rate limited (ERL) metabolite disposition. Iv PCr caused a significantly elevated and long-lasing myocardial ATP and Cr levels. The Pit-induced myocardial ischemia brings slower elimination of PCr and Cr and higher peak concentrations of Cr and ATP in myocardium. The metabolite Cr at least partially mediates PCr-caused rise in myocardial ATP level and also possibly the cardio-protective effects of PCr.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Medical Affairs, The First Affiliated Hospital, Dalian Medical University, Dalian, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chang-Yuan</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lv</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ke-Xin</ForeName>
                    <Initials>KX</Initials>
                    <Affiliation>Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Hui-Jun</ForeName>
                    <Initials>HJ</Initials>
                    <Affiliation>Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China. Electronic address: sunhuijun@hotmail.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Guo-Zhu</ForeName>
                    <Initials>GZ</Initials>
                    <Affiliation>Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China. Electronic address: hgzhx2236@sina.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Pharmacol Rep</MedlineTA>
            <NlmUniqueID>101234999</NlmUniqueID>
            <ISSNLinking>1734-1140</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Creatine</Keyword>
            <Keyword MajorTopicYN="N">HPLC</Keyword>
            <Keyword MajorTopicYN="N">Mouse</Keyword>
            <Keyword MajorTopicYN="N">Pharmacokinetics</Keyword>
            <Keyword MajorTopicYN="N">Phosphocreatine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1734-1140(14)00209-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pharep.2014.05.013</ArticleId>
            <ArticleId IdType="pubmed">25150000</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149996</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1734-1140</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological reports : PR</Title>
                <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Possible involvement of GABAergic and nitriergic systems for antianxiety-like activity of piperine in unstressed and stressed mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>885-91</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharep.2014.05.008</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1734-1140(14)00204-7</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An investigation was made to explore the possibility of anxiolytic activity of piperine in unstressed and stressed mice along with the underlying role of nitriergic and GABAergic modulation for the noted activity of piperine.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Piperine (5, 10 and 20mg/kg, ip) was administered to unstressed mice. In another groups of animals, piperine was administered 30min before subjecting them to immobilization stress for 6h. Antianxiety activity was evaluated by employing elevated plus maze, light-dark box and social interaction test. Diazepam was employed as standard anxiolytic drug.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Piperine produced significant antianxiety-like activity in unstressed and stressed mice. The anxiolytic-like activity of piperine was comparable to diazepam. In unstressed mice, piperine significantly increased brain GABA levels, but could not produce any change in plasma nitrite levels. Meanwhile, in stressed mice, piperine did not produce any significant change in GABA levels, but significantly decreased nitrite levels. Pre-treatment with aminoguanidine (50mg/kg, ip), an inducible nitric oxide synthase (NOS) inhibitor, significantly potentiated the anxiolytic-like activity of piperine, as compared to piperine and aminoguanidine alone in stressed mice. On the other hand, pretreatment with 7-nitroindazole (20mg/kg, ip), a neuronal NOS inhibitor significantly potentiated the antianxiety-like activity of piperine, as compared to piperine and 7-nitroindazole alone in unstressed mice.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data suggest that the piperine produced significant anxiolytic activity in unstressed mice possibly through increase in GABA levels and inhibition of neuronal NOS. On the other hand, antianxiety activity in stressed mice might be through inhibition of inducible NOS.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gilhotra</LastName>
                    <ForeName>Neeraj</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India. Electronic address: neerajmdu@rediffmail.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dhingra</LastName>
                    <ForeName>Dinesh</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Guru Jambeshwar University of Science and Technology, Hisar, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Pharmacol Rep</MedlineTA>
            <NlmUniqueID>101234999</NlmUniqueID>
            <ISSNLinking>1734-1140</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anxiety</Keyword>
            <Keyword MajorTopicYN="N">GABA</Keyword>
            <Keyword MajorTopicYN="N">Inducible NOS</Keyword>
            <Keyword MajorTopicYN="N">Neuronal NOS</Keyword>
            <Keyword MajorTopicYN="N">Piperine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1734-1140(14)00204-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pharep.2014.05.008</ArticleId>
            <ArticleId IdType="pubmed">25149996</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149990</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1734-1140</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological reports : PR</Title>
                <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Vague effects of chronic topiramate administration on maximal electroshock-induced seizures in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>852-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharep.2014.05.006</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1734-1140(14)00202-3</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Almost all experimental studies evaluating interactions between antiepileptic and non-antiepileptic drugs are based on their single administration, whereas epileptic patients require chronic pharmacotherapy. Herein, we attempted to figure out whether single and repeated administration of topiramate leads to the same anticonvulsant and undesired effects.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Experiments were conducted in the model of maximal electroshock in mice. Motor coordination was evaluated in the chimney test. Brain concentrations of topiramate were determined by high-performance liquid chromatography and triple quadrupole mass spectrometry.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The anticonvulsant activity of topiramate administered once or twice a day for 7 days did not significantly differ from the respective effect of topiramate given acutely in a single injection. However, calculating of 50% effective doses for topiramate applied in 14-days protocol (once or two times a day) was impossible. The antiepileptic administered at the dose range of 80-150mg/kg did not offer protection in more than 50% of mice. This phenomenon cannot be attributed to pharmacokinetic events, because there were no significant differences between plasma and brain concentrations of topiramate after its acute and chronic administration. Topiramate (150mg/kg) did not affect motor performance in mice.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Maximal electroshock in mice does not seem to be an appropriate seizure model to test anticonvulsant effects of chronic topiramate.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Banach</LastName>
                    <ForeName>Monika</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Independent Unit of Experimental Neuropathophysiology, Department of Pathophysiology, Medical University of Lublin, Lublin, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Szpot</LastName>
                    <ForeName>Pawe??</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>The Laboratory of Forensic Toxicology, Medical University of Lublin, Lublin, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buszewicz</LastName>
                    <ForeName>Grzegorz</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>The Laboratory of Forensic Toxicology, Medical University of Lublin, Lublin, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borowicz</LastName>
                    <ForeName>Kinga K</ForeName>
                    <Initials>KK</Initials>
                    <Affiliation>Independent Unit of Experimental Neuropathophysiology, Department of Pathophysiology, Medical University of Lublin, Lublin, Poland. Electronic address: kinga.borowicz@umlub.pl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Pharmacol Rep</MedlineTA>
            <NlmUniqueID>101234999</NlmUniqueID>
            <ISSNLinking>1734-1140</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Chronic treatment</Keyword>
            <Keyword MajorTopicYN="N">Electroshock maximal</Keyword>
            <Keyword MajorTopicYN="N">Topiramate</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1734-1140(14)00202-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pharep.2014.05.006</ArticleId>
            <ArticleId IdType="pubmed">25149990</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149987</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1734-1140</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological reports : PR</Title>
                <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neuroligins, synapse balance and neuropsychiatric disorders.</ArticleTitle>
            <Pagination>
                <MedlinePgn>830-835</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S1734-1140(14)00167-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.pharep.2014.04.011</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Neuroligins are postsynaptic adhesion molecules that are involved in the regulation of synapse organisation and function. Four neuroligin proteins have been identified (neuroligin 1, 2, 3, 4), which are differentially enriched in the postsynaptic specialisation of synapses. Neuroligin 1 is localised on excitatory (glutamatergic) synapses, whereas neuroligin 2 is located on inhibitory (GABAergic/glycinergic) synapses. Neuroligin 3 and 4 are present on both types of synapses. Recent data indicate that neuroligins are involved in synapse maturation and specification. Because of their synaptic localisation and function, neuroligins control the balance between excitatory and inhibitory synapses. Animal studies with neuroligin transgenic mice showed the involvement of neuroligin 1 in memory formation, and neuroligin 2, 3 or 4 in social behaviour. Interestingly, genetic analysis of humans showed a mutation in the neuroligin 2 gene in schizophrenic patients, while mutations in neuroligin 3 or 4 genes were found in autism.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ma??kowiak</LastName>
                    <ForeName>Marzena</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratory of Pharmacology and Brain Biostructure, Institute of Pharmacology, Polish Academy of Sciences, Krak??w, Poland. Electronic address: mackow@if-pan.krakow.pl.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mordalska</LastName>
                    <ForeName>Patrycja</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Laboratory of Pharmacology and Brain Biostructure, Institute of Pharmacology, Polish Academy of Sciences, Krak??w, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>W??dzony</LastName>
                    <ForeName>Krzysztof</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratory of Pharmacology and Brain Biostructure, Institute of Pharmacology, Polish Academy of Sciences, Krak??w, Poland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pharmacol Rep</MedlineTA>
            <NlmUniqueID>101234999</NlmUniqueID>
            <ISSNLinking>1734-1140</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Autism</Keyword>
            <Keyword MajorTopicYN="N">Cell adhesion molecules</Keyword>
            <Keyword MajorTopicYN="N">Neuroligin</Keyword>
            <Keyword MajorTopicYN="N">Schizophrenia</Keyword>
            <Keyword MajorTopicYN="N">Synapse</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1734-1140(14)00167-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pharep.2014.04.011</ArticleId>
            <ArticleId IdType="pubmed">25149987</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149984</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1734-1140</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological reports : PR</Title>
                <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neuropharmacological effect of novel 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on chronic unpredictable mild stress-induced molecular and cellular response: Behavioural and biochemical evidences.</ArticleTitle>
            <Pagination>
                <MedlinePgn>804-10</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharep.2014.05.002</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1734-1140(14)00198-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chronic unpredictable stressors can produce a situation similar to human depression and such animal models can be used for the preclinical evaluation of antidepressants. The 5-HT3 receptor antagonists modulate serotonergic pathways and show antidepressant-like effect in various animal models of depression.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In this study, a novel and potential 5-HT3 receptor antagonist N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) with good Log P (2.52) value and pA2 (7.6) values, synthesized in our laboratory was explore to study the effects on CUMS-induced behavioural and biochemical alterations in mice. Mice were subjected to different stress paradigms daily for a period of 28 days to induce depressive-like behaviour.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">CUMS caused depression-like behaviour in mice, as indicated by the significant decrease in sucrose consumption and increase in immobility time in the forced swim test (FST) while there was no significant effect on spontaneous locomotor activity (SLA) observed. In addition it was found that lipid peroxide and nitrite levels were significantly increased, whereas glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) levels were decreased in brain tissue of CUMS-treated mice. Compound 6n (1 and 2mg/kg, po, 21 days) and fluoxetine treatment (20mg/kg, po, 21 days) significantly altered the CUMS-induced behavioural (increased immobility period, reduced sucrose preference) and biochemical (increased lipid peroxidation, increased brain nitrite; decreased GSH, SOD and CAT levels) parameters while there was no significant effect of observed on SLA.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Compound 6n produced antidepressant-like effects in behavioural despair paradigm in chronically stressed mice by restoring antioxidant enzyme activity up to significant level.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bhatt</LastName>
                    <ForeName>Shvetank</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pharmacy, Birla Institute of Technology &amp; Science, Pilani, India. Electronic address: shvetankbhatt@gmail.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahesh</LastName>
                    <ForeName>Radhakrishnan</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Pharmacy, Birla Institute of Technology &amp; Science, Pilani, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jindal</LastName>
                    <ForeName>Ankur</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pharmacy, Birla Institute of Technology &amp; Science, Pilani, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Devadoss</LastName>
                    <ForeName>Thangaraj</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Pharmacy, Birla Institute of Technology &amp; Science, Pilani, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Pharmacol Rep</MedlineTA>
            <NlmUniqueID>101234999</NlmUniqueID>
            <ISSNLinking>1734-1140</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">5-HT(3) receptor antagonist</Keyword>
            <Keyword MajorTopicYN="N">6n</Keyword>
            <Keyword MajorTopicYN="N">CUMS</Keyword>
            <Keyword MajorTopicYN="N">Catalase</Keyword>
            <Keyword MajorTopicYN="N">Glutathione</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1734-1140(14)00198-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pharep.2014.05.002</ArticleId>
            <ArticleId IdType="pubmed">25149984</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149981</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1734-1140</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological reports : PR</Title>
                <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Curcumin influences semen quality parameters and reverses the di(2-ethylhexyl)phthalate (DEHP)-induced testicular damage in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>782-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharep.2014.04.010</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1734-1140(14)00166-2</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Curcumin is a phytochemical derived from rhizome of turmeric Curcuma longa, present in the curry spice. Recently, it has attracted the attention of researchers and clinicians as an anti-inflammatory and anti-oxidant agent with a potential use in therapy of many diseases with an inflammatory component. Interestingly, curcumin despite its very low bioavailability showed protective activity against many organ lesions.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In the present study we investigated the effects of curcumin treatment on mice semen quality parameters in vitro and on semen and testicular damage induced by di(2-ethylhexyl)phthalate in vivo.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The study demonstrated protective effects of low concentrations (1-50??M) of curcumin on mouse sperm motility in vitro and on DEHP-induced damage of seminiferous tubules in testes and its ability to diminish the decrease in sperm motility in vivo. In contrast, curcumin used in high concentration (100??M) decreased sperm motility and viability in vitro.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The effects of curcumin were dependent on its concentration. In male germ cells in vivo the protective effect was seen despite the low bioavailability of curcumin. In contrast, high, unattainable in the organism, concentration of curcumin had a cytotoxic effect on male reproductive cells in vitro. Curcumin also had a protective effect against the harmful impact of DEHP on the male reproductive system.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>G??ombik</LastName>
                    <ForeName>Katarzyna</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Krak??w, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Basta-Kaim</LastName>
                    <ForeName>Agnieszka</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Krak??w, Poland. Electronic address: basta@if-pan.krakow.pl.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sikora-Polaczek</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Genetics and Evolution, Institute of Zoology, Jagiellonian University, Krak??w, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kubera</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Krak??w, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Starowicz</LastName>
                    <ForeName>Gabriela</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Krak??w, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Styrna</LastName>
                    <ForeName>J??zefa</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Genetics and Evolution, Institute of Zoology, Jagiellonian University, Krak??w, Poland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Pharmacol Rep</MedlineTA>
            <NlmUniqueID>101234999</NlmUniqueID>
            <ISSNLinking>1734-1140</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Curcumin</Keyword>
            <Keyword MajorTopicYN="N">DEHP</Keyword>
            <Keyword MajorTopicYN="N">Semen quality parameters</Keyword>
            <Keyword MajorTopicYN="N">Testicular damage</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1734-1140(14)00166-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pharep.2014.04.010</ArticleId>
            <ArticleId IdType="pubmed">25149981</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149976</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1734-1140</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological reports : PR</Title>
                <ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>741-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharep.2014.03.007</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1734-1140(14)00104-2</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The endogenous opioid system constitutes an attractive target in the treatment of GI disorders, including inflammatory bowel diseases (IBD). The aim of our study was to characterize the anti-inflammatory and antinociceptive effect of P-317, a novel cyclic analog of opioid peptide morphiceptin, in animal models of IBD.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The anti-inflammatory effect of P-317 after intraperitoneal (ip) and oral (po) administration was assessed in two mouse models of IBD - Crohn's disease, induced by intracolonic instillation of trinitrobenzenesulfonic acid (TNBS) and ulcerative colitis, induced by addition of dextran sodium sulfate (DSS) into drinking water. The antinociceptive action of P-317 was characterized in mice with acute colitis using mustard oil-induced pain test. Real time RT PCR was used to assess semiquantitatively the expression of IL-1?? and TNF-?? mRNA in mouse colonic samples. To translate our results to clinical conditions, MOP and KOP mRNA were quantified in human colonic biopsies from IBD patients.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">P-317 (0.1mg/kg, ip and 1mg/kg, po) alleviated colonic inflammation in TNBS- and DSS-treated mice in the opioid receptor-dependent manner. The anti-inflammatory effect of P-317 was associated with the decrease in mRNA expression of proinflammatory cytokines. The antinociceptive effect of P-317 was observed after ip and po administration in mice with acute colitis.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results show a potent anti-inflammatory and antinociceptive effect of P-317 in mouse models of colitis upon activation of opioid receptors. The unique bioavailability of P-317 after oral administration suggests that it is a promising drug candidate for future treatment of IBD.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &amp; Partner Sp. z o.o. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sobczak</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zakrzewski</LastName>
                    <ForeName>Piotr K</ForeName>
                    <Initials>PK</Initials>
                    <Affiliation>Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cygankiewicz</LastName>
                    <ForeName>Adam I</ForeName>
                    <Initials>AI</Initials>
                    <Affiliation>Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mokrowiecka</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Chunqiu</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Gastroenterological Surgery, Tenth People's Hospital of Shanghai, School of Medicine, Tongji University, Shanghai, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sa??aga</LastName>
                    <ForeName>Maciej</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma??ecka-Panas</LastName>
                    <ForeName>Ewa</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kordek</LastName>
                    <ForeName>Radzis??aw</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Pathology, Faculty of Medicine, Medical University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krajewska</LastName>
                    <ForeName>Wanda M</ForeName>
                    <Initials>WM</Initials>
                    <Affiliation>Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, ????d??, Poland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fichna</LastName>
                    <ForeName>Jakub</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, ????d??, Poland; Department of Gastroenterological Surgery, Tenth People's Hospital of Shanghai, School of Medicine, Tongji University, Shanghai, China. Electronic address: jakub.fichna@umed.lodz.pl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Pharmacol Rep</MedlineTA>
            <NlmUniqueID>101234999</NlmUniqueID>
            <ISSNLinking>1734-1140</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Abdominal pain</Keyword>
            <Keyword MajorTopicYN="N">Cyclic opioid peptides</Keyword>
            <Keyword MajorTopicYN="N">Endogenous opioid system</Keyword>
            <Keyword MajorTopicYN="N">Inflammatory bowel diseases</Keyword>
            <Keyword MajorTopicYN="N">Morphiceptin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1734-1140(14)00104-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pharep.2014.03.007</ArticleId>
            <ArticleId IdType="pubmed">25149976</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149914</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-8111</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuroscience research</Title>
                <ISOAbbreviation>Neurosci. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aberrant fragment of Dab1 protein is present in yotari mouse.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0168-0102(14)00141-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.neures.2014.08.001</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The Reelin-Dab1 pathway plays important roles in the development of central nervous system. In the autosomal recessive mutant mouse yotari, there is a replacement of a part of Dab1 gene with a long interspersed nuclear element fragment, and it was previously suggested that no protein derived from this gene was present. We here show that an aberrant fragment of Dab1 protein (p64/60) is present in the brain of yotari mouse. The amount of p64/60 is relatively abundant in the embryonic stages and decreased in the postnatal ones. Unlike wild-type Dab1 protein, p64/60 is not phosphorylated by Fyn kinase and localizes considerably to the nucleus. These data suggested the possibility that some phenotypes of yotari may be attributable to the presence of p64/60. It also raises a caveat that a tissue from yotari is not a perfect control for immunostaining of Dab1 protein.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Onoue</LastName>
                    <ForeName>Aya</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Takeuchi</LastName>
                    <ForeName>Mari</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kohno</LastName>
                    <ForeName>Takao</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hattori</LastName>
                    <ForeName>Mitsuharu</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan. Electronic address: mhattori@phar.nagoya-cu.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurosci Res</MedlineTA>
            <NlmUniqueID>8500749</NlmUniqueID>
            <ISSNLinking>0168-0102</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Dab1</Keyword>
            <Keyword MajorTopicYN="N">Monoclonal antibody</Keyword>
            <Keyword MajorTopicYN="N">Neuronal migration</Keyword>
            <Keyword MajorTopicYN="N">Reelin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0168-0102(14)00141-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neures.2014.08.001</ArticleId>
            <ArticleId IdType="pubmed">25149914</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149907</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0007</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental eye research</Title>
                <ISOAbbreviation>Exp. Eye Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Retinal macroglia changes in a triple transgenic mouse model of Alzheimer's disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4835(14)00227-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.exer.2014.08.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The retinas of Alzheimer's disease (AD) patients and transgenic AD animal models display amyloid beta deposits and degeneration of ganglion cells. Little is known, however, about the glial changes in the AD retina. The present study used a triple transgenic mouse model (3xTG-AD), which carries mutated human amyloid precursor protein, tau, and presenilin 1 genes and closely mimics the human brain pathology, to investigate retinal glial changes in AD. AD cognitive symptoms are known to begin in the 3xTG-AD mice at four months of age but plaques and tangles are not seen until six to twelve months. M??ller cells in 3xTG-AD animals were GFAP-positive, indicating activation, at the earliest time point investigated, nine months. Astrocyte activation was also suggested in the 3xTG-AD mice by an apparent increase in size and process number. Another glial marker, S100, was expressed by astrocytes in both the non-transgenic (NTG) controls and 3xTG-AD retinas. Labeling was predominantly nuclear in nine month non-transgenic (NTG) control mice but was also seen in the cytoplasm and processes at 18 months of age. Interestingly, the nuclear localization was not as prominent in the 3xTG-AD retina even at nine months with labelling observed in astrocyte processes. The diffusion of S100 suggests the possible secretion of this protein, as is seen in the brain, with age and, more profoundly, associated with AD. Several dense, abnormally shaped, opaque structures were noted in all 3xTG-AD mice investigated. These structures, which were enveloped by GFAP and S100-positive astrocytes and M??ller cells, were positive for amyloid beta, suggesting that they are amyloid plaques. Staining control retinas with amyloid showed similar structures in 30% of NTG animals but these were fewer in number and not associated with glial activation. The results herein indicate retinal glia activation in the 3xTG-AD mouse retina.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Edwards</LastName>
                    <ForeName>Malia M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Wilmer Eye Institute, Johns Hopkins Hospital, M023 Smith Building, 400 N. Broadway Baltimore, MD 21287 USA. Electronic address: medwar28@jhmi.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rodr??guez</LastName>
                    <ForeName>Jos?? J</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>Department of Neurosciences, University of Basque Country, UPV/EHU, Leioa, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. Electronic address: j.rodriguez-arellano@ikerbasque.org.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lanza</LastName>
                    <ForeName>Raquel Gutierrez</ForeName>
                    <Initials>RG</Initials>
                    <Affiliation>Department of Neurosciences, University of Basque Country, UPV/EHU, Leioa, Spain. Electronic address: raquel.gutierrezlanza@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yates</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Wilmer Eye Institute, Johns Hopkins Hospital, M023 Smith Building, 400 N. Broadway Baltimore, MD 21287 USA. Electronic address: J.R.Yates@exeter.ac.uk.</Affiliation>
                </Author>
                <Author>
                    <LastName>Verkhratsky</LastName>
                    <ForeName>Alexei</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neurosciences, University of Basque Country, UPV/EHU, Leioa, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain; Faculty of Life Sciences, The University of Manchester, Oxford Road, Manchester M13 9PT UK. Electronic address: Alexej.Verkhratsky@manchester.ac.uk.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lutty</LastName>
                    <ForeName>Gerard A</ForeName>
                    <Initials>GA</Initials>
                    <Affiliation>Wilmer Eye Institute, Johns Hopkins Hospital, M023 Smith Building, 400 N. Broadway Baltimore, MD 21287 USA. Electronic address: glutty1@jhmi.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Eye Res</MedlineTA>
            <NlmUniqueID>0370707</NlmUniqueID>
            <ISSNLinking>0014-4835</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
            <Keyword MajorTopicYN="N">Astrogliosis</Keyword>
            <Keyword MajorTopicYN="N">GFAP</Keyword>
            <Keyword MajorTopicYN="N">M??ller cells</Keyword>
            <Keyword MajorTopicYN="N">Retina</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-4835(14)00227-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.exer.2014.08.006</ArticleId>
            <ArticleId IdType="pubmed">25149907</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149897</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1756-0500</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC research notes</Title>
                <ISOAbbreviation>BMC Res Notes</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neuroprotective effect of heme oxygenase-2 knockout in the blood injection model of intracerebral hemorrhage.</ArticleTitle>
            <Pagination>
                <MedlinePgn>561</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The toxicity of heme breakdown products may contribute to the pathogenesis of intracerebral hemorrhage (ICH). Heme catabolism is catalyzed by the heme oxygenase enzymes. We have previously reported that heme oxygenase-2 (HO-2), the constitutive isoform, protects neurons from hemin in vitro and reduces oxidative stress after striatal blood injection. In order to further evaluate HO-2 as a therapeutic target, we tested the hypothesis that HO-2 gene deletion protects neurons and attenuates behavioral deficits after ICH FINDINGS: Injection of 20 mul blood into the right striatum of HO-2 wild-type mice resulted in loss of approximately one third of striatal neurons 4-8 days later. Neuronal survival was significantly increased in HO-2 knockout mice at both time points. This was associated with reduced motor deficit as detected by the corner test; however, no differences were detected in spontaneous activity or the adhesive removal or elevated body swing tests CONCLUSION: HO-2 knockout attenuates perihematomal neuron loss in the blood injection ICH model, but has a weak and variable effect on neurological outcome.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chen-Roetling</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Cai</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Regan</LastName>
                    <ForeName>Raymond F</ForeName>
                    <Initials>RF</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Res Notes</MedlineTA>
            <NlmUniqueID>101462768</NlmUniqueID>
            <ISSNLinking>1756-0500</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1756-0500-7-561</ArticleId>
            <ArticleId IdType="doi">10.1186/1756-0500-7-561</ArticleId>
            <ArticleId IdType="pubmed">25149897</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149763</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6613</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endothelial JAM-A Promotes Reovirus Viremia and Bloodstream Dissemination.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jiu476</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Viruses that cause systemic disease often spread through the bloodstream to infect target tissues. Although viremia is an important step in the pathogenesis of many viruses, how viremia is established is not well understood. Reovirus has been used to dissect mechanisms of viral pathogenesis and is being evaluated in clinical trials as an oncolytic agent. After peroral entry into mice, reovirus replicates within the gastrointestinal tract and disseminates systemically via hematogenous or neural routes. Junctional adhesion molecule-A (JAM-A) is a tight junction protein that serves as a receptor for reovirus. JAM-A is required for establishment of viremia and viral spread to sites of secondary replication. JAM-A also is expressed on the surface of circulating hematopoietic cells. To determine contributions of endothelial and hematopoietic JAM-A to reovirus dissemination and pathogenesis, we generated strains of mice with altered JAM-A expression in these cell types and assessed bloodstream spread of reovirus strain type 1 Lang (T1L), which disseminates solely by hematogenous routes. We found that endothelial but not hematopoietic JAM-A facilitates reovirus T1L bloodstream entry and egress. Understanding how viruses establish viremia may aid in development of inhibitors of this critical step in viral pathogenesis and foster engineering of improved oncolytic viral vectors.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lai</LastName>
                    <ForeName>Caroline M</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boehme</LastName>
                    <ForeName>Karl W</ForeName>
                    <Initials>KW</Initials>
                    <Affiliation>Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pruijssers</LastName>
                    <ForeName>Andrea J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Parekh</LastName>
                    <ForeName>Vrajesh V</ForeName>
                    <Initials>VV</Initials>
                    <Affiliation>Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Van Kaer</LastName>
                    <ForeName>Luc</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Parkos</LastName>
                    <ForeName>Charles A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dermody</LastName>
                    <ForeName>Terence S</ForeName>
                    <Initials>TS</Initials>
                    <Affiliation>Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA terry.dermody@vanderbilt.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jiu476</ArticleId>
            <ArticleId IdType="doi">10.1093/infdis/jiu476</ArticleId>
            <ArticleId IdType="pubmed">25149763</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149666</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0712</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmacology</Title>
                <ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of Ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in High fat diet-fed C57BL/6J mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-2999(14)00569-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ejphar.2014.07.032</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">This study investigated the combined effect of ursolic acid (UA) and rosiglitazone (RSG) on lipid regulatory genes in high fat diet (HFD)-fed mice. Male C57BL/6J mice were fed either normal diet or HFD for 10 weeks, after which animals in each dietary group were divided into following six groups, (normal diet, normal diet plus UA and RSG, HFD alone, HFD plus UA, HFD plus RSG, and HFD plus UA and RSG), for the next 5 weeks. UA (5mg/kg BW) and RSG (4mg/kg BW) were administered as suspensions directly into the stomach using a gastric tube. At the end of the study (106(th) day), their liver was analyzed for lipid content. RT-PCR and western blotting methods were used to analyze lipid regulatory genes. HFD-fed mice showed increased activities of hepatic marker enzymes (aspartate aminotransferase and alanine aminotransferase) in plasma and an increased concentration of total cholesterol, triglyceride and free fatty acid in liver. These results were confirmed by upregulated mRNA expression of lipogenic genes such as sterol-regulatory-element-binding protein-1c, fatty acid synthase and acetyl-CoA carboxylase and downregulated mRNA expression of fatty acid oxidative genes such as carnitine palmitoyltransferase-1, acetyl-CoA carboxylase and peroxisome proliferator activated receptor-?? in HFD-fed mice. Combined treatment (UA/RSG) significantly reduced the hepatic marker enzyme activities and decreased the lipid accumulation in liver. Further, combination treatment (UA/RSG) down regulated lipogenic genes and upregulated fatty acid oxidative genes in HFD-fed mice. This study suggests that UA in combination with RSG reduced lipid accumulation in liver.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sundaresan</LastName>
                    <ForeName>Arjunan</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Faculty of Science, Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar-608 002, Tamilnadu, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Radhiga</LastName>
                    <ForeName>Thangaiyan</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Faculty of Science, Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar-608 002, Tamilnadu, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pugalendi</LastName>
                    <ForeName>Kodukkur Viswanathan</ForeName>
                    <Initials>KV</Initials>
                    <Affiliation>Faculty of Science, Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar-608 002, Tamilnadu, India. Electronic address: pugalendipugalendi27@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Pharmacol</MedlineTA>
            <NlmUniqueID>1254354</NlmUniqueID>
            <ISSNLinking>0014-2999</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">C57BL/6J mice</Keyword>
            <Keyword MajorTopicYN="N">Dyslipidemia</Keyword>
            <Keyword MajorTopicYN="N">High fat diet</Keyword>
            <Keyword MajorTopicYN="N">Rosiglitazone</Keyword>
            <Keyword MajorTopicYN="N">Ursolic acid</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-2999(14)00569-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejphar.2014.07.032</ArticleId>
            <ArticleId IdType="pubmed">25149666</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149664</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0712</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmacology</Title>
                <ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dissection of mechanisms that account for imidazoline-induced lowering of Blood glucose in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-2999(14)00599-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ejphar.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Multiple mechanisms have been suggested to be responsible for the insulinotropic and blood glucose lowering effects of imidazoline compounds. This study was to unravel which mechanism predominantly accounts for glucose lowering by the prototypical imidazolines idazoxan and phentolamine. To this end, an ??2-adrenoceptor agonist (UK14,304) and a KATP channel opener (diazoxide) were used to inhibit insulin release from isolated perifused mouse islets and to induce hyperglycaemia in conscious mice. Potentials of idazoxan and phentolamine to counteract these effects were examined in a comparative manner. In perifused islets, idazoxan increased insulin release only in the presence of the ??2-agonist, whereas phentolamine strongly counteracted both inhibitors of insulin release. In vivo, a lower dose of idazoxan was necessary to ameliorate hyperglycaemia induced by the ??2-agonist than by the KATP channel opener, indicating ??2A-antagonism as the predominant mechanism of action (decrease in incremental area under the glucose curve induced by 0.1mg/kg idazoxan: under diazoxide, -3??7%, versus under UK14,304, -34??9%, P&lt;0.02). In contrast, identical doses of phentolamine were required to counteract hyperglycaemia induced by the two inhibitors of insulin release, implicating involvement of another mechanism beside ??2A-antagonism (2mg/kg phentolamine: diazoxide, -11??8%, versus UK14,304, -15??9%, ns; 4mg/kg phentolamine: diazoxide, -48??6%, versus UK14,304, -48??8%, ns). The results show that imidazolines can lower blood glucose via more than one mechanism of action, with the relative contributions of the mechanisms varying considerably between individual compounds. Dissection of the involved mechanisms could help to develop imidazoline drugs for the treatment of type 2 diabetes.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Karin</LastName>
                    <ForeName>Stadlbauer</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Endocrinology &amp; Metabolism, Department of Medicine III, Medical University of Vienna, W??hringer G??rtel 18-20, 1090 Vienna, Austria. Electronic address: karin.stadlbauer@gmx.at.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zsuzsanna</LastName>
                    <ForeName>Lehner</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Division of Endocrinology &amp; Metabolism, Department of Medicine III, Medical University of Vienna, W??hringer G??rtel 18-20, 1090 Vienna, Austria. Electronic address: Zsuzsanna.Lehner@gmx.at.</Affiliation>
                </Author>
                <Author>
                    <LastName>Natasa</LastName>
                    <ForeName>Stamenkovic</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Endocrinology &amp; Metabolism, Department of Medicine III, Medical University of Vienna, W??hringer G??rtel 18-20, 1090 Vienna, Austria. Electronic address: n0701994@students.meduniwien.ac.at.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ingo</LastName>
                    <ForeName>Rustenbeck</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institute of Pharmacology and Toxicology, University of Braunschweig, Mendelssohnstra??e 1, 38106 Braunschweig, Germany. Electronic address: i.rustenbeck@tu-bs.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lidia</LastName>
                    <ForeName>Surman</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Endocrinology &amp; Metabolism, Department of Medicine III, Medical University of Vienna, W??hringer G??rtel 18-20, 1090 Vienna, Austria. Electronic address: lidia.surman@yahoo.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Anton</LastName>
                    <ForeName>Luger</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Division of Endocrinology &amp; Metabolism, Department of Medicine III, Medical University of Vienna, W??hringer G??rtel 18-20, 1090 Vienna, Austria. Electronic address: anton.luger@meduniwien.ac.at.</Affiliation>
                </Author>
                <Author>
                    <LastName>Clemens</LastName>
                    <ForeName>F??rnsinn</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Division of Endocrinology &amp; Metabolism, Department of Medicine III, Medical University of Vienna, W??hringer G??rtel 18-20, 1090 Vienna, Austria. Electronic address: clemens.fuernsinn@meduniwien.ac.at.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Pharmacol</MedlineTA>
            <NlmUniqueID>1254354</NlmUniqueID>
            <ISSNLinking>0014-2999</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">304 (CID 2435)</Keyword>
            <Keyword MajorTopicYN="N">Idazoxan</Keyword>
            <Keyword MajorTopicYN="N">Imidazoline</Keyword>
            <Keyword MajorTopicYN="N">K(ATP) channel</Keyword>
            <Keyword MajorTopicYN="N">Phentolamine</Keyword>
            <Keyword MajorTopicYN="N">UK14</Keyword>
            <Keyword MajorTopicYN="N">diazoxide (CID 58 3019)</Keyword>
            <Keyword MajorTopicYN="N">idazoxan (CID 54459)</Keyword>
            <Keyword MajorTopicYN="N">phentolamine (CID 5775)</Keyword>
            <Keyword MajorTopicYN="N">??(2)-adrenoceptor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-2999(14)00599-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejphar.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25149664</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149650</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-0283</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell biochemistry and biophysics</Title>
                <ISOAbbreviation>Cell Biochem. Biophys.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anticancer Effects of Chemokine Receptor 4(CXCR4) Gene Silenced by CXCR4-siRNA in Nude Mice Model of Ovarian Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The aim is to study the anticancer effect of CXCR4 gene knockdown by CXCR4-siRNA in nude mice model of ovarian cancer. Injecti the SW626 tumor cells which had been transfected by vectors to make nude mouse model of ovarian cancer. The model mice were divided into interference group, negative control group, and blank control group. When the level of target genes were knocked down, the tumor volume was monitored and the tumor quality was measured; the expression of CXCR4 gene in the xenograft tumor was detected by RT-PCR, Western blot, and immunohistochemical staining. Nude mice model with implanted tumor were built successfully, after observing for 20??days. While the CXCR4 was knocked down, the abilities of invasion were weakened; the tumor volume and the tumor quality were also decreased. The CXCR4 mRNA and protein of the interference group decreased significantly (P??&lt;??0.05). The animal experiment was confirmed that silencing of CXCR4 gene by siRNA can obviously inhibit the tumorigenesis of ovarian cancer. Our work will provide the theoretical basis for genes interference therapy of ovarian cancer in future.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>The Department of Obstetrics and Gynecology, Liaocheng People's Hospital, Liaocheng, 252000, Shandong, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yueyun</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Hongying</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Aixia</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Biochem Biophys</MedlineTA>
            <NlmUniqueID>9701934</NlmUniqueID>
            <ISSNLinking>1085-9195</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12013-014-0148-5</ArticleId>
            <ArticleId IdType="pubmed">25149650</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149649</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-0283</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell biochemistry and biophysics</Title>
                <ISOAbbreviation>Cell Biochem. Biophys.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Recovery Process of Mice Tracheal Epithelium Injured by 5-FU and Its Microarray Analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Although the research on the localization of trachea stem cells has made a rapid progress, the mechanism of proliferation and differentiation of trachea stem cells remains unclear. The objective of this study is to observe and analyze the recovery process of mice tracheal epithelium injured by 5-FU, and to investigate the mechanism involved in the regulation of tracheal stem cells proliferation and differentiation through morphological, immunofluorescence, and microarray analysis. After treatment with 5-FU, the mature cells were dead and desquamated. Only a few G0 phase cells remained on the basement membrane. When supplied with normal culture media, the cells eventually became flat, cubic, and restored as pseudostratified epithelium. These G0 phase cells were ABCG2 positive. It suggested that these cells could differentiate into cilia cells or Clara cells, and had the multi-differentiation ability of stem cells. We examinated the expression profile of genes involved in the stem cell differentiation in normal tracheal epithelial cells and the regenerated epithelial cells at 24 and 48??h after injured by 5-FU using gene microarray. After 24??h treatment, 8 genes were up-regulated and 31 genes were down-regulated. After 48??h treatment, 5 genes were up-regulated and 42 genes were down-regulated. The differential gene expressions in gene microarray analysis focused on cell cycle regulation, intercellular junction, fibroblast growth factors, bone morphogenetic protein, Notch and Wnt-signaling pathways, which suggested that the differential gene expressions might be closely associated with the proliferation and differentiation of tracheal stem cells.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Jing-Ru</ForeName>
                    <Initials>JR</Initials>
                    <Affiliation>Department of Pathology, College of Basic Medical Sciences, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Nan</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Jia</LastName>
                    <ForeName>Xin-Shan</ForeName>
                    <Initials>XS</Initials>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Shan-Liang</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Xiao-Bo</ForeName>
                    <Initials>XB</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>En-Hua</ForeName>
                    <Initials>EH</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Biochem Biophys</MedlineTA>
            <NlmUniqueID>9701934</NlmUniqueID>
            <ISSNLinking>1085-9195</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12013-014-0115-1</ArticleId>
            <ArticleId IdType="pubmed">25149649</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149641</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7209</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Angiogenesis</Title>
                <ISOAbbreviation>Angiogenesis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Angiogenesis and airway reactivity in asthmatic Brown Norway rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Expanded and aberrant bronchial vascularity, a prominent feature of the chronic asthmatic airway, might explain persistent airway wall edema and sustained leukocyte recruitment. Since it is well established that there are causal relationships between exposure to house dust mite (HDM) and the development of asthma, determining the effects of HDM in rats, mammals with a bronchial vasculature similar to humans, provides an opportunity to study the effects of bronchial angiogenesis on airway function directly. We studied rats exposed bi-weekly to HDM (Der p 1; 50????g/challenge by intranasal aspiration, 1, 2, 3??weeks) and measured the time course of appearance of increased blood vessels within the airway wall. Results demonstrated that within 3??weeks of HDM exposure, the number of vessels counted within airway walls of bronchial airways (0.5-3??mm perimeter) increased significantly. These vascular changes were accompanied by increased airway responsiveness to methacholine. A shorter exposure regimen (2??weeks of bi-weekly exposure) was insufficient to cause a significant increase in functional vessels or reactivity. Yet, (19)F/(1)H MR imaging at 3T following ??v??3-targeted perfluorocarbon nanoparticle infusion revealed a significant increase in (19)F signal in rat airways after 2??weeks of bi-weekly HDM, suggesting earlier activation of the process of neovascularization. Although many antigen-induced mouse models exist, mice lack a bronchial vasculature and consequently lack the requisite human parallels to study bronchial edema. Overall, our results provide an important new model to study the impact of bronchial angiogenesis on chronic inflammation and airways hyperreactivity.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wagner</LastName>
                    <ForeName>Elizabeth M</ForeName>
                    <Initials>EM</Initials>
                    <Affiliation>Department of Medicine, Johns Hopkins University, Baltimore, MD, USA, wagnerem@jhmi.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jenkins</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Schmieder</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Eldridge</LastName>
                    <ForeName>Lindsey</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Qiong</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>Moldobaeva</LastName>
                    <ForeName>Aigul</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Huiying</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Allen</LastName>
                    <ForeName>John S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Xiaoxia</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Mitzner</LastName>
                    <ForeName>Wayne</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Keupp</LastName>
                    <ForeName>Jochen</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Caruthers</LastName>
                    <ForeName>Shelton D</ForeName>
                    <Initials>SD</Initials>
                </Author>
                <Author>
                    <LastName>Wickline</LastName>
                    <ForeName>Samuel A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author>
                    <LastName>Lanza</LastName>
                    <ForeName>Gregory M</ForeName>
                    <Initials>GM</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Angiogenesis</MedlineTA>
            <NlmUniqueID>9814575</NlmUniqueID>
            <ISSNLinking>0969-6970</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10456-014-9441-6</ArticleId>
            <ArticleId IdType="pubmed">25149641</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149634</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-2218</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Surgical endoscopy</Title>
                <ISOAbbreviation>Surg Endosc</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Successful in vivo tumor visualization using fluorescence laparoscopy in a mouse model of disseminated alveolar rhabdomyosarcoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Surgery for rhabdomyosarcoma is challenging due to a lack of clear delineation between tumor and surrounding tissue. Mutilating surgery can be necessary in difficult tumor localizations. Therefore, novel diagnostic and therapeutic modalities are required. The aim of this study was to evaluate the in vivo tumor detection of RMS using fluorescence laparoscopy and to analyze the efficacy of hypericin-induced photodynamic therapy in a mouse model.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Seventeen NOD/LtSz-scid IL2R??null-mice were divided into four groups. In group 1, mCherry-expressing tumor cells and in group 2-4 non-transfected tumor cells were xenotransplanted. Three weeks later, one fluorochrome per group (ICG, ICG-cetuximab, hypericin) was injected. Fluorescence laparoscopy was carried out and tumors were resected using fluorescence guidance. In the hypericin group, photodynamic therapy was performed using blue light and apoptosis was evaluated by TUNEL test.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A clear discrimination between healthy and tumor tissue was feasible by fluorescending properties with mCherry expressing tumor cells and after injection of hypericin. No fluorescence was detected in mice injected with ICG and ICG-labeled cetuximab. Hypericin photodynamic therapy induced apoptosis of tumor cells after exposure to blue light.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intraoperative photodynamic diagnosis was feasible using mCherry-transfected tumor cells or hypericin. Additionally, intraoperative photodynamic therapy was possible and effective.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Urla</LastName>
                    <ForeName>Cristian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital T??bingen, Hoppe-Seyler-Strasse 3, 72076, T??bingen, Germany, Cristian.Urla@med.uni-tuebingen.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Armeanu-Ebinger</LastName>
                    <ForeName>Sorin</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Fuchs</LastName>
                    <ForeName>J??rg</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Seitz</LastName>
                    <ForeName>Guido</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Surg Endosc</MedlineTA>
            <NlmUniqueID>8806653</NlmUniqueID>
            <ISSNLinking>0930-2794</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00464-014-3770-9</ArticleId>
            <ArticleId IdType="pubmed">25149634</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149631</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-7544</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuroscience</Title>
                <ISOAbbreviation>Neuroscience</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dopamine D1 and D3 receptors mediate reconsolidation of cocaine memories in mouse models of drug self-administration.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0306-4522(14)00657-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.neuroscience.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Memories of drug experience and drug-associated environmental cues can elicit drug-seeking and taking behaviors in humans. Disruption of reconsolidation of drug memories dampens previous memories and therefore may provide a useful way to treat drug abuse. We and others previously demonstrated that dopamine D1 and D3 receptors play differential roles in acquiring cocaine-induced behaviors. Moreover, D3 receptors contribute to the reconsolidation of cocaine-induced conditioned place preference. In the present study, we examined effects of manipulating D1 or D3 receptors on reconsolidation of cocaine memories in mouse models of drug self-administration. We found that pharmacological blockade of D1 receptors or a genetic mutation of the D3 receptor gene attenuated reconsolidation that lasted for at least 1 week after the memory retrieval. In contrast, with no memory retrieval, pharmacological antagonism of D1 receptors or the D3 receptor gene mutation did not significantly affect reconsolidation of cocaine memories. Pharmacological blockade of D3 receptors also attenuated reconsolidation in wild-type mice that lasted for at least 1 week after the memory retrieval. These results suggest that D1 and D3 receptors and related signaling mechanisms play key roles in reconsolidation of cocaine memories in mice, and that these receptors may serve as novel targets for the treatment of cocaine abuse in humans.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Yijin</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Anesthesia and Critical Care, The University of Chicago, Chicago, IL, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Newman</LastName>
                    <ForeName>Amy Hauck</ForeName>
                    <Initials>AH</Initials>
                    <Affiliation>Medicinal Chemistry Section, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Anesthesia and Critical Care, The University of Chicago, Chicago, IL, USA. Electronic address: mxu@dacc.uchicago.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neuroscience</MedlineTA>
            <NlmUniqueID>7605074</NlmUniqueID>
            <ISSNLinking>0306-4522</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antagonists</Keyword>
            <Keyword MajorTopicYN="N">Cocaine self-administration</Keyword>
            <Keyword MajorTopicYN="N">Dopamine D1 and D3 receptors</Keyword>
            <Keyword MajorTopicYN="N">Drug memory</Keyword>
            <Keyword MajorTopicYN="N">Gene mutation</Keyword>
            <Keyword MajorTopicYN="N">Reconsolidation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0306-4522(14)00657-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25149631</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149571</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1995-7645</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Asian Pacific journal of tropical medicine</Title>
                <ISOAbbreviation>Asian Pac J Trop Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antimalarial activity and toxicity of Garcinia mangostana Linn.</ArticleTitle>
            <Pagination>
                <MedlinePgn>693-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1995-7645(14)60118-8</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1995-7645(14)60118-8</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the antimalarial activity and toxicity of the crude ethanolic extract of its pericarp both in vitro and in vivo.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The antimalarial activity of Garcinia mangostana (G. mangostana) Linn. extract against 3D7 and K1 Plasmodium falciparum (P. falciparum) clone were assessed using SYBR green I-based assay. A 4-day suppressive test of Plasmodium berghei (P. berghei) infected mouse was performed to investigate in vivo antimalarial activity.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The in vitro antimalarial activity was selective (SI &gt; 5) and classified as weak and good to moderate activity against both 3D7 and K1 P. falciparum clones with median IC50 (range) values of 11.12 (10.94-11.29) and 7.54 (6.80-7.68) ??g/mL, respectively. The extract was considered non-toxic to mice. The maximum tolerated doses for acute and subacute toxicity in mice were 5 000 and 2 000 mg/kg, respectively. Median (range) parasite density on day 4 of the negative control group (25% Tween-80), mice treated with 250, 500, 1???000, and 2 000 mg/kg body weight of the extract, and 10 mg/kg body weight of chloroquine for 14 d were 12.8 (12.2-13.7), 11.4 (9.49-13.8), 11.6 (9.9-12.5), 11.7 (10.6-12.8), 10.9 (9.4-11.6) and 0 (0-0)% respectively. Parasite density on day 4 in the control group treated with Tween-80 was higher than the groups treated with chloroquine and all dose levels of the extract.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">G. mangostana Linn. showed weak antimalarial activity of the extract both in vitro and in vivo could be due to limitation of absorption of the active compounds.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Hainan Medical College. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bunyong</LastName>
                    <ForeName>Ratchanu</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chaijaroenkul</LastName>
                    <ForeName>Wanna</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plengsuriyakarn</LastName>
                    <ForeName>Tullayakorn</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Na-Bangchang</LastName>
                    <ForeName>Kesara</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand. Electronic address: kesaratmu@yahoo.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Singapore</Country>
            <MedlineTA>Asian Pac J Trop Med</MedlineTA>
            <NlmUniqueID>101533720</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antimalarial activity</Keyword>
            <Keyword MajorTopicYN="N">Garcinia mangostana Linn.</Keyword>
            <Keyword MajorTopicYN="N">Plasmodium berghei</Keyword>
            <Keyword MajorTopicYN="N">Plasmodium falciparum</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1995-7645(14)60118-8</ArticleId>
            <ArticleId IdType="doi">10.1016/S1995-7645(14)60118-8</ArticleId>
            <ArticleId IdType="pubmed">25149571</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149570</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1995-7645</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Asian Pacific journal of tropical medicine</Title>
                <ISOAbbreviation>Asian Pac J Trop Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aristolochia gehrtii inhibits liver toxicity and apoptosis in Schistosoma malayensis infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>685-92</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1995-7645(14)60117-6</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1995-7645(14)60117-6</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate a protective effect of Aristolochia gehrtii (A. gehrtii) leaves to inhibit liver toxicity and apoptosis in Schistosoma malayensis (S. malayensis) infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Forty male albino mice were divided into four equal groups: group 1 control including non-infected healthy mice and groups 2, 3 &amp; 4 subcutaneously infected with S. malayensis cercariae where groups 3 &amp; 4 pretreated with A. gehrtii leaves (200 mg/kg, bwt) &amp; cinnamoylamide (250 mg/kg, bwt), respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">S. malayensis caused a significant increase in serum AST, ALT, ALP, MDA, NO, bilirubin, urea, creatinine, total cholesterol, LDL, triglycerides, and HDL levels. The pretreatment of A. gehrtii leaves and cinnamoylamide significantly inhibited that increase. On the other hand, S. malayensis induced a significant decrease in serum total protein, albumin, globulin, albumin/globulin ratio, blood SOD and GPx, while A. gehrtii leaves and cinnamoylamide pretreatment increased the above parameters. Treatment with A. gehrtii leaves and cinnamoylamide to S. malayensis infected mice increased p53 expression but decreased bcl-2 expression. These results were supported by histopathological investigations.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A. gehrtii inhibits liver toxicity and apoptosis in S. malayensis infection and this effect is associated with the major cinnamoylamide ingredient of A. gehrtii leaves.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Hainan Medical College. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Koriem</LastName>
                    <ForeName>Khaled M M</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), 13200 Kepala Batas, Pulau Pinang, Malaysia; Department of Medical Physiology, National Research Centre, 12622 Dokki, Giza, Egypt. Electronic address: kkoriem@yahoo.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shahabudin</LastName>
                    <ForeName>Razmy E</ForeName>
                    <Initials>RE</Initials>
                    <Affiliation>Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), 13200 Kepala Batas, Pulau Pinang, Malaysia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jamaludin</LastName>
                    <ForeName>Rafiq Z</ForeName>
                    <Initials>RZ</Initials>
                    <Affiliation>Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), 13200 Kepala Batas, Pulau Pinang, Malaysia.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Singapore</Country>
            <MedlineTA>Asian Pac J Trop Med</MedlineTA>
            <NlmUniqueID>101533720</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Aristolochia gehrtii</Keyword>
            <Keyword MajorTopicYN="N">Aristolochiaceae</Keyword>
            <Keyword MajorTopicYN="N">Liver</Keyword>
            <Keyword MajorTopicYN="N">Mice</Keyword>
            <Keyword MajorTopicYN="N">Schistosoma malayensis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1995-7645(14)60117-6</ArticleId>
            <ArticleId IdType="doi">10.1016/S1995-7645(14)60117-6</ArticleId>
            <ArticleId IdType="pubmed">25149570</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149567</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-6815</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental gerontology</Title>
                <ISOAbbreviation>Exp. Gerontol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Coenzyme Q10 and ??-tocopherol reversed age-associated functional impairments in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0531-5565(14)00243-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.exger.2014.08.007</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The purpose of this study was to determine if intake of the antioxidants coenzyme Q10 (CoQ10) or ??-tocopherol (Toc), either alone or in combination, could ameliorate cognitive and psychomotor impairments of aged mice, as well as reduce oxidative burden in tissues. For a period of 10weeks, male C57BL/6J mice (3 or 18months) were fed either a control diet, or one of three diets supplemented with Toc, CoQ10 or their combination, and were tested for cognitive and psychomotor functions. Old mice on the Toc or Toc/CoQ10 diets showed improved coordinated running performance. Mice on the diet containing Toc/CoQ10 demonstrated improved performance in the discriminated avoidance task. CoQ10 and Toc alone also resulted in improved performance, albeit to a lesser degree. Protein damage was decreased especially when the mice received Toc+CoQ10 combination. Overall, these results suggest that, Toc and CoQ supplementation can ameliorate age-related impairment and reduce protein oxidation. Moreover, concurrent supplementation of CoQ10 and Toc may be more effective than either antioxidant alone.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Shetty</LastName>
                    <ForeName>Ritu A</ForeName>
                    <Initials>RA</Initials>
                    <Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA; Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ikonne</LastName>
                    <ForeName>Uzoma S</ForeName>
                    <Initials>US</Initials>
                    <Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA; Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Forster</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA; Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sumien</LastName>
                    <ForeName>Nathalie</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA; Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA. Electronic address: nathalie.sumien@unthsc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Gerontol</MedlineTA>
            <NlmUniqueID>0047061</NlmUniqueID>
            <ISSNLinking>0531-5565</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antioxidants</Keyword>
            <Keyword MajorTopicYN="N">Behavior</Keyword>
            <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0531-5565(14)00243-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.exger.2014.08.007</ArticleId>
            <ArticleId IdType="pubmed">25149567</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149566</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1991</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>4</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell calcium</Title>
                <ISOAbbreviation>Cell Calcium</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ligand-selective activation of heterologously-expressed mammalian olfactory receptor.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0143-4160(14)00116-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ceca.2014.07.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mammalian olfactory receptors (ORs) appear to have the capacity to couple to multiple G protein-coupled signaling pathways in a ligand-dependent selective manner. To better understand the mechanisms and molecular range of such ligand selectivity, we expressed the mouse eugenol OR (mOR-EG) in HEK293T cells together with G??15 to monitor activation of the phospholipase-C (PLC) signaling pathway and/or G??olf to monitor activation of the adenylate cyclase (AC) signaling pathway, resulting in intracellular Ca(2+) release and/or Ca(2+) influx through a cyclic nucleotide-gated channel, respectively. PLC-dependent responses differed dynamically from AC-dependent responses, allowing them to be distinguished when G??15 and G??olf were co-expressed. The dynamic difference in readout was independent of the receptor, the heterologous expression system, and the ligand concentration. Of 17 reported mOR-EG ligands tested, including eugenol, its analogs, and structurally dissimilar compounds (mousse cristal, nootkatone, orivone), some equally activated both signaling pathways, some differentially activated both signaling pathways, and some had no noticeable effect even at 1-5mM. Our findings argue that mOR-EG, when heterologously expressed, can couple to two different signaling pathways in a ligand selective manner. The challenge now is to determine the potential of mOR-EG, and perhaps other ORs, to activate multiple signaling pathways in a ligand selective manner in native ORNs.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ukhanov</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Whitney Laboratory, Center for Smell and Taste, and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, United States. Electronic address: ukhanov@mbi.ufl.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bobkov</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Whitney Laboratory, Center for Smell and Taste, and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Corey</LastName>
                    <ForeName>E A</ForeName>
                    <Initials>EA</Initials>
                    <Affiliation>Whitney Laboratory, Center for Smell and Taste, and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ache</LastName>
                    <ForeName>B W</ForeName>
                    <Initials>BW</Initials>
                    <Affiliation>Whitney Laboratory, Center for Smell and Taste, and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, United States; Department of Biology, University of Florida, Gainesville, FL 32610, United States; Department of Neuroscience, University of Florida, Gainesville, FL 32610, United States.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Calcium</MedlineTA>
            <NlmUniqueID>8006226</NlmUniqueID>
            <ISSNLinking>0143-4160</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Biased signaling</Keyword>
            <Keyword MajorTopicYN="N">Functional assay</Keyword>
            <Keyword MajorTopicYN="N">HEK293T</Keyword>
            <Keyword MajorTopicYN="N">Olfactory receptor</Keyword>
            <Keyword MajorTopicYN="N">mOR-EG</Keyword>
            <Keyword MajorTopicYN="N">olfr73</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0143-4160(14)00116-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ceca.2014.07.012</ArticleId>
            <ArticleId IdType="pubmed">25149566</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149543</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Wogonin, a flavonoid derived from Scutellaria baicalensis Georgi, has been demonstrated to be highly effective in treating hematologic malignancies. In this study, we investigated the anticancer effects of wogonin on K562 cells, K562 imatinib-resistant cells, and primary patient-derived CML cells. Wogonin up-regulated transcription factor GATA-1 and enhanced binding between GATA-1 and FOG-1, thereby increasing expression of erythroid-differentiation genes. Wogonin also up-regulated the expression of p21 and induced cell cycle arrest. Studies employing benzidine staining and analyses of cell surface markers glycophorin A (GPA) and CD71 indicated that wogonin promoted differentiation of K562, imatinib-resistant K562, and primary patient-derived CML cells. Wogonin also enhanced binding between GATA-1 and MEK, resulting in inhibition of the growth of CML cells. Additionally, in vivo studies showed that wogonin decreased the number of CML cells and prolonged survival of NOD/SCID mice injected with K562 and imatinib-resistant K562 cells. These data suggested that wogonin induces cycle arrest and erythroid differentiation in vitro and inhibits proliferation in vivo.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hui</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Qian</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Yuxin</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Hematology, The First Affiliated Hospital of Nanjing Medical University; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Xiaotang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Chemistry and Biochemistry, Florida International University, Miami, FL, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>You</LastName>
                    <ForeName>Qidong</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Qinglong</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Na</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, People's Republic of China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2340</ArticleId>
            <ArticleId IdType="pubmed">25149543</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149540</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>6</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fucoidan inhibition of lung cancer in vivo and in vitro : role of the Smurf2-dependent ubiquitin proteasome pathway in TGF?? receptor degradation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Fucoidan, a polysaccharide extracted from brown seaweeds, reduces tumor cell proliferation. In this study, we demonstrate that fucoidan reduces tumor size in LLC1-xenograft male C57BL/6 mice. Moreover, we found that LLC1-bearing mice continuously fed fucoidan showed greater antitumor activity than mice with discontinuous feeding. Fucoidan inhibited the in vitro growth of lung cancer cells. Transforming growth factor ?? (TGF??) receptors (TGFRs) play important roles in the regulation of proliferation and progression, and high TGFRI expression in lung cancer specimens is associated with a worse prognosis. Herein, using lung cancer cells, we found that fucoidan effectively reduces TGFRI and TGFRII protein levels in vivo and in vitro. Moreover, fucoidan reduces TGFR downstream signaling events, including those in Smad2/3 and non-Smad pathways: Akt, Erk1/2, and FAK phosphorylation. Furthermore, fucoidan suppresses lung cancer cell mobility upon TGF?? stimulation. To elucidate how fucoidan decreases TGFR proteins in lung cancer cells, we found that fucoidan enhances the ubiquitination proteasome pathway (UPP)-mediated degradation of TGFRs in A549 and CL1-5 cells. Mechanistically, fucoidan promotes Smurf2 and Smad7 to conjugate TGFRs, resulting in TGF degradation; however, Smurf2-shRNA abolishes fucoidan-enhanced UPP-mediated TGFR degradation. Our study is the first to identify a novel mechanism for the antitumor activity of fucoidan, namely decreasing tumor growth by modulating the TGFR/Smad7/Smurf2-dependent axis, leading to TGFR protein degradation and inhibition of lung cancer cell progression in vitro and in vivo. Our current findings indicate that fucoidan is a potential therapeutic agent or dietary supplementation for lung cancer, acting via the Smurf2-dependent ubiquitin degradation of TGF?? receptors.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Hsien-Yeh</ForeName>
                    <Initials>HY</Initials>
                    <Affiliation>Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan. The Genomics Research Center, Academia Sinica, Taipei, Taiwan. Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Tung-Yi</ForeName>
                    <Initials>TY</Initials>
                    <Affiliation>Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan. Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Yu-Chung</ForeName>
                    <Initials>YC</Initials>
                    <Affiliation>Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan. School of Medicine, National Yang-Ming University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tsao</LastName>
                    <ForeName>Shu-Ming</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hwang</LastName>
                    <ForeName>Pai-An</ForeName>
                    <Initials>PA</Initials>
                    <Affiliation>Seafood Technology Division, Fisheries Research Institute, Council of Agriculture, Keelung, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shih</LastName>
                    <ForeName>Yu-Wei</ForeName>
                    <Initials>YW</Initials>
                    <Affiliation>Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Jason</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Fordham University, New York, NY, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2317</ArticleId>
            <ArticleId IdType="pubmed">25149540</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149539</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>4</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protein kinase D1 attenuates tumorigenesis in colon cancer by modulating ??-catenin/T cell factor activity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Over 80% of colon cancer development and progression is a result of the dysregulation of ??-catenin signaling pathway. Herein, for the first time, we demonstrate that a serine-threonine kinase, Protein Kinase D1 (PKD1), modulates the functions of ??-catenin to suppress colon cancer growth. Analysis of normal and colon cancer tissues reveals downregulation of PKD1 expression in advanced stages of colon cancer and its co-localization with ??-catenin in the colon crypts. This PKD1 downregulation corresponds with the aberrant expression and nuclear localization of ??-catenin. In-vitro investigation of the PKD1-??-catenin interaction in colon cancer cells reveal that PKD1 overexpression suppresses cell proliferation and clonogenic potential and enhances cell-cell aggregation. We demonstrate that PKD1 directly interacts with ??-catenin and attenuates ??-catenin transcriptional activity by decreasing nuclear ??-catenin levels. Additionally, we show that inhibition of nuclear ??-catenin transcriptional activity is predominantly influenced by nucleus targeted PKD1. This subcellular modulation of ??-catenin results in enhanced membrane localization of ??-catenin and thereby increases cell-cell adhesion. Studies in a xenograft mouse model indicate that PKD1 overexpression delayed tumor appearance, enhanced necrosis and lowered tumor hypoxia. Overall, our results demonstrate a putative tumor-suppressor function of PKD1 in colon tumorigenesis via modulation of ??-catenin functions in cells.possible CD8+-dependency and beneficial effect of nuclear IL-23p19 on overall patient survival.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sundram</LastName>
                    <ForeName>Vasudha</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Cancer Biology Research Center, Sanford Research/USD, Sioux Falls, SD, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ganju</LastName>
                    <ForeName>Aditya</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hughes</LastName>
                    <ForeName>Joshua E</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Cancer Biology Research Center, Sanford Research/USD, Sioux Falls, SD, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Khan</LastName>
                    <ForeName>Sheema</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chauhan</LastName>
                    <ForeName>Subhash C</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jaggi</LastName>
                    <ForeName>Meena</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2277</ArticleId>
            <ArticleId IdType="pubmed">25149539</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149536</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">BAG3, member the HSP70 co-chaperones family, has been shown to play a relevant role in the survival, growth and invasiveness of different tumor types. In this study, we investigate the expression of BAG3 in 66 specimens from different lung tumors and the role of this protein in small cell lung cancer (SCLC) tumor growth. Normal lung tissue did not express BAG3 while we detected the expression of BAG3 by immunohistochemistry in all the 13 squamous cell carcinomas, 13 adenocarcinomas and 4 large cell carcinomas. Furthermore, we detected BAG3 expression in 22 of the 36 SCLCs analyzed. The role on SCLC cell survival was determined by down-regulating BAG3 levels in two human SCLC cell lines, i.e. H69 and H446, in vitro and measuring cisplatin induced apoptosis. Indeed down-regulation of BAG3 determines increased cell death and sensitizes cells to cisplatin treatment. The effect of BAG3 down-regulation on tumor growth was also investigated in an in vivo xenograft model by treating mice with an adenovirus expressing a specific bag3 siRNA. Treatment with bag3 siRNA-Ad significantly reduced tumor growth and improved animal survival. In conclusion we show that a subset of SCLCs over express BAG3 that exerts an anti-apoptotic effect resulting in resistance to chemotherapy.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chiappetta</LastName>
                    <ForeName>Gennaro</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Functional Genomic Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Basile</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pharmacy, University of Salerno, Fisciano, Italy. BIOUNIVERSA S.r.l., University of Salerno, Fisciano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Barbieri</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Animal Facility Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Falco</LastName>
                    <ForeName>Antonia</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pharmacy, University of Salerno, Fisciano, Italy. BIOUNIVERSA S.r.l., University of Salerno, Fisciano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rosati</LastName>
                    <ForeName>Alessandra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pharmacy, University of Salerno, Fisciano, Italy. BIOUNIVERSA S.r.l., University of Salerno, Fisciano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Festa</LastName>
                    <ForeName>Michelina</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmacy, University of Salerno, Fisciano, Italy. BIOUNIVERSA S.r.l., University of Salerno, Fisciano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pasquinelli</LastName>
                    <ForeName>Rosa</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Functional Genomic Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Califano</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Functional Genomic Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Palma</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Animal Facility Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Costanzo</LastName>
                    <ForeName>Raffaele</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Medical Oncology Unit, Thoraco-Pulmonary Department, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Barcaroli</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Experimental and Clinical Sciences, University G. D'Annunzio and Fondazione G. D'Annunzio, Ce.S.I., Chieti, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Capunzo</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Medicine and Surgery, University of Salerno, Fisciano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Franco</LastName>
                    <ForeName>Renato</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rocco</LastName>
                    <ForeName>Gaetano</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Thoracic Surgery Unit, Thoraco-Pulmonary Department, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pascale</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmacy, University of Salerno, Fisciano, Italy. BIOUNIVERSA S.r.l., University of Salerno, Fisciano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Turco</LastName>
                    <ForeName>Maria Caterina</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>BIOUNIVERSA S.r.l., University of Salerno, Fisciano, Italy. Department of Medicine and Surgery, University of Salerno, Fisciano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>De Laurenzi</LastName>
                    <ForeName>Vincenzo</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>BIOUNIVERSA S.r.l., University of Salerno, Fisciano, Italy. Department of Experimental and Clinical Sciences, University G. D'Annunzio and Fondazione G. D'Annunzio, Ce.S.I., Chieti, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Arra</LastName>
                    <ForeName>Claudio</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Animal Facility Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;, IRCCS, Naples, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2261</ArticleId>
            <ArticleId IdType="pubmed">25149536</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149535</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase which inhibits STAT3 phosphorylation and tumor growth. Here we investigated the effects of AZD1480 on the function of different immune cell populations in a melanoma model. When MO4 tumor-bearing mice were treated with AZD1480 we observed a strong inhibition of tumor growth as well as a prolonged survival. Moreover, a significant decrease in the percentage of myeloid-derived suppressor cells (MDSCs) was observed after treatment with AZD1480. However, AZD1480 enhanced the suppressive capacity of murine MDSCs while at the same time impairing the proliferative as well as the IFN-?? secretion capacity of murine T cells. The addition of AZD1480 to co-cultures of human MDSCs and T cells does not affect the suppressive activity of MDSCs but it does reduce the IFN-?? secretion and the proliferative capacity of T cells. We showed that although AZD1480 has the ability to delay the tumor growth of MO4 tumor-bearing mice, this drug has detrimental effects on several aspects of the immune system. These data indicate that systemic targeting of the JAK/STAT pathway by JAK1/2 inhibition can have divergent effects on tumor growth and anti-tumor immune responses.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Maenhout</LastName>
                    <ForeName>Sarah K</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Du Four</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium. Department of Medical Oncology, Universiteit Ziekenhuis Brussel, Brussels, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Corthals</LastName>
                    <ForeName>Jurgen</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Neyns</LastName>
                    <ForeName>Bart</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium. Department of Medical Oncology, Universiteit Ziekenhuis Brussel, Brussels, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thielemans</LastName>
                    <ForeName>Kris</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aerts</LastName>
                    <ForeName>Joeri L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2254</ArticleId>
            <ArticleId IdType="pubmed">25149535</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149534</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The majority of human breast cancers express estrogen receptor alpha (ER), which is important for therapy with anti-estrogens. Here we describe the role of BCL9-2, a proto-oncogene previously characterized as co-activator of Wnt/??-catenin signaling, for mammary tumorigenesis in mice and human. ER positive human breast cancers showed overexpression of BCL9-2 and tamoxifen treated patients with high BCL9-2 demonstrated a better survival. BCL9-2 was upregulated during puberty and pregnancy in normal mammary epithelia, but downregulated in the involuted gland. BCL9-2 overexpression in vivo delayed the mammary involution and induced alveolar hyperplasia. Moreover, aged BCL9-2 transgenic mice developed ductal-like mammary tumors with high nuclear ER expression. We found, that primary cell cultures of BCL9-2 breast tumors responded to tamoxifen treatment. Moreover, BCL9-2 regulated the expression of ER and the proliferation of human breast cancer cells independently of ??-catenin. Finally, we describe a novel mechanism, how BCL9-2 regulates ER transcription by interaction with Sp1 through the proximal ESR1 gene promoter. In summary, BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ??-catenin independent mechanism in breast cancer cells, and might predict the therapy response to tamoxifen treatment.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zatula</LastName>
                    <ForeName>Nathalie</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Tumor Biology and Signal Transduction, Georg-August-University G??ttingen, Germany. Dept. of Hematology and Medical Oncology, Georg-August-University G??ttingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wiese</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Tumor Biology and Signal Transduction, Georg-August-University G??ttingen, Germany. Dept. of Hematology and Medical Oncology, Georg-August-University G??ttingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bunzendahl</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Tumor Biology and Signal Transduction, Georg-August-University G??ttingen, Germany. Dept. of Hematology and Medical Oncology, Georg-August-University G??ttingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Birchmeier</LastName>
                    <ForeName>Walter</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Perske</LastName>
                    <ForeName>Christina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Dept. of Pathology, Georg-August-University G??ttingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bleckmann</LastName>
                    <ForeName>Annalen</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Dept. of Hematology and Medical Oncology, Georg-August-University G??ttingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Brembeck</LastName>
                    <ForeName>Felix H</ForeName>
                    <Initials>FH</Initials>
                    <Affiliation>Tumor Biology and Signal Transduction, Georg-August-University G??ttingen, Germany. Dept. of Hematology and Medical Oncology, Georg-August-University G??ttingen, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2252</ArticleId>
            <ArticleId IdType="pubmed">25149534</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149532</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Tumor-angiogenesis is the multi-factorial process of sprouting of endothelial cells (EC) into micro-vessels to provide tumor cells with nutrients and oxygen. To explore miRNAs as therapeutic angiogenesis-inhibitors, we performed a functional screen to identify miRNAs that are able to decrease EC viability. We identified miRNA-7 (miR-7) as a potent negative regulator of angiogenesis. Introduction of miR-7 in EC resulted in strongly reduced cell viability, tube formation, sprouting and migration. Application of miR-7 in the chick chorioallantoic membrane assay led to a profound reduction of vascularization, similar to anti-angiogenic drug sunitinib. Local administration of miR-7 in an in vivo murine neuroblastoma tumor model significantly inhibited angiogenesis and tumor growth. Finally, systemic administration of miR-7 using a novel integrin-targeted biodegradable polymeric nanoparticles that targets both EC and tumor cells, strongly reduced angiogenesis and tumor proliferation in mice with human glioblastoma xenografts. Transcriptome analysis of miR-7 transfected EC in combination with in silico target prediction resulted in the identification of OGT as novel target gene of miR-7. Our study provides a comprehensive validation of miR-7 as novel anti-angiogenic therapeutic miRNA that can be systemically delivered to both EC and tumor cells and offers promise for miR-7 as novel anti-tumor therapeutic.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Babae</LastName>
                    <ForeName>Negar</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Utrecht Institute for Pharmaceutical Sciences, University Utrecht, Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bourajjaj</LastName>
                    <ForeName>Meriem</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>InteRNA Technologies B.V., Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Yijia</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Aparna Biosciences Corporation, Rockville MD, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Van Beijnum</LastName>
                    <ForeName>Judy R</ForeName>
                    <Initials>JR</Initials>
                    <Affiliation>VU University Medical Center, MB Amsterdam, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cerisoli</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>InteRNA Technologies B.V., Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Scaria</LastName>
                    <ForeName>Puthupparampil V</ForeName>
                    <Initials>PV</Initials>
                    <Affiliation>Aparna Biosciences Corporation, Rockville MD, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Verheul</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>InteRNA Technologies B.V., Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Van Berkel</LastName>
                    <ForeName>Maaike P</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>VU University Medical Center, MB Amsterdam, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pieters</LastName>
                    <ForeName>Ebel H E</ForeName>
                    <Initials>EH</Initials>
                    <Affiliation>Utrecht Institute for Pharmaceutical Sciences, University Utrecht, Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Van Haastert</LastName>
                    <ForeName>Rick J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>InteRNA Technologies B.V., Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yousefi</LastName>
                    <ForeName>Afrouz</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Utrecht Institute for Pharmaceutical Sciences, University Utrecht, Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mastrobattista</LastName>
                    <ForeName>Enrico</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Utrecht Institute for Pharmaceutical Sciences, University Utrecht, Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Storm</LastName>
                    <ForeName>Gert</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>MIRA Institute for Biomedical Technology and Technical Medicine, Faculty of Science and Technology, University of Twente, AE Enschede, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Berezikov</LastName>
                    <ForeName>Eugene</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Hubrecht Institute, Cancer Genomics Center and University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cuppen</LastName>
                    <ForeName>Edwin</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Hubrecht Institute, Cancer Genomics Center and University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Woodle</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Aparna Biosciences Corporation, Rockville MD, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schaapveld</LastName>
                    <ForeName>Roel Q J</ForeName>
                    <Initials>RQ</Initials>
                    <Affiliation>InteRNA Technologies B.V., Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Prevost</LastName>
                    <ForeName>Gregoire P</ForeName>
                    <Initials>GP</Initials>
                    <Affiliation>InteRNA Technologies B.V., Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Griffioen</LastName>
                    <ForeName>Arjan W</ForeName>
                    <Initials>AW</Initials>
                    <Affiliation>VU University Medical Center, MB Amsterdam, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Van Noort</LastName>
                    <ForeName>Paula I</ForeName>
                    <Initials>PI</Initials>
                    <Affiliation>InteRNA Technologies B.V., Utrecht, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schiffelers</LastName>
                    <ForeName>Raymond M</ForeName>
                    <Initials>RM</Initials>
                    <Affiliation>Laboratory Clinical Chemistry and Haematology, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2235</ArticleId>
            <ArticleId IdType="pubmed">25149532</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149528</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0945</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental and molecular pathology</Title>
                <ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Inflammasome in Alcoholic Hepatitis: Its Relationship with Mallory-Denk Body Formation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4800(14)00132-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.yexmp.2014.08.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Recent studies indicate that the inflammasome activation plays important roles in the pathogenesis of alcoholic hepatitis (AH). Nod-like receptor protein 3 (NLRP3) is a key component of the macromolecular complex that is so called the inflammasome that triggers caspase 1-dependent maturation of the precursors of IL-1?? and IL-18 cytokines. It is also known that the adaptor proteins including apoptosis-associated speck-like protein containing CARD (ASC) and the mitochondrial antiviral signaling protein (MAVS) are necessary for NLRP3-dependent inflammasome function. Steatohepatitis frequently includes Mallory-Denk body (MDB) formation. In the case of alcoholic steatohepatitis, MDB formation occurs in 80% of biopsies (French 1981; French 1981). While previous studies have focused on in vitro cell lines and mouse models, we are the first group to investigate inflammasome activation in AH liver biopsy specimen and correlate it with MDB formation. Expression of NOD1, NLRP3, ASC, NAIP, MAVS, caspase 1, IL-1??, IL-18, and other inflammatory components including IL-6, IL-10, TNF-??, IFN-??, STAT3, and p65 was measured in three to eight formalin-fixed paraffin-embedded AH specimens and control normal liver specimens by immunofluorescence staining and quantified by immunofluorescence intensity. The specimens were double stained with ubiquitin to demonstrate the relationship between inflammasome activation and MDB formation. MAVS, caspase1, IL-18, and TNF-?? showed increases in expression in AH compared to the controls (p&lt;0.05), and NAIP expression markedly increased in AH compared to the controls (p&lt;0.01). There was a trend that levels of NLRP3, ASC, caspase1, IL-18, IL-10, and p65 expression correlated with the number of MDBs found in the same field of measurement (correlation coefficients were between 0.62 and 0.93, p&lt;0.05). Our results demonstrate the activation of the inflammasome in AH and suggest that MDB could be an indicator of the extent of inflammasome activation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Peng</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>LABioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>French</LastName>
                    <ForeName>Barbara A</ForeName>
                    <Initials>BA</Initials>
                    <Affiliation>LABioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tillman</LastName>
                    <ForeName>Brittany</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>LABioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morgan</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>VA Medical Center, Department of Medicine, Long Beach, CA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>French</LastName>
                    <ForeName>Samuel W</ForeName>
                    <Initials>SW</Initials>
                    <Affiliation>LABioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA. Electronic address: sfrench@labiomed.org.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Mol Pathol</MedlineTA>
            <NlmUniqueID>0370711</NlmUniqueID>
            <ISSNLinking>0014-4800</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alcoholic steatohepatitis</Keyword>
            <Keyword MajorTopicYN="N">Inflammasome</Keyword>
            <Keyword MajorTopicYN="N">Liver disease development</Keyword>
            <Keyword MajorTopicYN="N">Mallory???Denk bodies (MDBs)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-4800(14)00132-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexmp.2014.08.006</ArticleId>
            <ArticleId IdType="pubmed">25149528</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149497</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1192</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mast cell-mediated reactions in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn>239-47</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1173-8_18</ELocationID>
            <Abstract>
                <AbstractText>Mast cells are involved in many physiological reactions in which their functions can be very diverse. Models of allergic skin inflammation and systemic anaphylactic reactions in mice are validated methods in which the role of mast cells is well established. In this chapter, we therefore present protocols for passive cutaneous anaphylaxis and contact hypersensitivity, i.e., models which can be used to identify and characterize the role of mast cells as well as mast cell mediators and receptors in allergic IgE-dependent and -independent skin inflammation, and for passive systemic anaphylaxis, a model ideally suited to characterize the systemic effects of mast cell-derived mediators and mast cell receptors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gim??nez-Rivera</LastName>
                    <ForeName>Vladimir Andrey</ForeName>
                    <Initials>VA</Initials>
                    <Affiliation>Department of Dermatology and Allergy, Charit?? - Universit??tsmedizin Berlin, Charit??platz 1, 10117, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Metz</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siebenhaar</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1173-8_18</ArticleId>
            <ArticleId IdType="pubmed">25149497</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149484</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1192</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Generation of mast cells from murine stem cell progenitors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>63-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1173-8_5</ELocationID>
            <Abstract>
                <AbstractText>Mouse bone marrow-derived mast cells (mBMMCs) are an invaluable tool for the study of mast cell function from wild-type, knockout, and transgenic mice. This method describes the isolation of mast cell progenitors from the bone marrow of mouse femurs and their subsequent culture in an IL-3-rich culture medium. After 4 weeks, mBMMCs are obtained in high number and are of high purity. Assessment of their granularity by toluidine staining and IgE receptor expression by flow cytometry are also described. These cells are a useful tool in the determination of mast cell function in innate and adaptive immunity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Swindle</LastName>
                    <ForeName>Emily J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Faculty of Medicine, Academic Unit of Clinical and Experimental Sciences, Southampton General Hospital, University of Southampton, MPT 810, Rm LF73, SAB, Level F, Tremona Road, Southampton, SO16 6YD, UK, e.j.swindle@soton.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1173-8_5</ArticleId>
            <ArticleId IdType="pubmed">25149484</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149466</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1550-6606</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <ISOAbbreviation>J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Complement Component C5a Permits the Coexistence of Pathogenic Th17 Cells and Type I IFN in Lupus.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">1401322</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Systemic lupus erythematosus (SLE) is a type I IFN (IFN-I)-driven autoimmune disorder with exaggerated B and Th cell responses. Th17 cells, a recently identified Th cell subset, have been strongly implicated in the pathogenesis of SLE. Because IFN-I suppresses the generation and expansion of Th17 cells in an IL-27-dependent manner, it is unclear how pathogenic Th17 cells are generated in SLE in the presence of an environment characterized by high IFN-I levels. In this study, we showed that activation of c5aR on murine macrophages blocked IFN-I-mediated IL-27 production, thus permitting the development of Th17 cells. C5aR activation on IFN-I-responsive macrophages inhibits IRF-1-mediated transactivation of IL-27 gene expression via the PI3K/Akt pathway. Consistently, C5aR-deficient mice exhibited increased IL-27 expression and fewer Th17 cells and consequently developed reduced lupus nephritis in comparison with wild-type mice. In support of these findings in mice, we found that C5a inhibited IFN-I-induced IL-27 production from macrophages of lupus subjects. Moreover, the level of serum C5a correlated with Th17 frequency in peripheral blood. Collectively, these data indicate an essential role for C5a in the generation of pathogenic Th17 responses in SLE. Thus, therapeutic strategies to block C5aR activation may be beneficial for controlling pathogenic Th17-mediated inflammation in SLE.</AbstractText>
                <CopyrightInformation>Copyright ?? 2012 by The American Association of Immunologists, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Pawaria</LastName>
                    <ForeName>Sudesh</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261;</Affiliation>
                </Author>
                <Author>
                    <LastName>Ramani</LastName>
                    <ForeName>Kritika</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261;</Affiliation>
                </Author>
                <Author>
                    <LastName>Maers</LastName>
                    <ForeName>Kelly</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261;</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Youhua</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Division of Pathology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kane</LastName>
                    <ForeName>Lawrence P</ForeName>
                    <Initials>LP</Initials>
                    <Affiliation>Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15261.</Affiliation>
                </Author>
                <Author>
                    <LastName>Levesque</LastName>
                    <ForeName>Marc C</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261;</Affiliation>
                </Author>
                <Author>
                    <LastName>Biswas</LastName>
                    <ForeName>Partha S</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261; psb13@pitt.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Immunol</MedlineTA>
            <NlmUniqueID>2985117R</NlmUniqueID>
            <ISSNLinking>0022-1767</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jimmunol.1401322</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.1401322</ArticleId>
            <ArticleId IdType="pubmed">25149466</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149452</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2050-084X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>eLife</Title>
                <ISOAbbreviation>Elife</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e04177</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.7554/eLife.04177</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The eradication of tumor cells requires communication to and signaling by cells of the immune system. Natural killer (NK) cells are essential tumor-killing effector cells of the innate immune system; however, little is known about whether or how other immune cells recognize tumor cells to assist NK cells. Here, we show that the innate immune receptor Dectin-1 expressed on dendritic cells and macrophages is critical to NK-mediated killing of tumor cells that express N-glycan structures at high levels. Receptor recognition of these tumor cells causes the activation of the IRF5 transcription factor and downstream gene induction for the full-blown tumoricidal activity of NK cells. Consistent with this, we show exacerbated in vivo tumor growth in mice genetically deficient in either Dectin-1 or IRF5. The critical contribution of Dectin-1 in the recognition of and signaling by tumor cells may offer new insight into the anti-tumor immune system with therapeutic implications.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, Chiba et al.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chiba</LastName>
                    <ForeName>Shiho</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ikushima</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ueki</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yanai</LastName>
                    <ForeName>Hideyuki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kimura</LastName>
                    <ForeName>Yoshitaka</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hangai</LastName>
                    <ForeName>Sho</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nishio</LastName>
                    <ForeName>Junko</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Negishi</LastName>
                    <ForeName>Hideo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tamura</LastName>
                    <ForeName>Tomohiko</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Saijo</LastName>
                    <ForeName>Shinobu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Immunology, Medical Mycology Research Center, Chiba University, Chiba, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Iwakura</LastName>
                    <ForeName>Yoichiro</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Taniguchi</LastName>
                    <ForeName>Tadatsugu</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japantada@m.u-tokyo.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Elife</MedlineTA>
            <NlmUniqueID>101579614</NlmUniqueID>
            <ISSNLinking>2050-084X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Mouse</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.04177</ArticleId>
            <ArticleId IdType="pubmed">25149452</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149449</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0614</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Applied microbiology and biotechnology</Title>
                <ISOAbbreviation>Appl. Microbiol. Biotechnol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Low-shear force associated with modeled microgravity and spaceflight does not similarly impact the virulence of notable bacterial pathogens.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">As their environments change, microbes experience various threats and stressors, and in the hypercompetitive microbial world, dynamism and the ability to rapidly respond to such changes allow microbes to outcompete their nutrient-seeking neighbors. Viewed in that light, the very difference between microbial life and death depends on effective stress response mechanisms. In addition to the more commonly studied temperature, nutritional, and chemical stressors, research has begun to characterize microbial responses to physical stress, namely low-shear stress. In fact, microbial responses to low-shear modeled microgravity (LSMMG), which emulates the microgravity experienced in space, have been studied quite widely in both prokaryotes and eukaryotes. Interestingly, LSMMG-induced changes in the virulence potential of several Gram-negative enteric bacteria, e.g., an increased enterotoxigenic Escherichia coli-mediated fluid secretion in ligated ileal loops of mice, an increased adherent invasive E. coli-mediated infectivity of Caco-2 cells, an increased Salmonella typhimurium-mediated invasion of both epithelial and macrophage cells, and S. typhimurium hypervirulence phenotype in BALB/c mice when infected by the intraperitoneal route. Although these were some examples where virulence of the bacteria was increased, there are instances where organisms became less virulent under LSMMG, e.g., hypovirulence of Yersinia pestis in cell culture infections and hypovirulence of methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, and Listeria monocytogenes in a Caenorhabditis elegans infection model. In general, a number of LSMMG-exposed bacteria (but not all) seemed better equipped to handle subsequent stressors such as osmotic shock, acid shock, heat shock, and exposure to chemotherapeutics. This mini-review primarily discusses both LSMMG-induced as well as bona fide spaceflight-specific alterations in bacterial virulence potential, demonstrating that pathogens' responses to low-shear forces vary dramatically. Ultimately, a careful characterization of numerous bacterial pathogens' responses to low-shear forces is necessary to evaluate a more complete picture of how this physical stress impacts bacterial virulence since a &quot;one-size-fits-all&quot; response is clearly not the case.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rosenzweig</LastName>
                    <ForeName>Jason A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Department of Biology and Center for Bionanotechnology and Environmental Research, Texas Southern University, 3100 Cleburne Street, Houston, TX, 77004, USA, rosenzweigja@tsu.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ahmed</LastName>
                    <ForeName>Sandeel</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Eunson</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Chopra</LastName>
                    <ForeName>Ashok K</ForeName>
                    <Initials>AK</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Appl Microbiol Biotechnol</MedlineTA>
            <NlmUniqueID>8406612</NlmUniqueID>
            <ISSNLinking>0175-7598</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00253-014-6025-8</ArticleId>
            <ArticleId IdType="pubmed">25149449</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149441</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2164</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC genomics</Title>
                <ISOAbbreviation>BMC Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Using galaxy-P to leverage RNA-Seq for the discovery of novel protein variations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>703</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current practice in mass spectrometry (MS)-based proteomics is to identify peptides by comparison of experimental mass spectra with theoretical mass spectra derived from a reference protein database; however, this strategy necessarily fails to detect peptide and protein sequences that are absent from the database. We and others have recently shown that customized proteomic databases derived from RNA-Seq data can be employed for MS-searching to both improve MS analysis and identify novel peptides. While this general strategy constitutes a significant advance for the discovery of novel protein variations, it has not been readily transferable to other laboratories due to the need for many specialized software tools. To address this problem, we have implemented readily accessible, modifiable, and extensible workflows within Galaxy-P, short for Galaxy for Proteomics, a web-based bioinformatic extension of the Galaxy framework for the analysis of multi-omics (e.g. genomics, transcriptomics, proteomics) data.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We present three bioinformatic workflows that allow the user to upload raw RNA sequencing reads and convert the data into high-quality customized proteomic databases suitable for MS searching. We show the utility of these workflows on human and mouse samples, identifying 544 peptides containing single amino acid polymorphisms (SAPs) and 187 peptides corresponding to unannotated splice junction peptides, correlating protein and transcript expression levels, and providing the option to incorporate transcript abundance measures within the MS database search process (reduced databases, incorporation of transcript abundance for protein identification score calculations, etc.).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Using RNA-Seq data to enhance MS analysis is a promising strategy to discover novel peptides specific to a sample and, more generally, to improve proteomics results. The main bottleneck for widespread adoption of this strategy has been the lack of easily used and modifiable computational tools. We provide a solution to this problem by introducing a set of workflows within the Galaxy-P framework that converts raw RNA-Seq data into customized proteomic databases.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sheynkman</LastName>
                    <ForeName>Gloria M</ForeName>
                    <Initials>GM</Initials>
                </Author>
                <Author>
                    <LastName>Johnson</LastName>
                    <ForeName>James E</ForeName>
                    <Initials>JE</Initials>
                </Author>
                <Author>
                    <LastName>Jagtap</LastName>
                    <ForeName>Pratik D</ForeName>
                    <Initials>PD</Initials>
                </Author>
                <Author>
                    <LastName>Shortreed</LastName>
                    <ForeName>Michael R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author>
                    <LastName>Onsongo</LastName>
                    <ForeName>Getiria</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Frey</LastName>
                    <ForeName>Brian L</ForeName>
                    <Initials>BL</Initials>
                </Author>
                <Author>
                    <LastName>Griffin</LastName>
                    <ForeName>Timothy J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>Lloyd M</ForeName>
                    <Initials>LM</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Genomics</MedlineTA>
            <NlmUniqueID>100965258</NlmUniqueID>
            <ISSNLinking>1471-2164</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2164-15-703</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2164-15-703</ArticleId>
            <ArticleId IdType="pubmed">25149441</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149432</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2518</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Vaccine</Title>
                <ISOAbbreviation>Vaccine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0264-410X(14)01129-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.vaccine.2014.08.016</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">&quot;Inverse vaccination&quot; refers to antigen-specific tolerogenic immunization treatments that are capable of inhibiting autoimmune responses. In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), initial trials using purified myelin antigens required repeated injections because of the rapid clearance of the antigens. This problem has been overcome by DNA-based vaccines encoding for myelin autoantigens alone or in combination with &quot;adjuvant&quot; molecules, such as interleukin (IL)-4 or IL-10, that support regulatory immune responses. Phase I and II clinical trials with myelin basic protein (MBP)-based DNA vaccines showed positive results in reducing magnetic resonance imaging (MRI)-measured lesions and inducing tolerance to myelin antigens in subsets of MS patients. However, DNA vaccination has potential risks that limit its use in humans. An alternative approach could be the use of protein-based inverse vaccines loaded in polymeric biodegradable lactic-glycolic acid (PLGA) nano/microparticles (NP) to obtain the sustained release of antigens and regulatory adjuvants. The aim of this work was to test the effectiveness of PLGA-NP loaded with the myelin oligodendrocyte glycoprotein (MOG)35-55 autoantigen and recombinant (r) IL-10 to inverse vaccinate mice with EAE. In vitro experiments showed that upon encapsulation in PLGA-NP, both MOG35-55 and rIL-10 were released for several weeks into the supernatant. PLGA-NP did not display cytotoxic or proinflammatory activity and were partially endocytosed by phagocytes. In vivo experiments showed that subcutaneous prophylactic and therapeutic inverse vaccination with PLGA-NP loaded with MOG35-55 and rIL-10 significantly ameliorated the course of EAE induced with MOG35-55 in C57BL/6 mice. Moreover, they decreased the histopathologic lesions in the central nervous tissue and the secretion of IL-17 and interferon (IFN)-?? induced by MOG35-55 in splenic T cells in vitro. These data suggest that subcutaneous PLGA-NP-based inverse vaccination may be an effective tool to treat autoimmune diseases.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cappellano</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy. Electronic address: giuseppe.cappellano@med.unipmn.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Woldetsadik</LastName>
                    <ForeName>Abiy Demeke</ForeName>
                    <Initials>AD</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Orilieri</LastName>
                    <ForeName>Elisabetta</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shivakumar</LastName>
                    <ForeName>Yogesh</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rizzi</LastName>
                    <ForeName>Manuela</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Innovative Research Laboratory for Wound Healing, Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Carniato</LastName>
                    <ForeName>Fabio</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Science and Technology, University of Eastern Piedmont &quot;A. Avogadro&quot;, viale Teresa Michel 11, 15121 Alessandria, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gigliotti</LastName>
                    <ForeName>Casimiro Luca</ForeName>
                    <Initials>CL</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boggio</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Clemente</LastName>
                    <ForeName>Nausicaa</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Comi</LastName>
                    <ForeName>Cristoforo</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dianzani</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Torino, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boldorini</LastName>
                    <ForeName>Renzo</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chiocchetti</LastName>
                    <ForeName>Annalisa</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ren??</LastName>
                    <ForeName>Filippo</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Innovative Research Laboratory for Wound Healing, Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dianzani</LastName>
                    <ForeName>Umberto</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), and Department of Health Sciences, University of Eastern Piedmont &quot;A. Avogadro&quot;, via Solaroli 17, 28100 Novara, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Vaccine</MedlineTA>
            <NlmUniqueID>8406899</NlmUniqueID>
            <ISSNLinking>0264-410X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Interleukin-10</Keyword>
            <Keyword MajorTopicYN="N">PLGA</Keyword>
            <Keyword MajorTopicYN="N">T(REG)</Keyword>
            <Keyword MajorTopicYN="N">Tolerogenic vaccine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0264-410X(14)01129-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.08.016</ArticleId>
            <ArticleId IdType="pubmed">25149432</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149366</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7549</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioural brain research</Title>
                <ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetic inactivation of midkine modulates behavioural responses to ethanol possibly by enhancing GABA(A) receptor sensitivity to GABA(A) acting drugs.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0166-4328(14)00535-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbr.2014.08.023</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Midkine (MK) is a cytokine with important functions in dopaminergic neurons that is found upregulated in the prefrontal cortex of alcoholics. We have studied the behavioural effects of ethanol in MK genetically deficient (MK-/-) and wild type (MK+/+) mice. A low dose of ethanol (1.0g/kg), unable to cause conditioned place preference (CPP) in MK+/+ mice, induced a significant CPP in MK-/- mice, suggesting that MK prevents the rewarding effects of low doses of ethanol. However, this difference between genotypes is lost when a higher, rewarding, dose of ethanol (2.0g/kg) is used. Accordingly, the anxiolytic effects of 1.0mg/kg diazepam, other GABA(A) acting drug, were significantly enhanced in MK-/- mice compared to MK+/+ mice; however, 2.0mg/kg diazepam caused increased anxiolytic effects in MK+/+ mice. In addition, MK-/- mice showed a significant delayed recovery from ethanol (2.0g/kg)-induced ataxia whereas the sedative effects induced by ethanol (3.6g/kg), tested in a loss of righting reflex paradigm, were found to be similar in MK-/- and MK+/+ mice. The data indicate that MK differentially regulates the behavioural responses to ethanol. The results suggest that differences in the sensitivity of GABA(A) receptors to GABA(A) acting drugs caused by genetic inactivation of MK could underlie the different behavioural responses to ethanol in MK-/- mice. Overall, these results suggest that MK may be a novel genetic factor of importance in alcohol use disorders, and that potentiation of MK signalling pathway may be a promising therapeutic strategy in the treatment of these disorders.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Vicente-Rodr??guez</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Pharmacology lab, Department of Pharmaceutical and Health Sciences. Facultad de Farmacia. Universidad CEU San Pablo, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>P??rez-Garc??a</LastName>
                    <ForeName>Carmen</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Pharmacology lab, Department of Pharmaceutical and Health Sciences. Facultad de Farmacia. Universidad CEU San Pablo, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Haro</LastName>
                    <ForeName>Mar??a</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Biochemistry lab, Department of Chemistry and Biochemistry. Facultad de Farmacia. Universidad CEU San Pablo, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ramos</LastName>
                    <ForeName>Mar??a P</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>Biochemistry lab, Department of Chemistry and Biochemistry. Facultad de Farmacia. Universidad CEU San Pablo, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Herrad??n</LastName>
                    <ForeName>Gonzalo</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Pharmacology lab, Department of Pharmaceutical and Health Sciences. Facultad de Farmacia. Universidad CEU San Pablo, Madrid, Spain. Electronic address: herradon@ceu.es.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Behav Brain Res</MedlineTA>
            <NlmUniqueID>8004872</NlmUniqueID>
            <ISSNLinking>0166-4328</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ALK</Keyword>
            <Keyword MajorTopicYN="N">Conditioned place preference</Keyword>
            <Keyword MajorTopicYN="N">addiction</Keyword>
            <Keyword MajorTopicYN="N">alcohol.</Keyword>
            <Keyword MajorTopicYN="N">fyn</Keyword>
            <Keyword MajorTopicYN="N">pleiotrophin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0166-4328(14)00535-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbr.2014.08.023</ArticleId>
            <ArticleId IdType="pubmed">25149366</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149363</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4539</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Circulation</Title>
                <ISOAbbreviation>Circulation</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CD82 Restrains Angiogenesis by Altering Lipid Raft Clustering and CD44 Trafficking in Endothelial Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">CIRCULATIONAHA.114.011096</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">-Angiogenesis is crucial for many pathological processes and becomes a therapeutic strategy against diseases ranging from inflammation to cancer. The regulatory mechanism of angiogenesis remains unclear. Although tetraspanin CD82 is widely expressed in various endothelial cells(ECs), its vascular function is unknown.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">-Angiogenesis was examined in Cd82-null mice with in vivo and ex vivo morphogenesis assays. Cellular functions, molecular interactions, and signaling were analyzed in Cd82-null ECs. Angiogenic responses to various stimuli became markedly increased upon Cd82 ablation. Major changes of Cd82-null ECs were enhanced migration and invasion, likely resulting from the upregulated expression of cell adhesion molecules (CAMs) such as CD44 and integrins at the cell surface and subsequently elevated outside-in signaling. Gangliosides, lipid raft clustering, and CD44-membrane microdomain interactions were increased in the plasma membrane of Cd82-null ECs, leading to less clathrin-independent endocytosis and then more surface presence of CD44.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">-Our study reveals that CD82 restrains pathological angiogenesis by inhibiting EC movement, lipid raft clustering and CAM trafficking modulate angiogenic potential, and the perturbation of CD82-ganglioside-CD44 signaling attenuates angiogenesis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wei</LastName>
                    <ForeName>Quan</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK &amp; West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Richardson</LastName>
                    <ForeName>Mekel M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Roy</LastName>
                    <ForeName>Nathan H</ForeName>
                    <Initials>NH</Initials>
                    <Affiliation>University of Vermont, Burlington, VT.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rodgers</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Yuechueng</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>Chenying</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>Yingjun</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK; Tongji Hospital, Wuhan, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Wenyuan</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>University of Tennessee, Memphis, TN.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Chao</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Yuanjian</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>University of Tennessee, Memphis, TN.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Yao</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>University of Tennessee, Memphis, TN.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>Lexi</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Jianxing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boulton</LastName>
                    <ForeName>Michael E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>Indiana University, Indianapolis, IN.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pasula</LastName>
                    <ForeName>Satish</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Oklahoma Medical Research Foundation, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wren</LastName>
                    <ForeName>Jonathan D</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Oklahoma Medical Research Foundation, Oklahoma City, OK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Xiaolin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Tongji Hospital, Wuhan, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tanaka</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>German Cancer Research Center, Heidelberg, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thali</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Vermont, Burlington, VT.</Affiliation>
                </Author>
                <Author>
                    <LastName>H??mmerling</LastName>
                    <ForeName>G??nter J</ForeName>
                    <Initials>GJ</Initials>
                    <Affiliation>German Cancer Research Center, Heidelberg, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Xin A</ForeName>
                    <Initials>XA</Initials>
                    <Affiliation>University of Oklahoma Health Science Center, Oklahoma City, OK xin-zhang-1@ouhsc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Circulation</MedlineTA>
            <NlmUniqueID>0147763</NlmUniqueID>
            <ISSNLinking>0009-7322</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">cell adhesion molecule</Keyword>
            <Keyword MajorTopicYN="N">lipids</Keyword>
            <Keyword MajorTopicYN="N">membrane lipids</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CIRCULATIONAHA.114.011096</ArticleId>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.011096</ArticleId>
            <ArticleId IdType="pubmed">25149363</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149359</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phosphodiesterase 4D Inhibitors Limit Prostate Cancer Growth Potential.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">molcanres.0110.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Phosphodiesterase 4D (PDE4D) has recently been implicated as a proliferation promoting factor in prostate cancer and is over-expressed in human prostate carcinoma. However, the effects of PDE4D inhibition using pharmacological inhibitors have not been examined in prostate cancer. These studies examined the effects of selective PDE4D inhibitors, NVP-ABE171 and cilomilast, as anti-prostate cancer therapies in both in vitro and in vivo models. The effects of PDE4D inhibitors on pathways that are critical in prostate cancer and/or downstream of cyclic AMP (cAMP) were examined. Both NVPABE171 and cilomilast decreased cell growth. In vitro, PDE4D inhibitors lead to decreased signaling of the sonic hedgehog (SHH), Androgen Receptor (AR), and MAPK pathways, but growth inhibition was best correlated to the sonic hedgehog pathway. PDE4D inhibition also reduced proliferation of epithelial cells induced by paracrine signaling from co-cultured stromal cells that had activated hedgehog signaling. In addition, PDE4D inhibitors decreased the weight of the prostate in wild-type mice. Prostate cancer xenografts grown in nude mice that were treated with cilomilast or NVPABE171 had decreased wet weight and increased apoptosis compared to vehicle treated controls. These studies suggest the pharmacological inhibition of PDE4D using small molecule inhibitors is an effective option for prostate cancer therapy. Implications: PDE4D inhibitors decrease the growth of prostate cancer cells in vivo and in vitro, and PDE4D inhibition has therapeutic potential in prostate cancer.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Powers</LastName>
                    <ForeName>Ginny L</ForeName>
                    <Initials>GL</Initials>
                    <Affiliation>Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hammer</LastName>
                    <ForeName>Kimberly D P</ForeName>
                    <Initials>KD</Initials>
                    <Affiliation>Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison.</Affiliation>
                </Author>
                <Author>
                    <LastName>Domenech</LastName>
                    <ForeName>Maribella</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Chemical Engineering, University of Puerto Rico.</Affiliation>
                </Author>
                <Author>
                    <LastName>Frantskevich</LastName>
                    <ForeName>Katsiaryna</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison.</Affiliation>
                </Author>
                <Author>
                    <LastName>Malinowski</LastName>
                    <ForeName>Rita L</ForeName>
                    <Initials>RL</Initials>
                    <Affiliation>Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bushman</LastName>
                    <ForeName>Wade</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Urology, University of Wisconsin School of Medicine and Public Health.</Affiliation>
                </Author>
                <Author>
                    <LastName>Beebe</LastName>
                    <ForeName>David J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>Department of Biomedical Engineering and Wisconsin Institute for Medical Research, University of Wisconsin-Madison.</Affiliation>
                </Author>
                <Author>
                    <LastName>Marker</LastName>
                    <ForeName>Paul C</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison marker@wisc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1541-7786.MCR-14-0110</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-14-0110</ArticleId>
            <ArticleId IdType="pubmed">25149359</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149332</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1525-3163</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of animal science</Title>
                <ISOAbbreviation>J. Anim. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Commercially available avian and mammalian whole prey diet items targeted for consumption by managed exotic and domestic pet felines: True metabolizable energy and amino acid digestibility utilizing the precision-fed cecectomized rooster assay.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jas.2013-7246</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Whole prey diets are commonly used in the zoo and home setting for captive exotic and domestic cats, respectively. Despite their increase in popularity, nutrient digestibility of such diets has been poorly studied. In this study, the precision-fed cecectomized rooster assay was utilized to determine the protein quality and nitrogen-corrected true metabolizable energy (TMEn) of 17 whole prey samples [mice (1 to 2 d, 10 to 13 d, 21 to 25 d, 30 to 40 d, and 150 to 180 d-old); rats (1 to 4 d, 10 to 13 d, 21 to 25 d, 32 to 42 d, and &gt; 60 d-old); rabbits (stillborn, 30 to 45 d, &gt; 65 d-old); chicken (1 to 3 d-old); and quail (1 to 3 d, 21 to 40 d, and &gt; 60 d-old)], and 2 ground poultry-based products (chicken; duck). Amino acid score (AAS) and protein digestibility corrected AAS (PDCAAS) were calculated utilizing the nutrient profile recommendations for domestic cat food as a reference value (AAFCO, 2012). Average individual indispensable amino acid (IAA) and total IAA (TIAA) digestibility coefficients ranged, but depended on amino acid (TIAA: 84 to 94%; Arg: 85 to 95%; His: 87 to 96%; Ile 82 to 92%; Leu: 84 to 94%; Lys: 85 to 93%; Met: 89 to 97%; Phe: 83 to 94%; Thr: 80 to 95%; Trp: 84 to 94%; Val: 80 to 93%) and sample. For a majority of the whole prey items, AA concentrations were greater than the AAFCO (2012) domestic cat nutrient profile recommendations for growth and reproduction and adult maintenance; however, some whole prey had AA concentrations below the AAFCO (2012) recommendations: Met + Cys (1.10% DM) in ground duck (1.06% DM), and Tau (0.20% DM) in 30 to 45 and &gt; 65 d-old rabbits (0.01 and 0.10% DM, respectively), 150 to 180 d-old mice (0.18% DM), and ground duck (0.15% DM). The TMEn (3.76 to 6.44 kcal/g DM) expressed as the percent of GE (i.e., TMEn/GE) ranged from 66 to 85%, demonstrating how variable the digestibility of these items may be and justifying more research in this area. Both Met and Tau are commonly added to commercial pet foods, so supplements are readily available to address potential deficiencies and improve protein quality. A direct comparison of the metabolizable energy of whole prey items by in vivo feline and rooster experiments is needed.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kerr</LastName>
                    <ForeName>K R</ForeName>
                    <Initials>KR</Initials>
                    <Affiliation>Division of Nutritional Sciences Department of Animal Sciences, University of Illinois, Urbana, IL 61801.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kappen</LastName>
                    <ForeName>K L</ForeName>
                    <Initials>KL</Initials>
                    <Affiliation>Department of Animal Sciences, University of Illinois, Urbana, IL 61801.</Affiliation>
                </Author>
                <Author>
                    <LastName>Garner</LastName>
                    <ForeName>L M</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>Department of Animal Sciences, University of Illinois, Urbana, IL 61801.</Affiliation>
                </Author>
                <Author>
                    <LastName>Utterback</LastName>
                    <ForeName>P L</ForeName>
                    <Initials>PL</Initials>
                    <Affiliation>Department of Animal Sciences, University of Illinois, Urbana, IL 61801.</Affiliation>
                </Author>
                <Author>
                    <LastName>Parsons</LastName>
                    <ForeName>C M</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Department of Animal Sciences, University of Illinois, Urbana, IL 61801.</Affiliation>
                </Author>
                <Author>
                    <LastName>Swanson</LastName>
                    <ForeName>K S</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>Division of Nutritional Sciences Department of Animal Sciences, University of Illinois, Urbana, IL 61801 ksswanso@illinois.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Anim Sci</MedlineTA>
            <NlmUniqueID>8003002</NlmUniqueID>
            <ISSNLinking>0021-8812</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Feline nutrition</Keyword>
            <Keyword MajorTopicYN="N">nutrient digestibility</Keyword>
            <Keyword MajorTopicYN="N">protein quality</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jas.2013-7246</ArticleId>
            <ArticleId IdType="doi">10.2527/jas.2013-7246</ArticleId>
            <ArticleId IdType="pubmed">25149332</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149315</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2334</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC infectious diseases</Title>
                <ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>456</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Presence of capsule enhances the virulence of bacteria that cause pneumonia, meningitis, cystic fibrosis, dental caries, periodontitis. Capsule is an important virulence factor for Klebsiella pneumoniae and infections due to this pathogen have been associated with high mortality rates. In the present study, use of an Aeromonas punctata derived capsule depolymerase against K. pneumoniae, to reinstate the efficacy of gentamicin during pneumonia and septicemia was investigated.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Depolymerase was administered in mice intraperitoneally (50 mug) alone as well in combination with gentamicin (1.5 mg/kg), 24 h post infection during acute lung infection and 6 h later during septicemia. Bacterial load, neutrophil infiltration and cytokine levels were estimated. The immunogenicity of protein was also studied.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In comparison to groups treated with gentamicin alone, combination treatment with depolymerase and gentamicin significantly reduced (P &lt; 0.01) bacterial titer in the lungs, liver, kidney, spleen and blood of experimental animals. Highly significant reduction in neutrophil infiltration and levels of pro-inflammatory and anti-inflammatory cytokines was also observed. This indicated an efficient capsule removal by the enzyme, that improved gentamicin efficacy in vivo. Although the enzyme was found to be immunogenic, but no significant reduction in treatment efficacy was observed in the preimmunized as well as naive mice. In addition, as confirmed through flow cytometry, the hyperimmune sera raised against the enzyme did not neutralize its activity.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results confirm that administration of enzyme 'depolymerase' along with gentamicin not only checked the virulence of K. pneumoniae in vivo but it also increased its susceptibility to gentamicin at a lower concentration. Such a strategy would help to avoid exposure to higher concentration of gentamicin. Moreover, since this decapsulating protein does not possess a lytic activity therefore there would be no chances of development of bacterial resistance against it. Therefore, it should be studied further for its successful inclusion in our prophylactic/therapeutic regimes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Bansal</LastName>
                    <ForeName>Shruti</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Harjai</LastName>
                    <ForeName>Kusum</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Chhibber</LastName>
                    <ForeName>Sanjay</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Infect Dis</MedlineTA>
            <NlmUniqueID>100968551</NlmUniqueID>
            <ISSNLinking>1471-2334</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2334-14-456</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2334-14-456</ArticleId>
            <ArticleId IdType="pubmed">25149315</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149277</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1591-9528</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental medicine</Title>
                <ISOAbbreviation>Clin. Exp. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Selective inhibition of CDK7 ameliorates experimental arthritis in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cyclin-dependent kinases (CDKs) have emerged as anti-inflammatory targets. The purpose of this study was to explore the therapeutic effects of a selective CDK7 inhibitor, BS-181, on mice with established collagen-induced arthritis (CIA). CIA mice were administered intraperitoneally with BS-181 (10??mg/kg) twice daily for 2??weeks. Control mice received vehicle only. Arthritis severity and joint histopathology were examined. The proinflammatory cytokines and anti-type II collagen antibodies (anti-CII) were determined by ELISA. IkB kinase (IKK)-??/NF-??B activation in the arthritic joints was assessed by Western blot. The ratio of Th17 cells was determined by flow cytometry. In vitro, splenocytes from mice with established CIA were stimulated with CII in the presence or absence of BS-181 and cytokines were detected. BS-181 treatment reduced the clinical score and histological damage in CIA mice. The serum proinflammatory cytokines (IL-6, IL-1?? and IL-17) and anti-CII IgG2a levels were also decreased by BS-181 administration. Moreover, IKK-??/NF-??B signaling pathway was inhibited in arthritic joints. BS-181 administration also decreased the ratio of Th17 cells. In addition, CIA splenocytes pretreated with BS-181 produced less proinflammatory cytokines in vitro. These findings indicate that CDK7 inhibition by BS-181 is effective in the treatment of CIA, which might be mediated by suppression of IKK-??/NF-??B activation and Th17 cell response.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Xia</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, No. 74 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China, gysyxy@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Li-Ying</ForeName>
                    <Initials>LY</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Mei-Ling</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Zheng</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Hong</LastName>
                    <ForeName>Hong-Hai</ForeName>
                    <Initials>HH</Initials>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Xu-Guang</ForeName>
                    <Initials>XG</Initials>
                </Author>
                <Author>
                    <LastName>Gao</LastName>
                    <ForeName>Guo-Quan</ForeName>
                    <Initials>GQ</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Exp Med</MedlineTA>
            <NlmUniqueID>100973405</NlmUniqueID>
            <ISSNLinking>1591-8890</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10238-014-0305-6</ArticleId>
            <ArticleId IdType="pubmed">25149277</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149275</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0878</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell and tissue research</Title>
                <ISOAbbreviation>Cell Tissue Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression and localization of somatostatin receptor types 3, 4 and 5 in the wild-type, SSTR1 and SSTR1/SSTR2 knockout mouse cochlea.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Somatostatin (SST) is a peptide hormone that exerts inhibitory effects mediated through binding to specific cell surface G protein-coupled receptors, of which five distinct subtypes (SSTR1-SSTR5) have been characterized. Our study performed on mouse cochlear hair cells shows the expression and localization of the three receptors (SSTR3-SSTR5) in wild-type (WT), single-knockout (SSTR1 KO) and double-knockout SSTR1/SSTR2 (DKO) mice. Similar SSTRs expression were observed in the inner hair cells (IHC), outer hair cells (OHC) and supporting cells of cultivated P7 mouse organ of Corti (OC) explants as well as in cultivated cochlear neuroepithelial supporting cells (NEsc). We found differences in the expression of SSTR3-5 in WT, SSTR1 KO and DKO mouse cochlea, which might be explained as a compensatory effect in the cochlea after the loss of SSTR1 and/or SSTR2.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Radojevic</LastName>
                    <ForeName>Vesna</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Biomedicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland, vesna.radojevic@unibas.ch.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bodmer</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Tissue Res</MedlineTA>
            <NlmUniqueID>0417625</NlmUniqueID>
            <ISSNLinking>0302-766X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-014-1977-7</ArticleId>
            <ArticleId IdType="pubmed">25149275</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149237</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-9939</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>107</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pesticide biochemistry and physiology</Title>
                <ISOAbbreviation>Pestic Biochem Physiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>cis-Bifenthrin enantioselectively induces hepatic oxidative stress in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>61-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pestbp.2013.05.006</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0048-3575(13)00090-4</ELocationID>
            <Abstract>
                <AbstractText>Bifenthrin (BF), as a chiral synthetic pyrethroid, is widely used to control field and household pests. In China, the commercial cis-BF contained two enantiomers including 1R-cis-BF and 1S-cis-BF. However, the difference in oxidative stress induced by the two enantiomers in mice still remains unclear. In the present study, 4 week-old adolescent male ICR mice were orally administered cis-BF, 1R-cis-BF or 1S-cis-BF daily for 2, 4 and 6weeks at doses of 5mg/kg/day, respectively. We found that the hepatic reactive oxygen species (ROS) levels, as well as the malondialdehyde (MDA) and glutathione (GSH) content both in the serum and liver increased significantly in the 4 or 6weeks 1S-cis-BF treated groups. The activities of superoxide dismutase (SOD) and catalase (CAT) also changed significantly in the serum and liver of 1S-cis-BF treated mice. More importantly, the significant differences in MDA content and CAT activity both in the serum and liver, and the activities of total antioxidant capacity (T-AOC) and SOD in serum were also observed between the 1S-cis-BF and 1R-cis-BF treated groups. Moreover, the transcription of oxidative stress response related genes including Sod1, Cat and heme oxygenase-1(Ho-1) in the liver of 1S-cis-BF treated groups were also significant higher than those in 1R-cis-BF treated group. Thus, it was concluded that cis-BF induced hepatic oxidative stress in an enantiomer specific manner in mice when exposed during the puberty, and that 1S-cis-BF showed much more toxic in hepatic oxidative stress than 1R-cis-BF.</AbstractText>
                <CopyrightInformation>Copyright ?? 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Yuanxiang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>College of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jiangcong</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>College of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Xiuhong</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>College of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Linggang</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>College of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Zhengwei</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>College of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310032, China. Electronic address: azwfu2003@yahoo.com.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>05</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pestic Biochem Physiol</MedlineTA>
            <NlmUniqueID>1301573</NlmUniqueID>
            <ISSNLinking>0048-3575</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Enantiomer</Keyword>
            <Keyword MajorTopicYN="N">Mice</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
            <Keyword MajorTopicYN="N">cis-Bifenthrin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0048-3575(13)00090-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pestbp.2013.05.006</ArticleId>
            <ArticleId IdType="pubmed">25149237</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149216</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1878-0814</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>127</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Progress in molecular biology and translational science</Title>
                <ISOAbbreviation>Prog Mol Biol Transl Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The retrograde response: a conserved compensatory reaction to damage from within and from without.</ArticleTitle>
            <Pagination>
                <MedlinePgn>133-54</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/B978-0-12-394625-6.00005-2</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">B978-0-12-394625-6.00005-2</ELocationID>
            <Abstract>
                <AbstractText>The retrograde response was discovered in Saccharomyces cerevisiae as a signaling pathway from the mitochondrion to the nucleus that triggers an array of gene regulatory changes in the latter. The activation of the retrograde response compensates for the deficits associated with aging, and thus it extends yeast replicative life span. The retrograde response is activated by the progressive decline in mitochondrial membrane potential during aging that is the result of increasing mitochondrial dysfunction. The ensuing metabolic adaptations and stress resistance can only delay the inevitable demise of the yeast cell. The retrograde response is embedded in a network of signal transduction pathways that impinge upon virtually every aspect of cell physiology. Thus, its manifestations are complicated. Many of these pathways have been implicated in life span regulation quite independently of the retrograde response. Together, they operate in a delicate balance in promoting longevity. The retrograde response is closely aligned with cell quality control, often performing when quality control is not sufficient to assure longevity. Among the key pathways related to this aspect of retrograde signaling are target of rapamycin and ceramide signaling. The retrograde response can also be found in other organisms, including Caenorhabditis elegans, Drosophila melanogaster, mouse, and human, where it exhibits an ever-increasing complexity that may be corralled by the transcription factor NF??B. The retrograde response may have evolved as a cytoprotective mechanism that senses and defends the organism from pathogens and environmental toxins.</AbstractText>
                <CopyrightInformation>?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jazwinski</LastName>
                    <ForeName>S Michal</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Tulane Center for Aging and Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Prog Mol Biol Transl Sci</MedlineTA>
            <NlmUniqueID>101498165</NlmUniqueID>
            <ISSNLinking>1877-1173</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">C. elegans</Keyword>
            <Keyword MajorTopicYN="N">Ceramide signaling</Keyword>
            <Keyword MajorTopicYN="N">Compensation</Keyword>
            <Keyword MajorTopicYN="N">Interorganelle communication</Keyword>
            <Keyword MajorTopicYN="N">Mitochondrial quality control</Keyword>
            <Keyword MajorTopicYN="N">Retrograde response</Keyword>
            <Keyword MajorTopicYN="N">Yeast</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">B978-0-12-394625-6.00005-2</ArticleId>
            <ArticleId IdType="doi">10.1016/B978-0-12-394625-6.00005-2</ArticleId>
            <ArticleId IdType="pubmed">25149216</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149213</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1878-0814</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>127</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Progress in molecular biology and translational science</Title>
                <ISOAbbreviation>Prog Mol Biol Transl Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mitochondrial DNA mutations in aging.</ArticleTitle>
            <Pagination>
                <MedlinePgn>29-62</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/B978-0-12-394625-6.00002-7</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">B978-0-12-394625-6.00002-7</ELocationID>
            <Abstract>
                <AbstractText>The relationship of mitochondrial DNA mutations to aging is still debated. Most mtDNA mutations are recessive: there are multiple copies per cell and mutation needs to clonally expand to cause respiratory deficiency. Overall mtDNA mutant loads are low, so effects of mutations are limited to critical areas where mutations locally reach high fractions. This includes respiratory chain deficient zones in muscle fibers, respiratory-deficient crypts in colon, and massive expansions of deleted mtDNA in substantia nigra neurons. mtDNA &quot;mutator&quot; mouse with increased rate of mtDNA mutations is a useful model, although rates and distribution of mutations may significantly deviate from what is observed in human aging. Comparison of species with different longevity reveals intriguing longevity-related traits in mtDNA sequence, although their significance is yet to be evaluated. The impact of somatic mtDNA mutations rapidly increases with age, so their importance is expected to grow as human life expectancy increases.</AbstractText>
                <CopyrightInformation>?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khrapko</LastName>
                    <ForeName>Konstantin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Turnbull</LastName>
                    <ForeName>Doug</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>LLHW Centre for Ageing and Vitality, Newcastle University, Newcastle, United Kingdom.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Prog Mol Biol Transl Sci</MedlineTA>
            <NlmUniqueID>101498165</NlmUniqueID>
            <ISSNLinking>1877-1173</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Aging</Keyword>
            <Keyword MajorTopicYN="N">Clonal expansion</Keyword>
            <Keyword MajorTopicYN="N">Evolution of aging</Keyword>
            <Keyword MajorTopicYN="N">Mitochondrial DNA</Keyword>
            <Keyword MajorTopicYN="N">Mutations</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">B978-0-12-394625-6.00002-7</ArticleId>
            <ArticleId IdType="doi">10.1016/B978-0-12-394625-6.00002-7</ArticleId>
            <ArticleId IdType="pubmed">25149213</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149207</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0542</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Immunology letters</Title>
                <ISOAbbreviation>Immunol. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clonal differences in IgE antibodies affect cutaneous anaphylaxis-associated thermal sensitivity in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0165-2478(14)00177-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.imlet.2014.08.007</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cellular and molecular mediators of immune responses are increasingly implicated in acute and chronic pain pathophysiologies. Here we demonstrate that passive cutaneous IgE/Ag anaphylaxis provokes increased thermal sensitivity in the hind paw tissue of mice. The murine anti-DNP IgE antibodies SPE-7 and ??26 are known to induce differential cytokine production in bone marrow cultured mast cells in vitro without antigen challenge. We found a novel, antigen-dependent heterogeneity in the thermal pain responses elicited in the hind paws between SPE-7 and ??26 sensitized DNP-challenged mice. Mice experienced pronounced hind paw thermal sensitivity lasting 6h after DNP challenge when sensitized with SPE-7 but not ??26 IgE. The two IgE clones induced equivalent hind paw edema, neutrophil influx, cytokine production, and reduction in tissue histamine content in vivo, and bound to the same or overlapping epitopes on the DNP antigen in vitro. Therefore IgE antibodies against the same antigen can induce comparable inflammation, yet contribute to markedly different anaphylaxis-associated pain within an allergic response, suggesting that non-canonical IgE binding partners such as sensory neurons may play a role in allergy-related pain responses.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mack</LastName>
                    <ForeName>Madison</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tonc</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ashbaugh</LastName>
                    <ForeName>Alyssa</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wetzel</LastName>
                    <ForeName>Abigail</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sykes</LastName>
                    <ForeName>Akilah</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Engblom</LastName>
                    <ForeName>Camilla</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shabani</LastName>
                    <ForeName>Estela</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mora-Solano</LastName>
                    <ForeName>Carolina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Trier</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Swanson</LastName>
                    <ForeName>Linnea</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ewan</LastName>
                    <ForeName>Emily</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Martinov</LastName>
                    <ForeName>Tijana</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chatterjea</LastName>
                    <ForeName>Devavani</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Macalester College, Department of Biology, Saint Paul, MN 55105, United States. Electronic address: chatterjead@macalester.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Immunol Lett</MedlineTA>
            <NlmUniqueID>7910006</NlmUniqueID>
            <ISSNLinking>0165-2478</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cytokinergic IgE</Keyword>
            <Keyword MajorTopicYN="N">Passive cutaneous anaphylaxis</Keyword>
            <Keyword MajorTopicYN="N">Thermal pain</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25149207</ArticleId>
            <ArticleId IdType="pii">S0165-2478(14)00177-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.imlet.2014.08.007</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149191</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-569X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of dermatological science</Title>
                <ISOAbbreviation>J. Dermatol. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Peroxisome proliferator-activated receptor ?? modulates MMP-2 secretion and elastin expression in human dermal fibroblasts exposed to ultraviolet B radiation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0923-1811(14)00184-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jdermsci.2014.07.011</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Changes in skin connective tissues mediated by ultraviolet (UV) radiation have been suggested to cause the skin wrinkling normally associated with premature aging of the skin. Recent investigations have shown that peroxisome proliferator-activated receptor (PPAR) ?? plays multiple biological roles in skin homeostasis.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We attempted to investigate whether PPAR?? modulates elastin protein levels and secretion of matrix metalloproteinase (MMP)-2 in UVB-irradiated human dermal fibroblasts (HDFs) and mouse skin.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">These studies were undertaken in primary HDFs or HR-1 hairless mice using Western blot analyses, small interfering (si)RNA-mediated gene silencing, and Fluorescence microscopy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In HDFs, UVB irradiation induced increased secretion of MMP-2 and reduced levels of elastin. Activation of PPAR?? by GW501516, a ligand specific for PPAR??, markedly attenuated UVB-induced MMP-2 secretion with a concomitant increase in the level of elastin. These effects were reduced by the presence of siRNAs against PPAR?? or treatment with GSK0660, a specific inhibitor of PPAR??. Furthermore, GW501516 elicited a dose- and time-dependent increase in the expression of elastin. Modulation of MMP-2 secretion and elastin levels by GW501516 was associated with a reduction in reactive oxygen species (ROS) production in HDFs exposed to UVB. Finally, in HR-1 hairless mice, administration of GW501516 significantly reduced UVB-induced MMP-2 expression with a concomitant increase in elastin levels, and these effects were significantly reduced by the presence of GSK0660.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that PPAR??-mediated modulation of MMP-2 secretion and elastin expression may contribute to the maintenance of skin integrity by inhibiting ROS generation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ham</LastName>
                    <ForeName>Sun Ah</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yoo</LastName>
                    <ForeName>Taesik</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hwang</LastName>
                    <ForeName>Jung Seok</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kang</LastName>
                    <ForeName>Eun Sil</ForeName>
                    <Initials>ES</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Paek</LastName>
                    <ForeName>Kyung Shin</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>Department of Nursing, Semyung University, Jechon, Chungbuk, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Chankyu</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jin-Hoi</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Do</LastName>
                    <ForeName>Jeong Tae</ForeName>
                    <Initials>JT</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Seo</LastName>
                    <ForeName>Han Geuk</ForeName>
                    <Initials>HG</Initials>
                    <Affiliation>Department of Animal Biotechnology, Konkuk University, Seoul, Republic of Korea. Electronic address: hgseo@konkuk.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Dermatol Sci</MedlineTA>
            <NlmUniqueID>9011485</NlmUniqueID>
            <ISSNLinking>0923-1811</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Elastin</Keyword>
            <Keyword MajorTopicYN="N">HDFs</Keyword>
            <Keyword MajorTopicYN="N">MMP-2</Keyword>
            <Keyword MajorTopicYN="N">PPAR??</Keyword>
            <Keyword MajorTopicYN="N">UVB</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0923-1811(14)00184-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2014.07.011</ArticleId>
            <ArticleId IdType="pubmed">25149191</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149188</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4571</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Circulation research</Title>
                <ISOAbbreviation>Circ. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Basigin Mediates Pulmonary Hypertension by Promoting Inflammation and Vascular Smooth Muscle Cell Proliferation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">CIRCRESAHA.114.304563</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Rationale: Cyclophilin A (CyPA) is secreted from vascular smooth muscle cells (VSMCs) by oxidative stress and promotes VSMC proliferation. However, the role of extracellular CyPA and its receptor Basigin (Bsg, encoded by Bsg) in the pathogenesis of pulmonary hypertension (PH) remains to be elucidated. Objective: To determine the role of CyPA/Bsg signaling in the development of PH. Methods and Results: In the pulmonary arteries (PA) of PH patients, immunostaining revealed strong expression of CyPA and Bsg. The PA of CyPA(+/-) and Bsg(+/-) mice exposed to normoxia did not differ in morphology compared with their littermate controls. In contrast, CyPA(+/-)and Bsg(+/-) mice exposed to hypoxia for 4 weeks revealed significantly reduced right ventricular systolic pressure (RVSP), PA remodeling and RV hypertrophy compared with their littermate controls. These features were unaltered by bone marrow reconstitution. To further evaluate the role of vascular Bsg, we harvested pulmonary VSMCs from Bsg(+/+) and Bsg(+/-) mice. Proliferation was significantly reduced in Bsg(+/-) compared with Bsg(+/+) VSMCs. Mechanistic studies demonstrated that Bsg(+/-) VSMCs revealed reduced extracellular signal-regulated kinase (ERK)1/2 activation and less secretion of cytokines/chemokines and growth factors (e.g. PDGF-BB). Finally, in the clinical study, plasma CyPA levels in PH patients were increased in accordance with the severity of pulmonary vascular resistance. Furthermore, event-free curve revealed that high plasma CyPA levels predicted poor outcome in PH patients. Conclusions: These results indicate the crucial role of extracellular CyPA and vascular Bsg in the pathogenesis of PH.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Satoh</LastName>
                    <ForeName>Kimio</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sato</LastName>
                    <ForeName>Taiju</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kikuchi</LastName>
                    <ForeName>Nobuhiro</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Omura</LastName>
                    <ForeName>Junichi</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kurosawa</LastName>
                    <ForeName>Ryo</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Suzuki</LastName>
                    <ForeName>Kota</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sugimura</LastName>
                    <ForeName>Koichiro</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aoki</LastName>
                    <ForeName>Tatsuo</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nochioka</LastName>
                    <ForeName>Kotaro</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tatebe</LastName>
                    <ForeName>Shunsuke</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miyamichi-Yamamoto</LastName>
                    <ForeName>Saori</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miura</LastName>
                    <ForeName>Masanobu</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shimizu</LastName>
                    <ForeName>Toru</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ikeda</LastName>
                    <ForeName>Shohei</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yaoita</LastName>
                    <ForeName>Nobuhiro</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fukumoto</LastName>
                    <ForeName>Yoshihiro</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Minami</LastName>
                    <ForeName>Tatsuro</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miyata</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nakamura</LastName>
                    <ForeName>Kazufumi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Cardiovascular Medicine, Okayama University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ito</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Cardiovascular Medicine, Okayama University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kadomatsu</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Biochemistry, Nagoya University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shimokawa</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Cardiovascular Medicine, Tohoku University Graduate School of Medicine shimo@cardio.med.tohoku.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Circ Res</MedlineTA>
            <NlmUniqueID>0047103</NlmUniqueID>
            <ISSNLinking>0009-7330</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">hypoxia</Keyword>
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">oxidative stress</Keyword>
            <Keyword MajorTopicYN="N">pulmonary circulation</Keyword>
            <Keyword MajorTopicYN="N">pulmonary hypertension</Keyword>
            <Keyword MajorTopicYN="N">vascular remodeling</Keyword>
            <Keyword MajorTopicYN="N">vascular smooth muscle</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CIRCRESAHA.115.304563</ArticleId>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.115.304563</ArticleId>
            <ArticleId IdType="pubmed">25149188</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149138</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2415</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC ophthalmology</Title>
                <ISOAbbreviation>BMC Ophthalmol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of netrin-1 receptors in retina of oxygen-induced retinopathy in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>102</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Netrin-1 has been reported to promote retinal neovascularization in oxygen-induced retinopathy (OIR). However, netrin-1 receptors, which may mediate netrin-1 action during retinal neovascularization, have not been characterized. In this study, we investigated netrin-1 receptor subtype expression and associated changes in the retinas of mice with OIR.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">C57BL/6J mice were exposed to 75+/-2% oxygen for 5 days and then returned to normal air to induce retinal neovascularization. Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot were used to examine the expression of netrin-1 receptor subtypes in the mouse retinas. Double staining of netrin-1 receptor subtypes and isolectin B4 was used to determine the location of the netrin-1 receptor subtypes in the retinas. Inhibition of retinal neovascularization was achieved by UNC5B shRNA plasmid intravitreal injection. Retinal neovascularization was examined by fluorescein angiography and quantification of preretinal neovascular nuclei in retinal sections.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">RT-PCR results showed that, except for UNC5A, netrin-1 receptor subtypes UNC5B, UNC5C, UNC5D, DCC, neogenin, and A2b were all expressed in the retinas of OIR mice 17 days after birth. Western blots showed that only UNC5B expression was significantly increased on that day, and immunofluorescence results showed that only UNC5B and neogenin were expressed in retinal vessels. Treatment of OIR mice with the UNC5B shRNA plasmid dramatically reduced neovascular tufts and neovascular outgrowth into the inner limiting membrane.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">UNC5B may promote retinal neovascularization in OIR mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Dan</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Xiong</LastName>
                    <ForeName>Si-Qi</ForeName>
                    <Initials>SQ</Initials>
                </Author>
                <Author>
                    <LastName>Shang</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Tian</LastName>
                    <ForeName>Xiao-Feng</ForeName>
                    <Initials>XF</Initials>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Xia</LastName>
                    <ForeName>Xiao-Bo</ForeName>
                    <Initials>XB</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Ophthalmol</MedlineTA>
            <NlmUniqueID>100967802</NlmUniqueID>
            <ISSNLinking>1471-2415</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2415-14-102</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2415-14-102</ArticleId>
            <ArticleId IdType="pubmed">25149138</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149126</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0720</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</Title>
                <ISOAbbreviation>Eur J Pharm Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>(18)FDG a PET tumor diagnostic tracer is not a substrate of the ABC transporter P-glycoprotein.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0928-0987(14)00311-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ejps.2014.08.002</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">2-[(18)F]fluoro-2-deoxy-D-glucose ((18)FDG) is a tumor diagnostic radiotracer of great importance in both diagnosing primary and metastatic tumors and in monitoring the efficacy of the treatment. P-glycoprotein (Pgp) is an active transporter that is often expressed in various malignancies either intrinsically or appears later upon disease progression or in response to chemotherapy. Several authors reported that the accumulation of (18)FDG in P-glycoprotein (Pgp) expressing cancer cells (Pgp(+)) and tumors is different from the accumulation of the tracer in Pgp nonexpressing (Pgp(-)) ones, therefore we investigated whether (18)FDG is a substrate or modulator of Pgp pump. Rhodamine 123 (R123) accumulation experiments and ATPase assay were used to detect whether (18)FDG is substrate for Pgp. The accumulation and efflux kinetics of (18)FDG were examined in two different human gynecologic (A2780/A2780AD and KB-3-1/KB-V1) and a mouse fibroblast (3T3 and 3T3MDR1) Pgp(+) and Pgp(-) cancer cell line pairs both in cell suspension and monolayer cultures. We found that (18)FDG and its derivatives did not affect either the R123 accumulation in Pgp(+) cells or the basal and the substrate stimulated ATPase activity of Pgp supporting that they are not substrates or modulators of the pump. Measuring the accumulation and efflux kinetics of (18)FDG in different Pgp(+) and Pgp(-) cell line pairs, we have found that the Pgp(+) cells exhibited significantly higher (p???0.01) (18)FDG accumulation and slightly faster (18)FDG efflux kinetics compared to their Pgp(-) counterparts. The above data support the idea that expression of Pgp may increase the energy demand of cells resulting in higher (18)FDG accumulation and faster efflux. We concluded that (18)FDG and its metabolites are not substrates of Pgp.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Krasznai</LastName>
                    <ForeName>Zo??rd T</ForeName>
                    <Initials>ZT</Initials>
                    <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>Trencs??nyi</LastName>
                    <ForeName>Gy??rgy</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>Krasznai</LastName>
                    <ForeName>Zolt??n</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mikecz</LastName>
                    <ForeName>P??l</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nizsal??czki</LastName>
                    <ForeName>Enik??</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>Szal??ki</LastName>
                    <ForeName>G??bor</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>Szab??</LastName>
                    <ForeName>Judit P</ForeName>
                    <Initials>JP</Initials>
                    <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>Balkay</LastName>
                    <ForeName>L??szl??</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
                <Author>
                    <LastName>M??ri??n</LastName>
                    <ForeName>Ter??z</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary. Electronic address: marian.terez@med.unideb.hu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Goda</LastName>
                    <ForeName>Katalin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Pharm Sci</MedlineTA>
            <NlmUniqueID>9317982</NlmUniqueID>
            <ISSNLinking>0928-0987</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">(18)FDG</Keyword>
            <Keyword MajorTopicYN="N">2-Chloro-2-deoxy-D-glucose (PubChem CID: 151933)</Keyword>
            <Keyword MajorTopicYN="N">2-Fluoro-2-deoxy-D-glucose (PubChem CID: 170049)</Keyword>
            <Keyword MajorTopicYN="N">2-deoxy-D-glucose (PubChem CID: 108223)</Keyword>
            <Keyword MajorTopicYN="N">Cyclosporin A (PubChem CID: 5284373)</Keyword>
            <Keyword MajorTopicYN="N">Doxorubicin (PubChem CID: 31703)</Keyword>
            <Keyword MajorTopicYN="N">Gynecologic cancer cells</Keyword>
            <Keyword MajorTopicYN="N">Multidrug resistance</Keyword>
            <Keyword MajorTopicYN="N">PET tumordiagnostic tracer</Keyword>
            <Keyword MajorTopicYN="N">Pgp substrate</Keyword>
            <Keyword MajorTopicYN="N">Rhodamine 123 (PubChem CID: 65217)</Keyword>
            <Keyword MajorTopicYN="N">Verapamil hydrochloride (PubChem CID: 62969)</Keyword>
            <Keyword MajorTopicYN="N">Vinblastine (PubChem CID: 241903_</Keyword>
            <Keyword MajorTopicYN="N">[(18)F]Fluoro-2-deoxy-2-D-glucose (PubChem CID: 3232583)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0928-0987(14)00311-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejps.2014.08.002</ArticleId>
            <ArticleId IdType="pubmed">25149126</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149125</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3476</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of pharmaceutics</Title>
                <ISOAbbreviation>Int J Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-5173(14)00593-6</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ijpharm.2014.08.027</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In this paper, a series of doxorubicin-loaded and negative-charge-functionalized mesoporous silica nanoparticles (DOX-MSN/COOH) was successfully prepared and used for imaging and targeting therapy of hepatocellular carcinoma. The nanoparticles were uniform and negatively charged, with a diameter of about 55nm, and a zeta potential of -20mV. In vitro study showed that the nanoparticles could easily be endocytosed by liver cancer cells (HepG2) and were well-accumulated in the liver by passive targeting. In vivo study proved the ability of DOX-MSN/COOH to inhibit the tumor growth and prolong the survival time of mice bearing hepatocellular carcinoma in situ, giving better results than free DOX. More importantly, histological examination showed no histopathological abnormalities of normal liver cells and heart cells after the administration of DOX-MSN/COOH, while the treatment with free DOX caused damage to those cells. In conclusion, DOX-MSN/COOH exhibited enhanced antitumor efficacy as well as reduced side effects for liver cancer therapy.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Meng</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang 212013, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Yuanguo</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>School of Chemistry and Chemical Engineering, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shen</LastName>
                    <ForeName>Haijun</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang 212013, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shen</LastName>
                    <ForeName>Song</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang 212013, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ge</LastName>
                    <ForeName>Yanru</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang 212013, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Jimin</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>School of Chemistry and Chemical Engineering, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, China. Electronic address: xiejm391@sohu.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int J Pharm</MedlineTA>
            <NlmUniqueID>7804127</NlmUniqueID>
            <ISSNLinking>0378-5173</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antitumor</Keyword>
            <Keyword MajorTopicYN="N">Biodistribution</Keyword>
            <Keyword MajorTopicYN="N">Doxorubicin</Keyword>
            <Keyword MajorTopicYN="N">Liver tumor in situ</Keyword>
            <Keyword MajorTopicYN="N">Mesoporous silica nanoparticles</Keyword>
            <Keyword MajorTopicYN="N">Survival rate</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-5173(14)00593-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2014.08.027</ArticleId>
            <ArticleId IdType="pubmed">25149125</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149124</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3476</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of pharmaceutics</Title>
                <ISOAbbreviation>Int J Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-tumor drug delivery system based on cyclodextrin-containing pH-responsive star polymer: In vitro and in vivo evaluation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-5173(14)00584-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ijpharm.2014.08.018</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">A cyclodextrin-containing pH-responsive star polymer, with cyclodextrin polymer and pH-sensitive poly(2-(dimethylamino)ethyl methacrylate) as the core and poly(ethylene glycol) as the arm, was evaluated as drug carriers in vitro and in vivo. Doxorubicin (DOX) was successfully loaded into the star polymer to form nanoparticles (DOX-NPs) via host-guest interaction. The physicochemical properties such as drug loading content, size, morphology, stability and physical state of DOX-NPs were characterized in detail by (1)H NMR, DLS, SEM and DSC. Uniform and stable DOX-NPs with high encapsulation efficiency of 77.1% were obtained, and they also exhibited sustainable and controllable release of DOX in vitro. The cellular uptake of DOX-NPs was in concentration-, time- and cell type-dependent manners, and the cytotoxicity of the DOX-NPs were significantly high toward HeLa and HepG2 cancer cells. Furthermore, in vivo anti-tumor experiment on BALB/c mice bearing cervical tumor showed that DOX-NPs could effectively suppress the growth of tumor without significant side effect. These findings suggest that the cyclodextrin-containing pH-responsive star polymer has a promising potential in developing novel drug delivery system for cancer therapy.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Xiong</LastName>
                    <ForeName>Qingqing</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin 300192, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Mingming</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin 300192, PR China. Electronic address: mingmingz@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Zhibao</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin 300192, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shen</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin 300192, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Lingrong</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin 300192, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Qiqing</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin 300192, PR China; Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou 350002, PR China. Electronic address: zhangqiq@126.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int J Pharm</MedlineTA>
            <NlmUniqueID>7804127</NlmUniqueID>
            <ISSNLinking>0378-5173</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">2-(Dimethylamino)ethyl methacrylate</Keyword>
            <Keyword MajorTopicYN="N">Anti-tumor drug delivery</Keyword>
            <Keyword MajorTopicYN="N">Cellular uptake</Keyword>
            <Keyword MajorTopicYN="N">Cyclodextrin-containing polymer</Keyword>
            <Keyword MajorTopicYN="N">Star polymer</Keyword>
            <Keyword MajorTopicYN="N">pH-response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-5173(14)00584-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2014.08.018</ArticleId>
            <ArticleId IdType="pubmed">25149124</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149102</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2968</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical pharmacology</Title>
                <ISOAbbreviation>Biochem. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cyclooxygenase-2-dependent oxidative stress mediates palmitate-induced impairment of endothelium-dependent relaxations in mouse arteries.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-2952(14)00464-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bcp.2014.08.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Palmitic acid, one of the saturated free fatty acids, impairs cardiovascular function as manifested by inducing vascular inflammation, apoptosis and over-production of reactive oxygen species (ROS) although the origin for ROS remains unclear. The present study investigated the cellular mechanisms underlying palmitate-induced impairment of endothelial function. Ex vivo treatment in tissue culture with palmitate concentration-dependently attenuated acetylcholine-induced endothelium-dependent relaxations, up-regulated the expression of cyclooxygenase-2 (COX-2) and elevated superoxide formation in mouse aortic endothelial cells (MAECs) measured by dihydroethidium (DHE) staining and electron paramagnetic resonance (EPR) spectroscopy. Superoxide scavengers, COX-2 inhibitor and thromboxane prostanoid (TP) receptor antagonist, but not COX-1 inhibitor reversed the harmful effects of palmitate. Furthermore, palmitate impaired acetylcholine-induced relaxations and raised superoxide in en face endothelium of aortas only from COX-1(-/-) mice but not from COX-2(-/-) mice. Palmitate increased the production and release of TXB2, a stable thromboxane A2 metabolite in mouse aortas, which was abolished by COX-2 inhibitor. Superoxide scavenger did not affect palmitate-induced up-regulated expression of COX-2 in MAECs. Both real time PCR and luciferase reporter gene assay confirmed COX-2 up-regulation in palmitate-treated MAECs and NF-??B was substantially involved in this up-regulation. The present study provides novel evidence that palmitate up-regulates COX-2 involving NF-??B activation and resultant COX-2-associated oxidative stress impairs endothelium-dependent relaxations in mouse aortas.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gao</LastName>
                    <ForeName>Zhen</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Institute of Vascular Medicine and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Huina</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Institute of Vascular Medicine and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong SAR, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute of Vascular Medicine and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lau</LastName>
                    <ForeName>Chi Wai</ForeName>
                    <Initials>CW</Initials>
                    <Affiliation>Institute of Vascular Medicine and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Pingsheng</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Zhen Yu</ForeName>
                    <Initials>ZY</Initials>
                    <Affiliation>School of Life Sciences and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Hung Kay</ForeName>
                    <Initials>HK</Initials>
                    <Affiliation>Department of Chemistry, Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tipoe</LastName>
                    <ForeName>George L</ForeName>
                    <Initials>GL</Initials>
                    <Affiliation>Department of Anatomy, University of Hong Kong, Hong Kong SAR, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ho</LastName>
                    <ForeName>Hing Man</ForeName>
                    <Initials>HM</Initials>
                    <Affiliation>School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yao</LastName>
                    <ForeName>Xiaoqiang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Institute of Vascular Medicine and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Vascular Medicine and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: yu-huang@cuhk.edu.hk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Pharmacol</MedlineTA>
            <NlmUniqueID>0101032</NlmUniqueID>
            <ISSNLinking>0006-2952</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">A23187 (PubChem CID: 11957499)</Keyword>
            <Keyword MajorTopicYN="N">DMPO (PubChem CID: 1774)</Keyword>
            <Keyword MajorTopicYN="N">DTPA (PubChem CID: 3053)</Keyword>
            <Keyword MajorTopicYN="N">L-NAME (PubChem CID 39836)</Keyword>
            <Keyword MajorTopicYN="N">S18886 (PubChem CID: 9938840)</Keyword>
            <Keyword MajorTopicYN="N">SC-560 (PubChem CID: 4306515)</Keyword>
            <Keyword MajorTopicYN="N">Sodium palmitate (PubChem CID: 2735111)</Keyword>
            <Keyword MajorTopicYN="N">TEMPONE-H (PubChem CID: 98642)</Keyword>
            <Keyword MajorTopicYN="N">acetylcholine (PubChem CID: 187)</Keyword>
            <Keyword MajorTopicYN="N">celecoxib (PubChem CID: 2662)</Keyword>
            <Keyword MajorTopicYN="N">cyclooxygenase-2</Keyword>
            <Keyword MajorTopicYN="N">dihydroethidium (PubChem CID: 128682)</Keyword>
            <Keyword MajorTopicYN="N">endothelium-dependent relaxations.</Keyword>
            <Keyword MajorTopicYN="N">hypoxanthine (Pubchem CID:790)</Keyword>
            <Keyword MajorTopicYN="N">palmitate</Keyword>
            <Keyword MajorTopicYN="N">parthenolide (PubChem CID: 6473881)</Keyword>
            <Keyword MajorTopicYN="N">phenylephrine (PubChem CID: 6041)</Keyword>
            <Keyword MajorTopicYN="N">superoxide</Keyword>
            <Keyword MajorTopicYN="N">tempol (PubChem CID: 137994)</Keyword>
            <Keyword MajorTopicYN="N">thromboxane B2 (Pubchem CID: 5283137)</Keyword>
            <Keyword MajorTopicYN="N">vitamin E (PubChem CID: 2116)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-2952(14)00464-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bcp.2014.08.009</ArticleId>
            <ArticleId IdType="pubmed">25149102</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149095</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1941-3297</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Circulation. Heart failure</Title>
                <ISOAbbreviation>Circ Heart Fail</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of Adiponectin on Calcium Handling Proteins in Heart Failure with Preserved Ejection Fraction.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">CIRCHEARTFAILURE.114.001279</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">-Despite the increasing prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) in humans, there remains no therapeutic options for HFpEF. Adiponectin (APN), an adipocyte-derived cytokine exerts cardioprotective actions and its deficiency is implicated in the development of hypertension and HF with reduced ejection fraction. Similarly APN deficiency in HFpEF exacerbates left ventricular hypertrophy (LVH), diastolic dysfunction and HF. However, the therapeutic effects of APN in HFpEF remain unknown. We sought to test the hypothesis that chronic APN overexpression protects against the progression of HF in a murine model of HFpEF.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">-APN transgenic (APNTG) and wild-type (WT) mice underwent uninephrectomy, a continuous saline or d-aldosterone infusion and given 1.0% sodium chloride drinking water for 4-weeks. Aldosterone-infused WT mice developed HFpEF with hypertension, LVH and diastolic dysfunction. Aldosterone infusion increased myocardial oxidative stress and decreased sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2a) protein expression in HFpEF. Although total phospholamban (PLN) protein expression was unchanged, there was decreased expression of PKA-dependent PLN phosphorylation at Ser16 and CaMKII-dependent PLN phosphorylation at Thr17. APN overexpression in aldosterone-infused mice ameliorated LVH, diastolic dysfunction, lung congestion and myocardial oxidative stress without affecting blood pressure (BP) and LVEF. This improvement in diastolic function parameters in aldosterone-infused APNTG mice was accompanied by preserved protein expression of PKA-dependent phosphorylation of PLN at Ser16. APN replacement prevented the progression of aldosterone-induced HFpEF, independent of BP, by improving diastolic dysfunction and modulating cardiac hypertrophy.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">-These findings suggest that APN may have therapeutic effects in patients with HFpEF.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tanaka</LastName>
                    <ForeName>Komei</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wilson</LastName>
                    <ForeName>Richard M</ForeName>
                    <Initials>RM</Initials>
                    <Affiliation>Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Essick</LastName>
                    <ForeName>Eric E</ForeName>
                    <Initials>EE</Initials>
                </Author>
                <Author>
                    <LastName>Duffen</LastName>
                    <ForeName>Jennifer L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Scherer</LastName>
                    <ForeName>Philipp E</ForeName>
                    <Initials>PE</Initials>
                    <Affiliation>Touchstone Diabetes Center, Departments of Internal Medicine and Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ouchi</LastName>
                    <ForeName>Noriyuki</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sam</LastName>
                    <ForeName>Flora</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA; Cardiovascular Section and Evans Department of Medicine, Boston University School of Medicine, Boston, MA flora.sam@bmc.org.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Circ Heart Fail</MedlineTA>
            <NlmUniqueID>101479941</NlmUniqueID>
            <ISSNLinking>1941-3289</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">adiponectin</Keyword>
            <Keyword MajorTopicYN="N">calcium handling proteins</Keyword>
            <Keyword MajorTopicYN="N">diastolic dysfunction</Keyword>
            <Keyword MajorTopicYN="N">heart failure with preserved ejection fraction</Keyword>
            <Keyword MajorTopicYN="N">left ventricular hypertrophy</Keyword>
            <Keyword MajorTopicYN="N">oxidative stress</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CIRCHEARTFAILURE.114.001279</ArticleId>
            <ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.114.001279</ArticleId>
            <ArticleId IdType="pubmed">25149095</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149090</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1749-8104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neural development</Title>
                <ISOAbbreviation>Neural Dev</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Spinal neurons require Islet1 for subtype-specific differentiation of electrical excitability.</ArticleTitle>
            <Pagination>
                <MedlinePgn>19</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the spinal cord, stereotypic patterns of transcription factor expression uniquely identify neuronal subtypes. These transcription factors function combinatorially to regulate gene expression. Consequently, a single transcription factor may regulate divergent development programs by participation in different combinatorial codes. One such factor, the LIM-homeodomain transcription factor Islet1, is expressed in the vertebrate spinal cord. In mouse, chick and zebrafish, motor and sensory neurons require Islet1 for specification of biochemical and morphological signatures. Little is known, however, about the role that Islet1 might play for development of electrical membrane properties in vertebrates. Here we test for a role of Islet1 in differentiation of excitable membrane properties of zebrafish spinal neurons.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We focus our studies on the role of Islet1 in two populations of early born zebrafish spinal neurons: ventral caudal primary motor neurons (CaPs) and dorsal sensory Rohon-Beard cells (RBs). We take advantage of transgenic lines that express green fluorescent protein (GFP) to identify CaPs, RBs and several classes of interneurons for electrophysiological study. Upon knock-down of Islet1, cells occupying CaP-like and RB-like positions continue to express GFP. With respect to voltage-dependent currents, CaP-like and RB-like neurons have novel repertoires that distinguish them from control CaPs and RBs, and, in some respects, resemble those of neighboring interneurons. The action potentials fired by CaP-like and RB-like neurons also have significantly different properties compared to those elicited from control CaPs and RBs.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, our findings suggest that, for both ventral motor and dorsal sensory neurons, Islet1 directs differentiation programs that ultimately specify electrical membrane as well as morphological properties that act together to sculpt neuron identity.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Moreno</LastName>
                    <ForeName>Rosa L</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author>
                    <LastName>Ribera</LastName>
                    <ForeName>Angeles B</ForeName>
                    <Initials>AB</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neural Dev</MedlineTA>
            <NlmUniqueID>101286574</NlmUniqueID>
            <ISSNLinking>1749-8104</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1749-8104-9-19</ArticleId>
            <ArticleId IdType="doi">10.1186/1749-8104-9-19</ArticleId>
            <ArticleId IdType="pubmed">25149090</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25149087</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1472-6882</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC complementary and alternative medicine</Title>
                <ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation of anxiolytic activity of the essential oil of the aerial part of Foeniculum vulgare Miller in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>310</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Foeniculum vulgare locally known as ensilal, is an aromatic plant widely cultivated in temperate and tropical regions. The anti-anxiety activity of the crude extract of F. vulgare has been reported. However, the fraction responsible for anxiolytic activity is not known and there is no any report on the anti-anxiety activity of the essential oil of F. vulgare. The objective of study was to evaluate the anxiolytic activity of the essential oil of Foeniculum vulgare Miller.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Adult Swiss albino male mice were randomly divided into six groups (n = 6). Groups I and II received Tween 80 (5%, v/v) and diazepam (0.5 mg/kg, ip), respectively, while groups III to V received orally 50, 100, and 200 and 400 mg/kg doses of the essential oil of F. vulgare, respectively. The mice were then individually placed in animal anxiety models: elevated plus maze (EPM), staircase test (SCT) and open field test (OFT) and evaluated for various parameters.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In EPM test, 100 and 200 mg/kg doses of the essential oil significantly increased percent number of entries and time spent in open arms compared to control. In SCT these doses also reduced rearing significantly compared to controls, while only the 200 mg/kg dose significantly increased number of squares crossed at the center in the OFT test.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The essential oil of F. vulgare was found to exhibit a promising anxiolytic activity.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mesfin</LastName>
                    <ForeName>Miraf</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Asres</LastName>
                    <ForeName>Kaleab</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Shibeshi</LastName>
                    <ForeName>Workineh</ForeName>
                    <Initials>W</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Complement Altern Med</MedlineTA>
            <NlmUniqueID>101088661</NlmUniqueID>
            <ISSNLinking>1472-6882</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1472-6882-14-310</ArticleId>
            <ArticleId IdType="doi">10.1186/1472-6882-14-310</ArticleId>
            <ArticleId IdType="pubmed">25149087</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25149009</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0308-8146</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>167</Volume>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jan</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Food chemistry</Title>
                <ISOAbbreviation>Food Chem</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preventive effects of cranberry products on experimental colitis induced by dextran sulphate sodium in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>438-46</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.foodchem.2014.07.006</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0308-8146(14)01029-2</ELocationID>
            <Abstract>
                <AbstractText>With the prevalence of inflammatory bowel disease (IBD) and its associated risk for development of colorectal cancer, it is of great importance to prevent and treat IBD. However, due to the complexity of etiology and potentially serious adverse effects, treatment options for IBD are relatively limited. Thus, the purpose of this study was to identify a safe food-based approach for the prevention and treatment of IBD. In this study, we tested the effects of cranberry products on preventing dextran sulphate sodium-induced murine colitis. Our results suggest that both cranberry extract and dried cranberries-fed groups had a significantly reduced disease activity index, where dried cranberries were more effective in preventing colitis than cranberry extract. Shortening of colon length, colonic myeloperoxidase activity and production of pro-inflammatory cytokines were attenuated in animals fed dried cranberries compared to the controls. The current report suggests that cranberries can be applied to prevent and reduce the symptoms of IBD.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xiao</LastName>
                    <ForeName>Xiao</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jonggun</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Quancai</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Daeyoung</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Mathematics and Statistics, University of Massachusetts, Amherst, MA 01003, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Cheon-Seok</ForeName>
                    <Initials>CS</Initials>
                    <Affiliation>Graduate School of Biotechnology and Institute of Life Science and Resources, Kyung Hee University, Yongin 446-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Tzong-Shi</ForeName>
                    <Initials>TS</Initials>
                    <Affiliation>Harvard Medical School, Brigham and Women's Hospital, HIM 550, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Yeonhwa</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA; Graduate School of Biotechnology and Institute of Life Science and Resources, Kyung Hee University, Yongin 446-701, Republic of Korea. Electronic address: ypark@foodsci.umass.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Food Chem</MedlineTA>
            <NlmUniqueID>7702639</NlmUniqueID>
            <ISSNLinking>0308-8146</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Colitis</Keyword>
            <Keyword MajorTopicYN="N">Cranberry</Keyword>
            <Keyword MajorTopicYN="N">DSS</Keyword>
            <Keyword MajorTopicYN="N">Inflammatory bowel diseases</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0308-8146(14)01029-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.foodchem.2014.07.006</ArticleId>
            <ArticleId IdType="pubmed">25149009</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148943</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>AGAP, a new recombinant neurotoxic polypeptide, targets the voltage-gated calcium channels in rat small diameter DRG neurons.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-291X(14)01466-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbrc.2014.08.051</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">A previous study showed that antitumor-analgesic peptide (AGAP), a novel recombinant polypeptide, which had been expressed in Escherichia coli, exhibits analgesic and antitumor effects in mice. In the present study, we investigated the underlying analgesic mechanism of AGAP. The effect of AGAP on voltage-gated calcium channels (VGCCs) was assessed in acutely isolated rat dorsal root ganglia (DRG) neurons using the whole-cell patch clamp technique. The results showed that AGAP potently inhibited VGCCs, especially high-voltage activated (HVA) calcium channels. AGAP inhibited HVA and T-type calcium currents in a dose-dependent manner, but had no significant effect on their dynamic functions in rat small-diameter DRG neurons. AGAP inhibited N- and L-type calcium currents at 78.2% and 57.3%, respectively. Thus, the present study demonstrates that AGAP affects calcium currents through the inhibition of N-, L- and T-type channels in DRG neurons, explaining the potential mechanisms of antinociception.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Xifang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Chunli</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China. Electronic address: lichunli_2014@126.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Jianzhao</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Du</LastName>
                    <ForeName>Jingnan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Jinghai</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Biochemistry, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Guixia</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jin</LastName>
                    <ForeName>Xiaoquan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, PR China. Electronic address: Chunfuw@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AGAP</Keyword>
            <Keyword MajorTopicYN="N">Calcium channel</Keyword>
            <Keyword MajorTopicYN="N">Dynamic function</Keyword>
            <Keyword MajorTopicYN="N">Scorpion toxin</Keyword>
            <Keyword MajorTopicYN="N">Whole-cell patch clamp</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25148943</ArticleId>
            <ArticleId IdType="pii">S0006-291X(14)01466-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.08.051</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148940</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CPuORF correlates with miRNA responsive elements on protein evolutionary rates.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-291X(14)01465-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbrc.2014.08.050</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">miRNA is increasingly being recognized as a key regulator of metabolism in animals. A wealth of evidence has suggested that miRNA mainly binds 3' UTR of mRNA and modulates the cell activities via repressing the mRNA translation. However, as the translation initiates at 5' UTR, cis elements like upstream open reading frame (uORF) resided in 5' UTR may also affect the translation efficiency or elongation. In this study, we performed a systematic analysis of miRNA responsive elements (MREs) and uORF of the same transcript in three model organisms (human, mouse, and Drosophila). Intriguingly, we found that the 3' UTR length grew with the complexity of species (human&gt;mouse&gt;Drosophila), in sharp contrast with the invariability of 5' UTR. Additionally, MRE number correlated well with the 3' UTR length, while uORF number showed a weak correlation with the 5' UTR length. Further, we found that human genes with conserved peptide upstream open reading frame (CPuORF) tend to have more MREs and lower evolutionary rates, which provides new insights into the correlation between UTR properties and translational control in animals.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Wangxiong</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China; Cancer Institute, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China; Zhejiang-California International Nanosystems Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Tingzhang</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Zhejiang Institute of Microbiology, Hangzhou, Zhejiang 310012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Yanmei</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Key Laboratory of Reproductive and Genetics, Ministry of Education, Women's Hospital, Zhejiang University, Hangzhou, Zhejiang 310006, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zheng</LastName>
                    <ForeName>Shu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Cancer Institute, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China; Zhejiang-California International Nanosystems Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China. Electronic address: zhengshu@zju.edu.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Correlation</Keyword>
            <Keyword MajorTopicYN="N">Housekeeping genes</Keyword>
            <Keyword MajorTopicYN="N">Upstream open reading frame</Keyword>
            <Keyword MajorTopicYN="N">miRNA responsive elements</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25148940</ArticleId>
            <ArticleId IdType="pii">S0006-291X(14)01465-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.08.050</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148938</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of invasion and metastasis by DMBT, a novel trehalose derivative, through Akt/GSK-3??/??-catenin pathway in B16BL6 cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0009-2797(14)00236-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.cbi.2014.08.004</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Invasion, either directly or via metastasis formation, is the main cause of death in cancer patients. Development of efficient anti-invasive agents is an important research challenge. 6, 6'-bis (2, 3-dimethoxybenzoyl)-a, a-D-trehalose (DMBT), one of brartemicin analogs, was found to be the most potent anti-invasive agent, but the underlying mechanisms are poorly understood. Our current study was to explore the effects of DMBT on invasion and metastasis in B16BL6 cells. Antiproliferation assay and trypan blue exclusion assay showed that no obvious inhibitory or cytotoxic effect of DMBT was found in B16BL6 cells. Wound healing demonstrated that DMBT could inhibit cell migration compared with the normal group. Transwell experiments showed that DMBT could significantly inhibit invasion to the reconstituted basement membrane (P&lt;0.01). We examined the effects of lung metastasis produced by highly metastatic B16BL6 melanoma cells by using experimental metastasis models and BLI analysis. DMBT could significantly suppress lung metastasis in mice. Results from immunohistochemical staining, Western blotting and Real-time PCR indicated that the chemopreventive effect of DMBT was attributed to the inhibition of the VEGF and MMP-9 through Akt/GSK-3??/??-catenin and Akt/mTOR signaling pathways. These results suggested that DMBT could be a promising lead molecule for the anti-metastasis and serve as a therapeutic agent to inhibit cancer cell invasion and metastasis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Linlin</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yue</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Yanna</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China; Key Laboratory of Chemical Biology of Natural Products, Ministry of Education.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yao</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Xiaowen</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tian</LastName>
                    <ForeName>Qi</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ge</LastName>
                    <ForeName>Lianping</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Zhaopeng</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of medicinal chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China; Key Laboratory of Chemical Biology of Natural Products, Ministry of Education.</Affiliation>
                </Author>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Xiuzhen</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, China; Key Laboratory of Chemical Biology of Natural Products, Ministry of Education. Electronic address: xzyhan@sdu.edu.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Akt</Keyword>
            <Keyword MajorTopicYN="N">DMBT</Keyword>
            <Keyword MajorTopicYN="N">Invasion</Keyword>
            <Keyword MajorTopicYN="N">Metastasis</Keyword>
            <Keyword MajorTopicYN="N">??-catenin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0009-2797(14)00236-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2014.08.004</ArticleId>
            <ArticleId IdType="pubmed">25148938</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148914</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7365</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Metabolic brain disease</Title>
                <ISOAbbreviation>Metab Brain Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TNFR1 absence protects against memory deficit induced by sepsis possibly through over-expression of hippocampal BDNF.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The involvement of TNF-?? type 1 receptor (TNFR1) in memory deficits induced by sepsis was explored by using TNFR1 knockout (KO) mice. We reported that wild type (WT) mice presented memory deficits in the novel object recognition test 10??days after sepsis induced by cecum ligation and perforation (CLP). These deficits were not observed in TNFR1 KO mice. The involvement of serum and brain cytokines TNF-??, IL-1??, IL-6, IFN-?? and IL-10 was then investigated. TNFR1 KO mice had higher serum levels of TNF-?? and IL-1??, and brain levels of TNF-?? than WT mice. After CLP, the brain levels of TNF-??, IL-1??, IL-6 and IFN-?? increased in both WT and KO mice. Our next step was to determine the expression of inflammatory cytokines, BDNF and TrKb in the hippocampus. The absence of TNFR1 in mice subjected to polymicrobial sepsis resulted in higher BDNF expression in the hippocampus. In conclusion, after CLP, memory is preserved in the absence of TNFR1. This finding was associated with increased BDNF expression in the hippocampus.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Calsavara</LastName>
                    <ForeName>Allan C</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>Interdisciplinary Laboratory of Medical Investigation, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil, allancalsavara@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Soriani</LastName>
                    <ForeName>Frederico M</ForeName>
                    <Initials>FM</Initials>
                </Author>
                <Author>
                    <LastName>Vieira</LastName>
                    <ForeName>Leda Q</ForeName>
                    <Initials>LQ</Initials>
                </Author>
                <Author>
                    <LastName>Costa</LastName>
                    <ForeName>Priscila A</ForeName>
                    <Initials>PA</Initials>
                </Author>
                <Author>
                    <LastName>Rachid</LastName>
                    <ForeName>Milene A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author>
                    <LastName>Teixiera</LastName>
                    <ForeName>Ant??nio L</ForeName>
                    <Initials>AL</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Metab Brain Dis</MedlineTA>
            <NlmUniqueID>8610370</NlmUniqueID>
            <ISSNLinking>0885-7490</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11011-014-9610-8</ArticleId>
            <ArticleId IdType="pubmed">25148914</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148907</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-1104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Invertebrate neuroscience : IN</Title>
                <ISOAbbreviation>Invert. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Conserved and divergent processing of neuroligin and neurexin genes: from the nematode C. elegans to human.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Neuroligins are cell-adhesion proteins that interact with neurexins at the synapse. This interaction may contribute to differentiation, plasticity and specificity of synapses. In humans, single mutations in neuroligin-encoding genes are implicated in autism spectrum disorder and/or mental retardation. Moreover, some copy number variations and point mutations in neurexin-encoding genes have been linked to neurodevelopmental disorders including autism. Neurexins are subject to extensive alternative splicing, highly regulated in mammals, with a great physiological importance. In addition, neuroligins and neurexins are subjected to proteolytic processes that regulate synaptic transmission modifying pre- and postsynaptic activities and may also regulate the remodelling of spines at specific synapses. Four neuroligin genes exist in mice and five in human, whilst in the nematode Caenorhabditis elegans, there is only one orthologous gene. In a similar manner, in mammals, there are three neurexin genes, each of them encoding two major isoforms named ?? and ??, respectively. In contrast, there is one neurexin gene in C. elegans that also generates two isoforms like mammals. The complexity of the genetic organization of neurexins is due to extensive processing resulting in hundreds of isoforms. In this review, a wide comparison is made between the genes in the nematode and human with a view to better understanding the conservation of processing in these synaptic proteins in C. elegans, which may serve as a genetic model to decipher the synaptopathies underpinning neurodevelopmental disorders such as autism.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Calahorro</LastName>
                    <ForeName>Fernando</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Centre for Biological Sciences, University of Southampton, Life Sciences Building 85, Southampton, SO17 1BJ, UK, F.Calahorro@soton.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invert Neurosci</MedlineTA>
            <NlmUniqueID>9602489</NlmUniqueID>
            <ISSNLinking>1354-2516</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10158-014-0173-5</ArticleId>
            <ArticleId IdType="pubmed">25148907</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148906</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-5010</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemical research in toxicology</Title>
                <ISOAbbreviation>Chem. Res. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ginger Compound [6]-Shogaol and Its Cysteine-conjugated Metabolite (M2) Activate Nrf2 in Colon Epithelial Cells in Vitro and in Vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In this study, we identified Nrf2 as a molecular target of [6]-shogaol (6S), a bioactive compound isolated from ginger, in colon epithelial cells in vitro and in vivo. Following 6S treatment of HCT-116 cells, the intracellular GSH/GSSG ratio was initially diminished but then elevated above the basal level. Intracellular reactive oxygen species (ROS) correlated inversely with the GSH/GSSG ratio. Further analysis using gene microarray showed that 6S up-regulated the expression of Nrf2 target genes (AKR1B10, FTL, GGTLA4 and HMOX1) in HCT-116 cells. Western blotting confirmed up-regulation, phosphorylation and nuclear translocation of Nrf2 protein followed by Keap1 decrease and up-regulation of Nrf2 target genes (AKR1B10, FTL, GGTLA4, HMOX1, and MT1) and glutathione synthesis genes (GCLC, GCLM). Pretreatment of cells with a specific inhibitor of p38 (SB202190), PI3K (LY294002), or MEK1 (PD098059) attenuated these effects of 6S. Using ultrahigh performance liquid chromatography-tandem mass spectrometry, we found that 6S modified multiple cysteine residues of Keap1 protein. In vivo 6S treatment induced Nrf2 nuclear translocation and significantly up-regulated the expression of MT1, HMOX1 and GCLC in the colon of wild-type (WT) mice, but not Nrf2-/- mice. Similar to 6S, a cysteine-conjugated metabolite of 6S (M2), which was previously found to be a carrier of 6S in vitro and in vivo, also activated Nrf2. Our data demonstrated that 6S and its cysteine-conjugated metabolite M2 activate Nrf2 in colon epithelial cells in vitro and in vivo through Keap1-dependent and -independent manners.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Huadong</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>Junsheng</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Yuhui</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Soroka</LastName>
                    <ForeName>Dominique N</ForeName>
                    <Initials>DN</Initials>
                </Author>
                <Author>
                    <LastName>Prigge</LastName>
                    <ForeName>Justin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Schmidt</LastName>
                    <ForeName>Edward E</ForeName>
                    <Initials>EE</Initials>
                </Author>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Major</LastName>
                    <ForeName>Michael B</ForeName>
                    <Initials>MB</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xiaoxin Luke</ForeName>
                    <Initials>XL</Initials>
                </Author>
                <Author>
                    <LastName>Sang</LastName>
                    <ForeName>Shengmin</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Chem Res Toxicol</MedlineTA>
            <NlmUniqueID>8807448</NlmUniqueID>
            <ISSNLinking>0893-228X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/tx500211x</ArticleId>
            <ArticleId IdType="pubmed">25148906</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148848</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-511X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Lipids in health and disease</Title>
                <ISOAbbreviation>Lipids Health Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins modulate adipocyte triglyceride content.</ArticleTitle>
            <Pagination>
                <MedlinePgn>136</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Excessive energy storage of adipose tissue makes contribution to the occurrence and progression of obesity, which accompanies with multiple adverse complications, such as metabolic syndrome, cardiovascular diseases. It is well known that apolipoprotein E, as a component of lipoproteins, performs a key role in maintaining plasma lipoproteins homeostasis. Interestingly, apolipoprotein E is highly expressed in adipocyte and has positive relation with body fat mass. Apolipoprotein E knock-out mice show small fat mass compared to wild type mice. Moreover, adipocyte deficiency in apolipoprotein E shows impaired lipoproeteins internalization and triglyceride accumulation. Apolipopreotein E-deficient lipoproteins can not induce preadipocyte to form round full-lipid adipocyte, whereas apolipoprotein E-containing lipoproteins can. This article mainly reviews the modulation of apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins in adipocyte triglyceride content.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yan-Hong</ForeName>
                    <Initials>YH</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Lipids Health Dis</MedlineTA>
            <NlmUniqueID>101147696</NlmUniqueID>
            <ISSNLinking>1476-511X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1476-511X-13-136</ArticleId>
            <ArticleId IdType="doi">10.1186/1476-511X-13-136</ArticleId>
            <ArticleId IdType="pubmed">25148848</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148830</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-5169</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Peptides</Title>
                <ISOAbbreviation>Peptides</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0196-9781(14)00231-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.peptides.2014.08.002</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P&lt;0.05 to P&lt;0.01) reduced circulating plasma insulin concentrations from day 6 onwards. Oral glucose tolerance and insulin sensitivity, as assessed by exogenous insulin administration, were significantly (P&lt;0.01 to P&lt;0.001) improved by both desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon. These metabolic benefits were accompanied by significantly (P&lt;0.01) increased pancreatic insulin stores. No significant differences in blood triacylglycerol or cholesterol levels were noted with desHis(1)Pro(4)Glu(9)-glucagon, however desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon treatment significantly (P&lt;0.01) increased HDL-cholesterol levels. Glucagon-mediated elevations of glucose and insulin were effectively (P&lt;0.01 to P&lt;0.001) annulled in both treatment groups on day 15. Interestingly, glucose levels during an intraperitoneal glucose tolerance test were not altered by either desHis(1)Pro(4)Glu(9)-glucagon or desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon treatment. These data provide further evidence that glucagon antagonism could provide an effective means of treating T2DM.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>McShane</LastName>
                    <ForeName>Laura M</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Franklin</LastName>
                    <ForeName>Zara J</ForeName>
                    <Initials>ZJ</Initials>
                    <Affiliation>SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>O'Harte</LastName>
                    <ForeName>Finbarr P M</ForeName>
                    <Initials>FP</Initials>
                    <Affiliation>SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Irwin</LastName>
                    <ForeName>Nigel</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK. Electronic address: n.irwin@ulster.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Peptides</MedlineTA>
            <NlmUniqueID>8008690</NlmUniqueID>
            <ISSNLinking>0196-9781</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Diabetes</Keyword>
            <Keyword MajorTopicYN="N">Glucagon antagonist</Keyword>
            <Keyword MajorTopicYN="N">Glucose tolerance</Keyword>
            <Keyword MajorTopicYN="N">Insulin sensitivity</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25148830</ArticleId>
            <ArticleId IdType="pii">S0196-9781(14)00231-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.peptides.2014.08.002</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148826</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1543-706X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>In vitro cellular &amp; developmental biology. Animal</Title>
                <ISOAbbreviation>In Vitro Cell. Dev. Biol. Anim.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanical stretch induces angiotensinogen expression through PARP1 activation in kidney proximal tubular cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Poly(ADP-ribose) polymerase 1 (PARP1) contributes to fibrosis in several disease models. Recent in vivo data indicate that loss of PARP1 attenuates renal fibrosis and inflammation independent on transforming growth factor-?? (TGF-??); however, the role of PARP1 in kidney tubular cells in response to tubulointerstitial fibrosis remains to be defined. Here, we report that PARP1 activation after mechanical stretch of kidney proximal tubular cells enhances angiotensinogen expression via nuclear factor kappa B (NF-??B) activation. Mechanical stretch for 24??h increased PARP1 expression and activation in mouse cortical proximal tubular (MCT) cells. Treatment with 3-aminobenzamide, a PARP1 inhibitor, efficaciously reduced the PARP1 activation induced by mechanical stretch. PARP1 inhibition also reduced angiotensinogen expression and NF-??B p65 phosphorylation induced by mechanical stretch. TGF-??1 expression and secretion were enhanced by mechanical stretch, but PARP1 inhibition did not change the levels of TGF-??1. These data demonstrate that mechanical stretch-induced PARP1 activation contributes to angiotensinogen expression and NF-??B activation in kidney proximal tubular cells, resulting in the promotion of renal tubulointerstitial fibrosis and inflammation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Jeong Soon</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Department of Mechanical and Materials Engineering, University of Nebraska-Lincoln, Lincoln, NE, 68588, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lim</LastName>
                    <ForeName>Jung Yul</ForeName>
                    <Initials>JY</Initials>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jinu</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>In Vitro Cell Dev Biol Anim</MedlineTA>
            <NlmUniqueID>9418515</NlmUniqueID>
            <ISSNLinking>1071-2690</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11626-014-9809-3</ArticleId>
            <ArticleId IdType="pubmed">25148826</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148799</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1735-1502</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Iranian journal of allergy, asthma, and immunology</Title>
                <ISOAbbreviation>Iran J Allergy Asthma Immunol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Interleukin-25 Enhances Allergic Inflammation through p38MAPK and NF-??B Pathways in Mouse Models of Allergic Rhinitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>412-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Interleukin (IL)-25, a cytokine of IL-17 family, can activate p38 Mitogen-Activated Protein kinases(MAPK) and Nuclear Factor(NF)-??B pathways to propagate Th2 responses. The allergic rhinitis mouse model was established by stimulating BALB/c mouse with ovalbumin (OVA). Then we detected expression of IL-25 and downstream p38MAPK and NF-??B. The expression of IL-25, p38MAPK and NF-??B were detected in the OVA-induced allergic rhinitis mouse model. The allergic parameters, such as allergic symptoms, serum OVA-specific immunoglobulin E (IgE) levels and eosinophil infiltration in the nasal mucosa were compared between OVA group and control group. OVA-induced mice displayed significantly higher allergic responses compared with the saline control group. OVA induced mice demonstrated more allergic symptoms, higher serum OVA-specific IgE levels and eosinophil infiltrations. The increased expression of IL-25, p38MAPK and NF-??B immunoreactivity were detected in epidermal cells in the OVA group. The mRNA measurement of IL-25, p38MAPK and NF-??B showed the same result. IL-25 enhances the OVA-induced allergic rhinitis by activating p38MAPK and NF-??B pathways.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhipeng</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. lizhipeng-rose@hotmail.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 317411734@qq.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Lisi</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. liulisient@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Iran J Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>101146178</NlmUniqueID>
            <ISSNLinking>1735-1502</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25148799</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148775</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2518</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Vaccine</Title>
                <ISOAbbreviation>Vaccine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immune responses elicited by Mycoplasma hyopneumoniae recombinant antigens and DNA constructs with potential for use in vaccination against porcine enzootic pneumonia.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0264-410X(14)01121-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.vaccine.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (PEP) and causes major economic losses to the pig industry worldwide. Commercially available vaccines provide only partial protection and are relatively expensive. In this study, we assessed the humoral and cellular immune responses to three recombinant antigens of M. hyopneumoniae. Immune responses to selected domains of the P46, HSP70 and MnuA antigens (P46102-253, HSP70212-601 and MnuA182-378), delivered as recombinant subunit or DNA vaccines, were evaluated in BALB/c mice. All purified recombinant antigens and two DNA vaccines, pcDNA3.1(+)/HSP70212-601 and pcDNA3.1(+)/MnuA182-378, elicited a strong humoral immune response, indicated by high IgG levels in the serum. The cellular immune response was assessed by detection of IFN-??, IL-10 and IL-4 in splenocyte culture supernatants. The recombinant subunit and DNA vaccines induced Th1-polarized immune responses, as evidenced by increased levels of IFN-??. All recombinant subunit vaccines and the pcDNA3.1(+)/MnuA182-378 vaccine also induced the secretion of IL-10, a Th2-type cytokine, in large quantities. The mixed Th1/Th2-type response may elicit an effective immune response against M. hyopneumoniae, suggesting that P46102-253, HSP70212-601 and MnuA182-378 are potential novel and promising targets for the development of vaccines against PEP.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Virginio</LastName>
                    <ForeName>Veridiana Gomes</ForeName>
                    <Initials>VG</Initials>
                    <Affiliation>Laborat??rio de Gen??mica Estrutural e Funcional, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil; Programa de P??s-Gradua????o em Biologia Celular e Molecular, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gonchoroski</LastName>
                    <ForeName>Taylor</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Laborat??rio de Gen??mica Estrutural e Funcional, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Paes</LastName>
                    <ForeName>J??ssica Andrade</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Laborat??rio de Gen??mica Estrutural e Funcional, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil; Programa de P??s-Gradua????o em Biologia Celular e Molecular, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schuck</LastName>
                    <ForeName>Desir??e Cigaran</ForeName>
                    <Initials>DC</Initials>
                    <Affiliation>Laborat??rio de Gen??mica Estrutural e Funcional, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zaha</LastName>
                    <ForeName>Arnaldo</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Laborat??rio de Gen??mica Estrutural e Funcional, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil; Programa de P??s-Gradua????o em Biologia Celular e Molecular, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil; Departamento de Biologia Molecular e Biotecnologia, Instituto de Bioci??ncias, UFRGS, Porto Alegre, RS, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ferreira</LastName>
                    <ForeName>Henrique Bunselmeyer</ForeName>
                    <Initials>HB</Initials>
                    <Affiliation>Laborat??rio de Gen??mica Estrutural e Funcional, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil; Programa de P??s-Gradua????o em Biologia Celular e Molecular, Centro de Biotecnologia, UFRGS, Porto Alegre, RS, Brazil; Departamento de Biologia Molecular e Biotecnologia, Instituto de Bioci??ncias, UFRGS, Porto Alegre, RS, Brazil. Electronic address: henrique@cbiot.ufrgs.br.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Vaccine</MedlineTA>
            <NlmUniqueID>8406899</NlmUniqueID>
            <ISSNLinking>0264-410X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antibody response</Keyword>
            <Keyword MajorTopicYN="N">Cellular immune response</Keyword>
            <Keyword MajorTopicYN="N">DNA vaccines</Keyword>
            <Keyword MajorTopicYN="N">Mycoplasma hyopneumoniae</Keyword>
            <Keyword MajorTopicYN="N">Recombinant subunit vaccines</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0264-410X(14)01121-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25148775</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148722</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1435-5922</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gastroenterology</Title>
                <ISOAbbreviation>J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Blockade of the apelin-APJ system promotes mouse liver regeneration by activating Kupffer cells after partial hepatectomy.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Liver regeneration after massive hepatectomy or living donor liver transplantation is critical. The apelin-APJ system is involved in the regulation of cardiovascular function, inflammation, fluid homeostasis, the adipo-insular axis, and angiogenesis, but its function in liver regeneration remains unclear.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We investigated the impact of pharmacologic blockade of the apelin-APJ system, using the specific APJ antagonist F13A on liver regeneration after hepatectomy in mice.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">F13A-treated mice had significantly higher serum concentrations of tumor necrosis factor (TNF)-?? and interleukin (IL)-6 than control mice, due to F13A-promoted activation of Kupffer cells. Compared with untreated mice, F13A enhanced the signal transducer and activator of transcription 3 and mitogen-activated protein kinase pathways, stimulated cell-cycle progression, and promoted hepatocyte proliferation and liver regeneration without inducing apoptosis or inflammation in regenerating livers. In vitro, Kupffer cells expressed APJ and were activated directly by F13A treatment, releasing TNF-?? and IL-6. Moreover, F13A-treated mice had a higher survival rate than untreated mice in the extended hepatectomy model.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">F13A treatment promotes early phase liver regeneration after hepatectomy by promoting the activation of Kupffer cells and increasing serum levels of TNF-?? and IL-6. F13A treatment may become a therapeutic option to facilitate efficient liver regeneration after liver surgery.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yoshiya</LastName>
                    <ForeName>Shohei</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan, yoshiya@surg2.med.kyushu-u.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shirabe</LastName>
                    <ForeName>Ken</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Imai</LastName>
                    <ForeName>Daisuke</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Toshima</LastName>
                    <ForeName>Takeo</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Yamashita</LastName>
                    <ForeName>Yo-Ichi</ForeName>
                    <Initials>YI</Initials>
                </Author>
                <Author>
                    <LastName>Ikegami</LastName>
                    <ForeName>Toru</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Okano</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Yoshizumi</LastName>
                    <ForeName>Tomoharu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Kawanaka</LastName>
                    <ForeName>Hirofumi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Maehara</LastName>
                    <ForeName>Yoshihiko</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Gastroenterol</MedlineTA>
            <NlmUniqueID>9430794</NlmUniqueID>
            <ISSNLinking>0944-1174</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-014-0992-5</ArticleId>
            <ArticleId IdType="pubmed">25148722</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148711</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6240</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain research</Title>
                <ISOAbbreviation>Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of p21-activated kinase 1 by IPA-3 attenuates secondary injury after traumatic brain injury in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-8993(14)01101-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.brainres.2014.08.026</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The p21-activated Kinase 1 (PAK1) is up-regulated in the brain following traumatic brain injury (TBI). Inhibition of PAK1 has been found to alleviate brain edema in a rat model of subarachnoid hemorrhage. Suppressing PAK1 activity might represent a novel therapeutics of attenuating secondary injury following TBI. Here we confirmed that the mRNA and protein levels of PAK1 and the protein level of p-PAK1 were significantly increased after inducing TBI in mice via M.A Flierl's weight-drop model. A single intraperitoneal administration of IPA-3, a specific PAK1 inhibitor, immediately after TBI significantly reduced the protein level of p-PAK1, cleaved caspase-3 level, the number of apoptotic cells at the lesion sites of TBI mice. It also reduced brain water content and the blood-brain barrier permeability in TBI mice. Furthermore, the administration of IPA-3 significantly reduced the neurological severity score and increased the grip test score in TBI mice. Taken together, we demonstrate that PAK1 inhibition by IPA-3 may attenuate the secondary injury following TBI, suggesting it might be a promising neuroprotective strategy for preventing the development of secondary injury after TBI.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ji</LastName>
                    <ForeName>Xinran</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>The General Hospital of People's Liberation Army(301 hospital), 28 fuxing road (wukesong), Beijing, China, 100000.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>The General Hospital of People's Liberation Army(301 hospital), 28 fuxing road (wukesong), Beijing, China, 100000.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Lihai</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>The General Hospital of People's Liberation Army(301 hospital), 28 fuxing road (wukesong), Beijing, China, 100000.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Licheng</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>The General Hospital of People's Liberation Army(301 hospital), 28 fuxing road (wukesong), Beijing, China, 100000.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Yiling</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>The General Hospital of People's Liberation Army(301 hospital), 28 fuxing road (wukesong), Beijing, China, 100000.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Peifu</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>The General Hospital of People's Liberation Army(301 hospital), 28 fuxing road (wukesong), Beijing, China, 100000. Electronic address: ortho301@163.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Res</MedlineTA>
            <NlmUniqueID>0045503</NlmUniqueID>
            <ISSNLinking>0006-8993</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BBB disruption</Keyword>
            <Keyword MajorTopicYN="N">Brain edema</Keyword>
            <Keyword MajorTopicYN="N">IPA-3</Keyword>
            <Keyword MajorTopicYN="N">Neurological functions</Keyword>
            <Keyword MajorTopicYN="N">PAK1</Keyword>
            <Keyword MajorTopicYN="N">Traumatic brain injury</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-8993(14)01101-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.08.026</ArticleId>
            <ArticleId IdType="pubmed">25148711</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148707</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6240</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain research</Title>
                <ISOAbbreviation>Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The neuroprotective effect of 17??-estradiol Is independent of its antioxidantive properties.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-8993(14)01104-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.brainres.2014.08.029</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">17??-estradiol (E2) is neuroprotective in experimental models of stroke. While some postulate a mainly antioxidative action due to E2's free C3 hydroxyl group at its A-ring, others suggest that neuroprotection is mediated by a hormonal, receptor mediated effect. The aim of the current study was to clarify this issue by testing whether E2 analogues lacking hormonal activity are also neuroprotective following cerebral ischemia.</AbstractText>
                <AbstractText Label="MATERIAL &amp; METHODS" NlmCategory="METHODS">Focal cerebral ischemia was induced in male C57/BL6 mice by laser-Doppler-controlled endovascular occlusion of the middle cerebral artery for 40min. Mice received either 1) memantine, a NMDA-receptor antagonist, as a positive control, 2) E2 (1400??g/kg b.w.), or 3) 2,4,6-trimethylphenol (TMP), an E2 analogue without hormonal activity (1400, 140, or 14??g/kg b.w.). Motor function was tested 3h and 24h after ischemia. Thereafter mice were sacrificed and brain damage was quantified by histomorphometry.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment with memantine or E2 significantly reduced infarct volume by &gt;40% and significantly improved neurological function while treatment with TMP had no effect.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">E2 is equally neuroprotective as antagonization of NMDA receptors while E2 analogues without hormonal activity are not neuroprotective. Therefore the current data suggest that the neuroprotection activity of E2 is independent of its free-radical scavenging properties.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gr??ger</LastName>
                    <ForeName>Moritz</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery; Institute for Surgical Research.</Affiliation>
                </Author>
                <Author>
                    <LastName>Plesnila</LastName>
                    <ForeName>Nikolaus</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute for Surgical Research; Institute for Stroke and Dementia Research, University of Munich Medical Center, Ludwig-Maximilians-University Munich, Germany. Electronic address: nikolaus.plesnila@med.uni-muenchen.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Res</MedlineTA>
            <NlmUniqueID>0045503</NlmUniqueID>
            <ISSNLinking>0006-8993</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">17??-estradiol</Keyword>
            <Keyword MajorTopicYN="N">Antioxidation</Keyword>
            <Keyword MajorTopicYN="N">Hormone</Keyword>
            <Keyword MajorTopicYN="N">Neuroprotection</Keyword>
            <Keyword MajorTopicYN="N">Phenol</Keyword>
            <Keyword MajorTopicYN="N">Stroke</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0006-8993(14)01104-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.08.029</ArticleId>
            <ArticleId IdType="pubmed">25148707</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148701</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-4598</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer</Title>
                <ISOAbbreviation>Mol. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>196</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Development of novel adjuvant therapy to eradicate tumor angiogenesis and metastasis is a pressing need for patients with advanced hepatocellular carcinoma (HCC). We aimed to investigate the clinical relevance and therapeutic potential of angiopoietin-like 4 (ANGPTL4) in HCC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">ANGPTL4 mRNA levels in tumor and non-tumor liver tissues of HCC patients were analyzed to investigate its clinical relevance. The mechanisms of deregulation of ANGPTL4 in HCC were studied by copy number variation (CNV) and CpG methylation analyses. The orthotopic liver tumor nude mice model was applied using a human metastatic cell line. ANGPTL4-overexpressing adenovirus (Ad-ANGPTL4) was injected via portal vein to investigate its anti-tumorigenic and anti-metastatic potentials.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">HCC tissues expressed significantly lower levels of ANGPTL4 mRNA than non-tumor tissues. The copy number of ANGPTL4 gene in tumor tissues was significantly lower than in non-tumor tissues of HCC patients. Higher frequency of methylation of CpG sites of ANGPTL4 promoter was detected in tumor tissues compared to non-tumor tissues. Downregulation of ANGPTL4 mRNA in HCC was significantly associated with advanced tumor stage, presence of venous infiltration, poor differentiation, higher AFP level, appearance of tumor recurrence, and poor postoperative overall and disease-free survivals of HCC patients. Treatment with Ad-ANGPTL4 significantly inhibited the in vivo tumor growth, invasiveness and metastasis by promoting tumoral apoptosis, inhibiting tumoral angiogenesis and motility, and suppressing tumor-favorable microenvironment. Moreover, administration of recombinant ANGPTL4 protein suppressed the motility of HCC cells and altered the secretion profile of cytokines from macrophages.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ANGPTL4 is a diagnostic and prognostic biomarker for HCC patients and a potential therapeutic agent to suppress HCC growth, angiogenesis and metastasis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ng</LastName>
                    <ForeName>Kevin Tak-Pan</ForeName>
                    <Initials>KT</Initials>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Aimin</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Qiao</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Dong Yong</ForeName>
                    <Initials>DY</Initials>
                </Author>
                <Author>
                    <LastName>Lim</LastName>
                    <ForeName>Zophia Xue-Hui</ForeName>
                    <Initials>ZX</Initials>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Chris Kin-Wai</ForeName>
                    <Initials>CK</Initials>
                </Author>
                <Author>
                    <LastName>Fung</LastName>
                    <ForeName>Jeffrey Hon-Sing</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author>
                    <LastName>Poon</LastName>
                    <ForeName>Ronnie Tung-Ping</ForeName>
                    <Initials>RT</Initials>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Sheung Tat</ForeName>
                    <Initials>ST</Initials>
                </Author>
                <Author>
                    <LastName>Lo</LastName>
                    <ForeName>Chung Mau</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author>
                    <LastName>Man</LastName>
                    <ForeName>Kwan</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cancer</MedlineTA>
            <NlmUniqueID>101147698</NlmUniqueID>
            <ISSNLinking>1476-4598</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1476-4598-13-196</ArticleId>
            <ArticleId IdType="doi">10.1186/1476-4598-13-196</ArticleId>
            <ArticleId IdType="pubmed">25148701</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148681</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5).</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jbc.M114.584342</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Soluble Amyloid-?? oligomers (A??o) can trigger Alzheimers disease (AD) pathophysiology by binding to cell surface Cellular Prion Protein (PrP(C)). PrP(C) interacts physically with metabotropic glutamate receptor 5 (mGluR5), and this interaction controls the transmission of neurotoxic signals to intracellular substrates. Since the interruption of the signal transduction from PrP(C) to mGluR5 has therapeutic potential for AD, we developed assays to explore the effect of endogenous ligands, agonists/antagonists and antibodies on the interaction between PrPC and mGluR5 in cell lines and mouse brain. We show that the PrP(C) segment of aa 91-153 mediates interaction with mGluR5. Agonists of mGluR5 increase the mGluR5/PrP(C) interaction, while mGluR5 antagonists suppress protein association. Synthetic A??o promotes the protein interaction in mouse brain and transfected human embryonic kidney-293 (HEK-293) cell membrane preparations. Critically, the interaction of PrP(C) and mGluR5 is dramatically enhanced in the brains of familial AD transgenic model mice. In brain homogenates with A??o, the interaction of PrP(C) and mGluR5 is reversed by mGluR5-directed antagonists or antibodies directed against PrP(C) segment of aa 91-153. Silent allosteric modulators of mGluR5 do not alter Glu or basal mGluR5 activity, but they disrupt A??o-induced interaction of mGluR5 with PrP(C). The assays described here have the potential to identify and develop new compounds that inhibit the interaction of PrP(C) and mGluR5, which plays a pivotal role in the pathogenesis of Alzheimer's disease by transmitting the signal from extracellular A??o into the cytosol.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Haas</LastName>
                    <ForeName>Laura T</ForeName>
                    <Initials>LT</Initials>
                    <Affiliation>Yale, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kostylev</LastName>
                    <ForeName>Mikhail A</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Yale, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Strittmatter</LastName>
                    <ForeName>Stephen M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Yale, United States stephen.strittmatter@yale.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer disease</Keyword>
            <Keyword MajorTopicYN="N">amyloid-beta (AB)</Keyword>
            <Keyword MajorTopicYN="N">metabotropic glutamate receptor (mGluR)</Keyword>
            <Keyword MajorTopicYN="N">neurodegenerative disease</Keyword>
            <Keyword MajorTopicYN="N">prion</Keyword>
            <Keyword MajorTopicYN="N">protein-protein interaction</Keyword>
            <Keyword MajorTopicYN="N">therapeutic modulation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25148681</ArticleId>
            <ArticleId IdType="pii">M114.584342</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M114.584342</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
